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Motivation of thesis
In the late eighties King’s College Hospital in England was already offering screening 
for the carrier status of haemoglobinopathy (HbP). All pregnant women regardless of 
their ethnic origin were offered a carrier test during the booking visit at the antenatal 
clinic. During this time I was a student midwife at the hospital. The catchment 
area of this London based academic hospital involved the areas of Brixton and 
Peckham; both known for their ethnic diverse populations, especially of African and 
Afro-Caribbean origin. The prevalence of sickle cell disease and a positive carrier 
status of HbP were and are high in this area. It was here that I experienced what 
it means for women to have sickle cell disease. Informing pregnant women about 
the reproductive risk related to HbP carrier status was the general responsibility 
of midwives and part of our education on this group of disorders consisted of a 
mandatory visit to the local Sickle Cell and Thalassaemia Centre which articulated 
the importance of information on screening. 
Great was my surprise that no one seemed to have any knowledge about this 
group of disorders when I eventually returned to the Netherlands (1992) to work as 
a primary care midwife. While working in my own midwifery practice in inner-city 
Amsterdam, which had a very ethnic diverse population, I found myself struggling 
with anaemia and its possible causes. This and the exposure to clients with different 
types of anaemia made it easy to decide on the topic of this thesis.
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General Introduction

The Netherlands has always known migrants; from British monks and travelling 
gypsies to merchants and labourers from the south and overseas. After World War II 
migrants from the former Dutch colonies and labourers from especially Morocco 
and Turkey arrived and the eighties saw an increase in political and economic 
refugees.1 This has resulted in the multi-cultural and ethnic diverse society that we 
live in today: approximately 20% of the Dutch population has a migrant background 
with much larger percentages among the inhabitants in the four big cities of the 
Netherlands (www.cbs.nl > themes population. Last accessed 1 May 2012). 
Since the nineties, researchers and policymakers have come to the realisation 
that major ethnic disparities exist in terms of health outcomes.2,3 This is not only 
a major issue in the Netherlands but Europe as a whole which experiences similar 
problems in health care.4-6 Studies have shown that pregnancy outcomes are not 
the same for all ethnic groups in the Netherlands7-10 and that access to health care 
is still a major issue.11 In 2009 the report of the Steering Party on Pregnancy and 
Childbirth advised more attention for women from ethnic minority backgrounds.12 
The research aims set out in this thesis are consistent with this advice. The subject 
of the thesis concentrates on anaemia and HbP carrier screening related to ethnicity 
before and during pregnancy.
Screening for anaemia in pregnancy
Anaemia means a low haemoglobin (Hb) level and is determined by a simple 
measurement of Hb by taking a blood sample. Screening for anaemia in pregnancy is 
standard midwifery practice, both in the Netherlands and elsewhere.13-17 The relevance of 
(screening for) anaemia in the Western world with regards to the outcome of pregnancy is 
however limited. Circulatory problems are only expected when haemoglobin (Hb) drops 
below 2.5-3.1 mmol/l.15 Studies have shown that physical or psychological symptoms 
in pregnancy are unrelated to a low Hb.18,19 A causal relationship between a low Hb 
and prematurity or intrauterine growth retardation (IUGR) has not been confirmed by 
scientific evidence. Although results are ambiguous, a possible relationship exists 
between anaemia in pregnancy and prematurity. However it is not certain whether 
outcomes will improve when anaemia is treated (i.e. with iron tablets in the case of iron 
deficiency anaemia). It is likely that a low Hb is an indicator for general poor maternal 
health resulting in a higher risk of prematurity.15
There is no literature available to support a relationship between low Hb and 
an increased risk for postpartum haemorrhage (PPH) or the safety of homebirth.15 
Theoretically more circulatory problems can be expected when a PPH occurs in 
an extremely anaemic woman. However, an appropriate evidence based reference 
value cannot not be established. Nevertheless, it is accepted practice to screen for 
anaemia during pregnancy.14-16
prevalence of anaemia in pregnancy
Anaemia in pregnancy is generally determined by measuring Hb levels. As a result 
of heterogeneity in definitions used, blood tests, reference values and populations 
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studied, it is difficult to determine the prevalence of anaemia in pregnancy. The 
literature presents a range of the prevalence of a low Hb between 2-28% during 
booking and 2.5-55% in the third trimester of pregnancy.20-23 The prevalence of iron 
deficiency anaemia (IDA) is estimated to be between 1-4% in pregnancy.15
The World Health Organisation (WHO) definition of anaemia in pregnancy is 
Hb  < 6.8 mmol/l (or < 110 g/l).24 A Dutch study in 1998 found a prevalence of 
anaemia in pregnant women of over 42% in the Northern part of the Netherlands, 
based on these reference values.20
cause of anaemia in pregnancy
A low Hb can be caused by iron deficiency or other pathology but in pregnancy 
the most likely cause is physiological haemodilution with the greatest drop in Hb 
occurring around 30-34 weeks gestation.20,22 Therefore, the parameters for anaemia 
in pregnancy are different compared to the parameters for non-pregnant women. In 
the KNOV (the Royal Dutch Organisation of Midwives) anaemia guideline this has 
resulted in gestation dependent reference values (Table 1).
Measuring Hb alone is insufficient to confirm iron deficiency anaemia (IDA) in 
pregnancy. The determination of Hb-levels is used as a screening test. If a low Hb 
is found during pregnancy, the Mean Corpuscular Volume (MCV), which is far less 
affected by haemodilution, is investigated to confirm physiological haemodilution 
or the diagnosis IDA.
No studies have been undertaken to describe the prevalence of anaemia in 
pregnancy according to the reference values used in the midwives’ guideline which 
take physiological haemodilution into account. It would therefore be of interest to 
know the prevalence of anaemia according to the reference values of the KNOV 
anaemia guideline.
table 1. Hb reference values (KNOV 2011)
preconception 7.5 mmol/l
pregnancy (in weeks gestation)
- 13 7.1 mmol/l
14 - 17 6.8 mmol/l
18 - 21 6.5 mmol/l
22 - 37 6.3 mmol/l
38 + 6.5 mmol/l
postpartum (in weeks) 
1- 5 6.5 mmol/l
6 7.2 mmol/l
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anaemia and ethnic background
There is discussion about a possible difference in Hb reference values amongst 
women with different ethnic backgrounds.15,25,26 In the KNOV guideline of 2000 lower 
Hb reference values were given for Black women than for other ethnic groups.27 
Although some studies have taken possible confounders, such as socio-economic 
status resulting in poor nutritional status, and geographic status resulting in a higher 
Hb because of altitude, into account, it is unclear whether results were corrected 
for the presence of HbP. Besides this midwives have questioned the prevalence 
of and the policy around anaemia amongst women with different ethnic origins.28 
Few studies have been carried out to substantiate the impression of midwives that 
pregnant ethnic minority women have a higher risk of anaemia in pregnancy and 
none according to the KNOV reference values. Before anaemia policy is adjusted 
for specific groups of pregnant women, we need to establish whether there is a 
problem and investigate the prevalence of anaemia in different subgroups. 
Depending on local policy, anaemia at the end of pregnancy may influence the 
decision about the place of birth. If anaemia prevalence truly depends on ethnic 
background, it would mean that some women may have less choice in the place of birth. 
haemoglobinopathy and genetic background
As a result of structural abnormality or a reduced production of normal globin 
proteins, a link exists between anaemia and HbP. HbP is the umbrella term for 
disorders such as sickle cell disease (SCD) and thalassaemia. These are autosomal 
recessive disorders that cause variable but life-long morbidity and a shortened 
lifespan due to multi-organ ischaemic damage.29-31 They are considered to be the 
most prevalent monogenetic disorders worldwide: each year approximately 300,000 
babies are born with a severe form of HbP. The prevalence of a positive HbP carrier 
status has been estimated at 0.03-40% depending on ethnic origin.31,32
As a result of the heterozygote advantage in malaria, HbP occur more frequently 
in those areas where malaria is or was endemic such as Africa, the Mediterranean 
region, the Middle East and South-East Asia. Because of migration, HbP now also 
occurs in non-endemic countries. In the Netherlands, each year approximately 
60 children are born with a serious HbP disorder.33 Carrier prevalence has been 
estimated at 4-26% for Dutch citizens of immigrant descent.34,35
types of haemoglobinopathy
There are over 700 structural Hb variants of which HbS is the most widely known. 
Homozygotes for HbS suffer from sickle cell disease (SCD). Other structural HbP variants 
with high frequencies are HbC and HbE.31 Combinations of HbS and other HbP variants 
may also lead to SCD. SCD results in red blood cells (RBC) with deviant (sickle) shapes 
which is caused by a mutation in the haemoglobin gene. This so-called sickling decreases 
the flexibility of the RBC, resulting in vaso-occlusion and a shortened red cell survival. 
Patients suffer from acute and extremely painful episodes or so called crisis, causing 
multi-organ damage and even stroke. Patients are also prone to infections.29,31.36
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Thalassaemia is an expressional defect, classified according to the globin chain 
that is affected. Alpha- and beta-thalassaemia are the most common. The alpha 
chain is produced by four alleles, two paternal and two maternal and the severity 
of the condition depends on how many of those alleles have been mutated. This 
includes mild hypochromic anaemia and HbH-disease. The most severe form is 
Bart’s hydrops foetalis which results in stillbirth. Patients with HbH-disease suffer 
from hepatosplenomegaly, jaundice and occasional bone changes.31,37
Beta-thalassaemia also runs a variable course but without adequate treatment 
such as blood transfusions and chelation therapy, death will occur in early childhood. 
With adequate treatment children will survive into adulthood. The only known 
cures for thalassaemia are bone marrow and cord blood transplantations but these 
treatments are not suitable for everyone and, moreover are expensive31 (www.nhs.uk. 
Last accessed 3 May 2012). Other types of HbP are the compound heterozygous 
SCD such as HbSC; HbSβ0 thalassaemia and HbSβ+ thalassaemia.
haemoglobinopathy (carrier) Screening 
Couples in which both partners are carriers of HbP have a one-in-four chance (25%) 
in each pregnancy of giving birth to an affected child. However, recessive disorders 
are not always apparent in families, which means that most couples are unaware of 
their carrier status38 and the birth of a child with a severe HbP disorder is therefore 
usually unexpected. Carriers can be identified by a simple and cheap blood test 
(High Performance Liquid Chromatography, HPLC). Prospective parents could then 
be informed about their risk and be given the opportunity to make an informed 
reproductive decision preferably before or otherwise in early pregnancy.
Despite the advice of the WHO, which advised countries to pay more attention 
to HbP disorders and to implement screening programmes for risk groups39, the 
Netherlands does not have a national screening programme for HbP carrier screening. 
In 2007, universal screening for SCD, and later beta-thalassaemia, was added to 
the Neonatal Screening (NNS) programme.40,41 The primary aim of this addition 
to the program is health gain for the affected newborn by means of preventing 
complications of the disorder or even early death. However, the screening method 
also leads to unsought identification of carriers; about 800 each year.42 Despite the 
fact that carrier testing in minors is advised against, in view of privacy, psychological 
burden, stigmatization and discrimination43, this unsought finding is reported to 
parents unless they have declined to be informed about this result by opting-out of 
the procedure.44 Those parents whose child is found to be an HbP carrier are invited 
by their general practitioner (GP) to be tested in order to give them the appropriate 
reproductive choices in case of a subsequent pregnancy. However, there is evidence 
that the uptake is minimal.42
Although not all carrier parents are identified by NNS, which explicitly is not the 
aim of the programme, more women will become aware of their HbP carrier status. 
The genetic relevance has been described above, however the effect, if any, of a 
positive carrier status on the outcome of pregnancy may also be important.
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Textbooks claim an increased risk of urinary tract infection (UTI) or suggest an 
increased risk of anaemia.45,46 In the Netherlands no negative effect is assumed 
for HbP carriers, except perhaps mild anaemia in people with alpha-thalassaemia 
minor.34,47 Empirical evidence, however, is inconclusive. It would be important for 
those involved in maternity care, such as midwives, obstetricians and GPs, to know 
if any effect of a positive HbP carrier status exists on the outcome of pregnancy, so 
that appropriate care can be given to those who need it.
haemoglobinopathy carrier status and ethnicity
Although HbP carrier status can easily be determined by an HPLC test, identification 
of ethnicity may be necessary regardless of how screening is carried out, not only 
to investigate mutations as type depends on the couples ethnic origin, but also to 
inform a couple of their personal risk. In England, where screening was introduced 
in 2004, ethnicity is determined by means of the Family Origin Questionnaire (FOQ) 
in both low prevalence areas where targeted screening is practiced, as in high 
prevalence areas where universal screening is the goal (http://sct.screening.nhs.uk. 
Last accessed 26 April 2012). 
Respect for autonomy and therefore informed choice is an important factor of 
any screening programme.48 Identification of risk, in this case by means of ethnicity, 
enables health care professionals to make adequate risk stratification and support 
women and couples to make an informed reproductive choice with regards to their 
(future) pregnancy.
In the Netherlands, midwives and GPs mainly work in primary care. Just like 
midwives, GPs play an important role in the reproductive lives of women and more 
than 80% of pregnant women start their antenatal care with a primary care midwife.49 
At present these health professionals might test clients and patients on the basis of 
unresolved anaemia, a positive family history or consanguinity.15,17,50-52 An increased 
risk on the basis of ethnic origin alone is very rarely considered an indication for 
testing53, which means that most carriers remain unidentified. 
In the Netherlands, many women and couples from those groups at higher HbP 
risk are probably unaware of the possibilities for carrier testing.54 However, those 
who do learn of the possibilities of (ethnicity-based) carrier testing have a positive 
attitude towards either preconceptional or prenatal carrier testing.55-57 Some study 
participants expressed that they preferred to be tested preconceptionally56,58 and 
that they want to be adequately informed about testing. One study showed people 
were in favour of carrier testing provided the costs involved are not too high.56
HbP screening did not attract much attention on a national level until the nineties 
when a discussion erupted in the medical press following a report commissioned by 
the Consultative Committee Minorities (CCM) of the Department of Health, Welfare 
and Sports (VWS). On the basis of a low prevalence of HbP, fear of stigmatisation 
of carriers, lack of knowledge amongst both professionals and those at risk, the 
report concluded that introducing a screening program was “not opportune”.59 A 
pilot study of Weinreich et al. among primary health providers and the population 
General Introduction
1
19
at risk showed that stigmatisation does not seem to be an issue amongst the 
groups at higher risk of being an HbP carrier.53 Although it has been subject to 
debate60,61, preconceptional and prenatal HbP carrier screening are still not part of 
routine healthcare in the Netherlands. Both the United Kingdom (UK) and United 
States (US) have known racial and social conditions related problems regarding 
the introduction of HbP carrier screening. Considerable barriers of inequality and 
(institutionalised) discrimination had to be overcome before positive results were 
achieved by exerting political pressure on the relevant agencies62 and according 
to some researchers every aspect of SCD in the US speaks to the problem of race 
and the social condition of African Americans.63 Would it be possible that similar 
issues to those in the UK and the US were part of the decision-making process in 
the Netherlands? If so it would of interest to know if these issues still exert influence 
on agenda-setting and the decision making process of today.
current situation
On a national policy basis carrier screening of any type of disorder is not available 
at present. The 2007 Health Council report on preconception care advised on a 
pilot study for HbP and CF carrier screening. However to date no official advice has 
been issued to set up a broad preconception and/or antenatal carrier screening 
programme for HbP (and CF) and the Health Council’s advice on a preconception 
programme was rejected by the Minister of Health.64 
Requests for ‘cascade’ carrier testing may ensue as a result of the expanded 
NNS. In addition, increased awareness in society at large may also lead to more 
frequent requests for carrier testing. However, a more active and broadened policy 
involving adult carrier testing is also conceivable as the effect of cascade screening 
has been shown to be limited.65 Such a policy could go beyond the current NNS 
program which is primarily meant for morbidity and mortality prevention. Apart 
from parents who already have an affected child, it would allow reproductive choice 
for other couples. Primary care providers such as midwives and GPs will be called 
upon to meet these needs. Achterbergh et al. argued that effective implementation 
of HbP carrier screening in the Netherlands will require changes among various 
stakeholders, at several levels of society.66
It seems that midwives and GPs have reservations about ordering an HbP 
carrier test solely on the basis of ethnicity which contrasts with the fact that they do 
take ethnicity into account, when diagnosing anaemic patients or assessing other 
aspects of their patients’ and clients’ health. They were also positive about patient 
HbP education programs. Despite a positive attitude towards patient education, 
the participants in this small pilot study did not feel that policy change was needed 
with respect to their own effectuation of carrier screening.53 This discrepancy echoes 
the analysis by Achterbergh et al. and results in an example of inequity in access to 
health care in the Netherlands that has been shown to exist in other areas as well.11
Because attitudes of health professionals may influence clinical practice, the 
specific attitudes of primary care health professionals such as midwives and GPs 
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towards ethnicity based HbP carrier screening are of interest. We therefore aimed to 
investigate midwives’ and GPs’ attitude, intention and behaviour towards ethnicity 
based HbP carrier screening as well as their ideas about existing barriers for the 
implementation of such a program. 
the concept of ethnicity
In this thesis the term ‘ethnicity’ will be used when discussing the risk amongst 
different groups for either anaemia or a positive HbP carrier status. The relationship 
between ethnicity and health has been described in textbooks and many studies 
and is currently widely accepted in health care.3,4,67,68 The aetiology behind this 
relationship partly depends on which health aspect is being looked at: some 
disorders have a direct genetic background such as cystic fibrosis (CF) or HbP; 
others are multi-factorial or not related to genetics at all, such as factors related to 
lifestyle, infections that are spread by human contacts, living environment and/or 
use of (preventive) health care services.69
As ethnic diversity is increasing, the ‘management’ of ethnic diversity increasingly 
becomes a key issue in terms of delivering equitable health care to all groups in society. 
In order to operationalise ethnicity and to investigate the relationship between health 
and ethnicity, categorisation of groups is often a necessity, but equally problematic, 
complex and sensitive. In the second chapter of the thesis, for example, ethnic 
categories have been used according to the current classification of the National 
Perinatal Database (http://www.perinatreg.nl. Last accessed 1 May 2012). Although 
ethnicity and ethnic groups are seen as potentially valuable exposure variables, they 
are not only difficult to define, but they are also recognised as complex concepts that 
need to be treated with careful consideration. Critical and cautious interpretation is 
therefore required, the implications of which are discussed here.
The word ‘ethnicity’ comes from the Greek word ‘ethnos’; meaning nation, people 
or tribe incorporating geographical and ancestral origins and cultural traditions. 
However nowadays the term is generally accepted to cover a complex set of values 
encompassing cultural differences, arising from ancestry, country of birth, migration 
history, language, lifestyle and religion68,70 but also of notions of belonging and 
external recognitions of such claims.67 It is important to realise that ethnicity, based 
on this definition, is not static nor simple but rather fluid and complex.
In the US the term ‘race’ is still acceptable and used by academics. Principally, 
this term is a biological concept whereby the division is made on the basis of visible 
physical characteristics.71 In Europe the term is negatively associated with slavery 
and colonialism, and is very rarely used. Currently, researchers in the US recognise 
the fact that ‘race’ has more meanings than mere physical differences and also 
emphasize the importance of social (and political) concepts in race.72,73 Nevertheless, 
Bhopal cautions against the use of this term for its history of misuse and injustice.71
In genetic medicine, ancestral origin is the more accepted concept. All 
populations originate from the same small group of common ancestors which have 
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evolved through geographic isolation, regional founder effects, catastrophic natural 
events and more and have formed the human gene pool that nowadays exists.74 
Ancestral origin determines a priori the risk of genetic disease or the risk of passing 
on the disease to a person’s offspring. This is certainly true for monogenic disorders 
such as HbP and CF. But in the case of multi-factorial diseases such as diabetes, 
hypertension or certain cancers, which can have a genetic component but which 
are also influenced by lifestyle factors, the issue is more complex and the use of 
ethnicity rather than ancestry might be more appropriate, because it may include 
both gene and environment. Although determining ancestral origin may appear 
straight forward, Aspinall et al. argue otherwise quoting a small study carried out 
by the National Office of Statistics (ONS) in Britain, showing that the term ancestry 
has its limits because of a lack of understanding by the users. Not all participants 
were certain how far back they should look at their lineage, uncertainties over their 
ancestry in Africa or parental origins in the Caribbean and some declined to answer 
at all, concluding that the term ancestry is therefore unstable.75 The Canadian 
Census test is also quoted with a 11.5% non-response mainly because of difficulties 
remembering the origins of parents and grandparents. Ancestry, whilst seemingly 
sufficiently describes the information needed for genetic screening such as HbP 
carrier screening, may not be appropriate in other situations whereby lifestyle and 
culture play a role such as diabetes. Aspinal also argues that answer categories may 
be of just as much importance.75 The same study shows similar answers for ancestry 
and ethnic group using the same answer categories. Answer categories may also 
introduce ambiguities for example when primarily based on colour. 
The term ethnic origin may therefore be more appropriate especially since 
ethnicity is the more accepted term in other parts of health care such as midwifery 
and obstetrics (http://www.perinatreg.nl. Last accessed 1 May 2012). Although not 
tested, it may be the clearer term for all involved, including health professionals. 
Fenton argues that what is true of ancestry is true of ethnicity: both are simultaneously 
socially grounded and socially constructed as the way in which people value and 
choose their ancestors differs.76 Context is therefore important.
In the Netherlands, the country of birth and that of (one of) the parents, is accepted 
in many epidemiological studies as a proxy for ethnicity: so called ‘allochtony’ a 
Dutch term meaning “someone with a foreign background” of whom at least one 
parent was born abroad.77,78 This “country of birth” definition of ethnicity is used 
by Statistics Netherlands (or CBS, Central Bureau of Statistics Netherlands as it is 
known in Dutch), the source of denominator data for many epidemiological studies 
in the Netherlands. The National Perinatal Registry (PRN) still uses an outdated 
classification system partly based on the history of the Dutch empire and the history 
of the first post-war migration waves, but is hoping to replace this soon with country 
of birth and ethnicity (http://www.perinatreg.nl. last accessed 1 May 2012). CBS also 
makes a subdivision between Western and non-Western allochtony but interestingly 
puts Indonesians and Japanese people in the Western allochtony group, allowing 
22
more than just ancestry to enter the municipal registers. Evidently when using the 
term ‘ethnicity’, historical context of concepts and terminology cannot be ignored.
Though information on country of birth is generally easy to ascertain, the sought 
after objectivity and stability may not always be present as argued by Stronks: 
people’s ethnicity may not be consistent with the country they are born in and 
an adequate gold standard is lacking78,79; reflecting the complexity of identity and 
the contingent nature of ethnicity. Also in genetic studies, self identified ancestry 
may often lead to a classification that differs from country of birth (of parents).80 
Besides, although the post-war population of immigrant descent is still relatively 
young, soon if not already, those beyond the second generation will be “lost to 
statistics” with this method. Stronks et al. have therefore proposed the use of 
additional indicators such as geographic origin of ancestors, language spoken and 
self-identified ethnicity.81 
It is clear that the conceptualisation and the use of ethnicity have been and still are 
being debated. It has also been argued from an ethical point of view that making 
ethnic diversity visible may be undesirable. Ahmad and Bradby even go as far 
to suggest that ‘ethnicity’ is an over-employed term, sometimes used with such 
imprecision that it risks losing its analytical value.67 They argue that using ethnicity as 
an explanation of inequality ignores underlying, often inequitable, power structures 
whereby the disadvantage of ethnic minority groups is usually defined by those 
in power and their disadvantage is related to genetic and dysfunctional cultural 
inheritance.82 This doesn’t only ignore the real issues at stake but also absolves 
governments and policymakers from responsibility. For example Agyemang et al. 
argue that the importance of the influence of the default or host country cannot 
be ignored when investigating health outcomes as similar ethnic groups have 
different health outcomes in other countries of residence83, showing the importance 
of national context in (in-) equalities in health. Even though all citizens are equal, 
some groups in society may need different services in order to provide equitable 
health care for all. As argued by Bhopal, ethnic variations in health and disease are 
too large to be ignored and that acknowledging and acting upon them is better 
than ignoring them despite the fact that this may widen ethnic divisions in society.84 
To add further complexity to these debates, operationalisation of ethnicity and 
classification of ethnic groups will influence outcomes. Failure to recognise the 
complexity of terminology and theory involved may lead to poor evidence of ethnic 
inequalities in health and inappropriate policy and practice. As Craig et al. point out 
in the introduction of their book; the fact that everyone has an ethnicity is very rarely 
acknowledged.85 Ethnic minority groups are usually set aside as ‘different’ from the 
default group who are taken for granted. It is essential to realise that inequalities 
often originate from inequalities in socio-economic status and that complex 
interactions exist also involving gender and migration status.76 Set alongside the 
current political climate in the Netherlands, this becomes an even more important 
General Introduction
1
23
argument for getting it right. It is conceivable that more than one approach is 
possible but whatever approach we take, the most important issue before making 
choices about terminology and definitions, is that we need to understand why we 
need to make certain distinctions amongst people and what information we are 
seeking. For example life style related health issues may need a different approach 
than care surrounding (the risk of) mono-genetic disorders. Since ethnicity is also 
used in politics, policy and the public debate it is important that the sensitivities 
involved are understood.
In light of the above the use of the PRN classifications in Dutch research has 
its limitations. However this is what is currently available to researchers who aim 
to use this extensive data-base. In the near future the new perinatal database will 
be implemented. Besides coding according to (parents) country of birth, ethnicity 
will be classified with a limited ethnicity question (http://www.perintareg.nl. Last 
accessed 1 may 2012). As argued, more complex issues are at stake. If we want 
to continue to monitor the health and outcome of pregnancy in the Netherlands, 
researchers and policymakers will have to think of adequate and sensitive ways of 
defining the variable ‘ethnicity’, ultimately depending on the outcome we wish to 
measure. The fact that most primary health care professionals are more familiar with 
the term ethnicity, together with the arguments discussed earlier, is the reason why 
the term ethnicity will be used in this thesis. 
aiM of thesis
The objective of the first part of this thesis (chapter 2 and 3) is to evaluate screening 
of anaemia and HbP carrier status against the background of ethnicity. 
The second part aims to gain insight into historical background of ethnicity 
based HbP carrier screening as well as the present attitudes and perceived barriers 
towards the ethnic registration by midwives and GPs related to preconceptional or 
antenatal HbP carrier testing.
research questions
1.  What is the prevalence of anaemia in pregnancy according to the cut-off points 
used in the KNOV anaemia guideline (2000)?
  Is there a difference in the prevalence of anaemia in pregnant women of non-
Northern European descent compared with pregnant women of Northern 
European descent?
  If so, does this difference result in a higher risk of a Transferred Home Delivery 
(THD), thus reducing the chance for non-Northern European women to choose 
their place of birth?
2.  Does being HbP carrier have any consequences for the health of pregnant 
women and does it have an effect on the outcome of their pregnancy?
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3.  When did the issue of preconception, antenatal or neonatal testing of 
asymptomatic persons at risk of HbP receive attention on the agenda of the 
Dutch public health authorities and what was the background to this agenda 
setting?
  To what extent was this influenced by the political climate at the time and 
potential concerns about the role of ethnicity and the fear of discrimination?
4.  What are the attitude, intention and behaviour of midwives and GPs towards 
ethnic registration and their willingness to undertake carrier testing for clients 
and patients on the basis of ethnicity?
  What factors play a role in midwives’ and GP’s attitudes towards ethnic registration 
related to preconceptional or antenatal HbP carrier testing?
  What are the perceived barriers of these health professionals if ethnicity-based 
HbP carrier screening would be implemented in the future?
outLine of thesis
Chapter 2 describes a retrospective cohort study which was carried out to investigate 
the prevalence of anaemia in groups of pregnant women of different ethnic origins. 
The data were also used to see if there was a difference in choice in place of birth 
for different groups as a result of a difference in anaemia.
Chapter 3 reports on the findings of systematic review of the literature on HbP 
carrier status, and the (absence or presence of) consequences for the health of 
pregnant women and the outcome of their pregnancies.
Chapter 4 describes the history of the decision making process surrounding HbP 
screening in the past and to date and reports on the exploration of the decision 
making process surrounding the introducing of a broad HbP (carrier) screening 
programme which is not implemented in the Netherlands (beyond neonatal 
screening). To what extent was this process influenced by the political climate at the 
time and potentially deep-seated concerns about the role of ethnicity and the fear 
of discrimination? The chapter reports on the investigation by means of a witness 
seminar as developed by the Centre for Contemporary British History (CCBH) in 
the UK (http://www.kcl.ac.uk/innovation/groups/ich/centres/ccbh/index.aspx. Last 
accessed 1 May 2012) .
Chapter 5 reports on the quantitative study that used a postal questionnaire to 
investigate the attitude, intention and behaviour of midwives and GPs towards 
ethnic registration and the willingness of these primary health care professionals to 
effectuate HbP carrier testing for clients and patients on the basis of ethnicity.
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Chapter 6 describes the qualitative study which used focus group discussions 
amongst midwives and GPs to explore factors that play a role in their attitudes and 
understandings of ethnicity and its use in every day practice as well as perceived 
barriers that prevent these health professionals from offering ethnicity based HbP 
carrier screening to their patients.
The final chapter (chapter 7) presents the general discussion of the results generated 
by the studies presented in the thesis, together with the clinical implications and 
suggestions for further research.
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abstract
objectives: to investigate the prevalence of anaemia in pregnancy according to 
the cut-off points used in the national clinical guideline ‘Anaemia in Primary Care 
Midwifery Practice’, and to investigate a possible difference in prevalence between 
pregnant women of Northern European descent compared with women of non-
Northern European descent. The study also investigated whether any difference in 
prevalence resulted in a higher risk of a transferred home delivery, thus reducing the 
chance for women to choose the place of birth.
design: Retrospective cohort study
Setting: Primary care midwifery practices in a highly urbanised area in Amsterdam, 
the Netherlands.
participants: All patients in three midwifery practices over 1 year were selected 
provided that they met the inclusion and exclusion criteria. The practices were 
selected on the basis of urbanisation, resulting in an adequate ethnic population 
which was comparable with the ethnic mix in other similarly urbanised areas in 
the Netherlands. This resulted in a study population of 828 pregnant women of 
Northern European and non-Northern European descent with low-risk singleton 
pregnancies during 2003.
analysis: Mean haemoglobin level and anaemia rate were computed for the total 
study population as well as separate ethnic groups. Differences between groups 
were determined using chi2 tests, and effect sizes were expressed in relative risks 
including 95% confidence intervals (CI).
findings: The prevalence of anaemia in pregnancy was 3.4% (n = 28) at booking 
(first visit) and 2.7% (n = 22) at approximately 30 weeks of gestation. The relative 
risk of anaemia at booking was 5.9 (95% CI 2.1-16.7) for pregnant women of non-
Northern European descent compared with those of Northern European descent. 
The relative risk of anaemia at approximately 30 weeks of gestation was 22 (95% CI 
3-162) for pregnant women of non-Northern European descent compared with 
those of Northern European descent. The incidence of transferred home delivery 
was 3.1% in the study population. The relative risk for transferred home delivery was 
24.1 (95% CI 3.3-176.7) for pregnant women of non-Northern European descent 
compared with those of Northern European descent.
Key conclusions and implications for practice: Pregnant women of non-Northern 
European descent are a specific group in terms of anaemia and are at high risk of a 
low haemoglobin level for all cut-off values; they have a higher chance of becoming 
anaemic in pregnancy than women of Northern European descent. As a result, they 
have a higher risk of a transferred home delivery, taking away their opportunity 
to choose the place of birth. Haemoglobinopathies did not explain the higher 
risk of anaemia in pregnant women of non-Northern European descent. Being of 
non-Northern European descent should be added as a risk factor for anaemia in 
pregnancy until more is known about the background of this risk factor.
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Detection of anaemia in pregnancy is standard practice. However, the question 
of how this should be done and whether detection of anaemia leads to better 
pregnancy outcomes has not been answered sufficiently.
In November 2000 the Royal Dutch Organization of Midwives (KNOV) launched 
its first national clinical guideline entitled ‘Anaemia in Primary Care Midwifery 
Practice’.1 The guideline is written for midwives working in a primary-care setting 
looking after women with low risk pregnancies.
The normal or reference values of haemoglobin (Hb) presented in the guideline 
are based on the observed values in two well-known Dutch studies2,3 and follow 
normal haemodilution in pregnancy. Normal values for Black women have been set 
0.5 mmol/l lower, based on mainly North American research data that had been 
adjusted for socio-economic status (SES), dietary influences and geographical factors. 
Haemoglobinopathies (HbPs) and other possible pathological factors were not taken 
into account in these studies.1 According to the World Health Organisation (WHO) 
5% of the world’s population are carriers for HbP. The prevalence of carriers in the 
Netherlands is approximately 0.1% among the local Dutch population (1:1300) and 
4-13.6% among the Dutch immigrant population (1:25-1:7). Approximately 140,000 
immigrants in the Netherlands are estimated to be carriers of HbPs4,5, but pregnant 
women of Non-Northern European descent are not routinely screened for HbPs. 
Discussion whether or not this should be introduced is ongoing.4-7 The discussion 
seems to be slowly turning in favour of screening as a result of the new neonatal 
screening programme which was introduced in the Netherlands on 1 January 2007 
and which screens all newborn babies for sickle cell disease.
The guideline operates as a screening instrument for the detection of anaemia 
in women with normal physiological pregnancies. It recommends Hb investigations 
at booking (approximately 12 weeks of gestation) and at approximately 30 weeks of 
gestation. If a pregnant woman belongs to one of the four risk groups for anaemia in 
pregnancy as defined in the guideline, such as teenage pregnancy, twin pregnancy, 
poor dietary habits or pregnant within 1 year after a previous birth, she will have 
an additional Hb investigation at approximately 20 weeks gestation. If an Hb level 
below the 5th percentile is found, the mean corpuscular volume (MCV) is checked. 
An MCV of below 80 fL. is considered to be representative of iron deficiency anaemia 
and therefore iron tablets should be prescribed. If the MCV is below 70fL or above 
100fL, or if anaemia is resistant to iron therapy, the woman should be referred to 
her general practitioner for further investigations. This referral should lead to an 
adequate detection of anaemia. 
In general, the guideline was received positively by midwives8, but it also has 
its critics. Elion-Gerritzen argued that the introduction of the guideline would 
lead to under detection of iron-deficiency anaemia and HbPs in pregnant women, 
and disagreed with separate cut-off values for pregnant Black women.6 Midwives, 
especially those working in highly urbanised areas with large immigrant populations, 
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have commented that the guideline fails to diagnose anaemia sufficiently early 
especially in immigrant women of non-Northern European descent.8
In the Amsterdam area, it is standard practice for women with an Hb level below 
6.0 mmol/l to be transferred to hospital for birth, a so-called ‘transferred home 
delivery’ (THD). If women with an immigrant background have a greater risk of 
severe uncorrected anaemia in pregnancy, than they would also have less chance of 
being able to choose the place of birth compared with women with a physiological 
pregnancy. This may result in less favourable outcomes.9
The guideline has been in existence for 6 years and is due to be reviewed in 
2008. No studies have been undertaken to describe the prevalence of anaemia in 
pregnancy according to the cut-off points used in the guideline or to substantiate 
the impression of midwives that pregnant women with an immigrant background 
have a higher risk of anaemia in pregnancy.
This study aimed to investigate the prevalence of anaemia in pregnancy 
according to the cut-off points used in the guideline, and to investigate whether 
there is a difference in the prevalence of anaemia in pregnant women of non-
Northern European descent when compared to pregnant women of Northern 
European descent. The study also investigated whether any difference in prevalence 
resulted in a higher risk of a THD, thus reducing the chance for women to choose 
the place of birth.
Methods
A retrospective cohort study was undertaken to evaluate anaemia in pregnancy 
between January 2003 and December 2003, when the guideline had been well 
established. Three primary care midwifery practices in Amsterdam, the Netherlands 
were selected on the basis that they were all located in highly urbanised areas, 
served a large multicultural population, and followed the national guideline routinely 
for Hb investigations (Hb cut-off points and anaemia management when indicated). 
HbPs were not investigated routinely in any of the practices.
All pregnant women who delivered their baby between 1st of January 2003 
and 31st of December 2003, and who were registered with a singleton low-risk 
pregnancy, at one of the three primary care midwifery practices were included 
in the study. Women whose care was transferred to hospital before 36 weeks of 
gestation for medical reasons other than anaemia, and women who suffered from 
bowel disease or vaginal bleeding other than slight spotting were excluded from 
the study. Registration with the practice should have been before 20 weeks of 
gestation; women who booked later than this were also excluded from the study. 
The guideline recommends that Hb should be investigated routinely at booking and 
again at approximately 30 weeks of gestation. Women who belonged to any of the 
four risk groups for anaemia were also investigated at 20 weeks of gestation. 
Ethical approval was not required because of the non-experimental nature of 
the study.
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data collection
Record keeping was computerised in two out of the three practises, and one practice 
kept their main records on paper. Demographic data collected were date of birth, 
ethnicity, gravidity, parity, date of booking, expected date of birth and, if applicable, 
birth year of last previous baby.
All data related to anaemia were collected such as Hb in mmol/l, MCV in fL, 
HbPs if found, treatment given, referrals for anaemia and risk groups for anaemia.
ethnicity
Ethnic origin was identified according to the Dutch obstetric registration system. 
This register classifies women into the following groups: Dutch, Mediterranean, 
other European, Creole, Hindu, Asian, other and unknown. The guideline makes a 
distinction between White and Black women. Since people with Turkish and Moroccan 
backgrounds are two large ethnic groups within Dutch society, Mediterranean 
women were investigated in depth. To accommodate the guideline, to depict the 
specific groups in Dutch society and to obtain a sufficiently large enough group for 
statistical analysis, the study population was divided into Northern European and 
non-Northern European. The latter group included Black, Mediterranean (Turkish 
and Moroccan) and ‘other’ women (consisting of Asians, Hindus, women from Indian 
descent living in Surinam, others and unknown).
Statistical analysis
Mean [standard deviation (S.D.)] Hb, prevalence of anaemia at booking and at 
approximately 30 weeks of gestation, and the rate of THD were calculated for the 
total study population. Subsequently differences in ethnic subgroups were analysed. 
Mean (S.D.) Hb was determined, as well as rates of Hb below the 5th percentile 
(considered to be the lowest acceptable normal level of Hb in pregnancy), and 
anaemia and Hb below 6.0 mmol/l at booking (considered to be a sign of possible 
pathology) and at 30 weeks of gestation (as this was a reason for THD). Descriptive 
statistics were used for all of these data.
The differences between pregnant women of Northern European and non-
Northern European descent were determined for the rates of low Hb, anaemia and 
the rate of THD using Chi2 tests. Effect sizes were expressed in relative risks (RR) and 
their 95% confidence intervals (CI).
Data were analysed using Statistical package for the Social Sciences version 
12.0.1 (SPSS Inc., Chicago, IL, USA) and a p-value of < 0.05 was considered to be 
statistically significant.
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findings
In total, 1181 cases were retrieved from the three midwifery practices, and 945 
(80%) were included in this study. 
The mean age of the excluded women was 29.9 years (S.D. 6.5), 42.4% were 
primiparous, 28.4% were of Northern European descent, 18.2% were Mediterranean, 
39.4% were Black, and 13.9% were other ethnic groups. The main reasons for 
exclusion were a medical indication for secondary care (45.3% ) and booking after 
20 weeks of gestation (44.5%); in addition, 5.1% of women were excluded because 
of bowel disease and 5.1% because of vaginal bleeding. Following exclusion of 
cases wit missing data (i.e. those without Hb taken at booking or approximately 30 
weeks of gestation), 828 cases (70%) remained for analysis.
The mean age of the included women was 30.5 years (S.D. 5.8). Approximately 
half of the study population were primiparous (49.6%). Approximately half of 
the population was of Northern European descent (48.9%) and the women of 
non-Northern European descent appeared to be a very heterogeneous group. 
Of the latter, the subgroups were Mediterranean 19.4%, Black 21.4% and other 
10.3% (Table 1).
The ‘other’ group consisted of 24% Hindus with origins in Surinam, 34% Asians, 
32% others (e.g. South American and Middle Eastern women) and 10% unknown.
In this study, mean Hb followed the physiological drop in Hb associated with 
gestation, ranging from a mean of 7.7 mmol/l (S.D. 0.6) at 10 to 13 weeks of 
gestation to 6.9 mmol/l (S.D. 0.66) at 22-37 weeks of gestation. The overall rates of 
table 1. Characteristics of studied population (n = 828).
included pregnant women n  %
Mean age (S.D.) 30.5 (5.8)
mean gestation in weeks
    Booking (S.D.) 13.3 (2.5)
    30 weeks (S.D.) 30.4 (3.2)
Primiparous 411 49.6
Multiparous 417 50.4
ethnicity
Northern European
    Dutch 379 45.8
    Other European 26 3.1
Non-Northern European
    Mediterranean 161 19.4
    Black 177 21.4
    Other non-Black 85 10.3
SD: Standard Deviation
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anaemia at booking and approximately 30 weeks of gestation were 3.4% and 2.7%, 
respectively (Table 2).
ethnic differences in hb and anaemia
At booking
Stratified analysis showed significant differences for the varying cut-off points of 
Hb in the guideline and for anaemia amongst the different ethnic groups studied 
(table 3). A significant difference was found in mean Hb at booking, regardless 
of gestation, between women of non-Northern European descent and women of 
Northern European descent (p=0.001). Non-Northern Europeans had a significantly 
higher risk for an Hb below the 5th percentile at booking when the booking 
took place before 14 weeks of gestation (RR 2.1, 95% CI 1.3–3.3). There was no 
difference if they booked later than 14 weeks of gestation. The difference between 
non-Northern Europeans and Northern Europeans was significant for an Hb below 
6.0 mmol/l at booking (RR 12.4, 95% CI 1.6–94.7). 
Women of non-Northern European descent also had a significantly higher risk 
for anaemia at booking (RR 5.9, 95% CI 2.1–16.7). 
No significant difference was found in mean Hb at booking regardless of gestation, 
between Mediterranean women and Northern European women. Mediterranean 
women had a higher risk for an Hb below the 5th percentile when the booking 
took place before 14 weeks of gestation (3.0, 95% CI 1.8–5.2). The difference 
between Mediterranean women and Northern European women was significant for 
an Hb below 6.0 mmol/l (RR 15.1, 95% CI 1.8–124.4). Mediterranean women had a 
significantly higher risk for anaemia at booking (RR 7.4, 95% CI 2.4–22.8). 
A significant difference was found in mean Hb at booking, regardless of 
gestation, between Black women and Northern European women (p = 0.008). 
They were not significantly different with regard to an Hb below the 5th percentile 
table 2. Mean haemoglobin (Hb) levels, anaemia prevalence and rate of transferred home 
delivery (THD) in entire study population.
gestation mean hb (mmol/l) S.d. n %
at booking
10 - 13 wks 7.7 0.6
14 - 17 wks 7.4 0.66
18 - 21 wks 7.0 0.73
Anaemia 28 3.4
 (mean Hb, SD.) 6.9 0.66
 Anaemia 22 2.7
THD 26 3.1
SD: Standard Deviation
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at booking before 14 weeks of gestation, but had a higher risk for an Hb below 
6.0 mmol/l (RR 13.7, 95% CI 1.7–113.2). Black women had a significantly higher risk 
for anaemia at booking (RR 4.0, 95% CI 1.2–13.4) compared to women of Northern 
European descent. 
No significant difference was found in mean Hb at booking regardless of gestation, 
between other ethnic groups and Northern Europeans. The other ethnic groups had a 
significantly higher risk for Hb below the 5th percentile before 14 weeks of gestation, 
(RR 2.7, 95% CI 1.4–5.0). There was no significant difference between other ethnic 
groups and Northern Europeans for an Hb below 6.0 mmol/l. Other ethnic groups 
had a significantly higher risk of anaemia at booking (RR 7.2, 95% CI 2.1–24.9).
At 30 weeks
Non-Northern Europeans had a higher risk for an Hb below the 5th percentile 
compared with Northern Europeans (RR 5.0, 95% CI 2.8–9.2). They also had a 
table 3. Characteristics of ethnic subgroups 
northern 
european
non-
northern 
european mediterranean black other
405 423 161 177 85
mean hb  
at booking mmol/l
   10-13 wks (S.D.) 7.8 (0.59) 7.5 (0.59) 7.5 (0.67) 7.4 (0.51) 7.5 (0.60)
   14-17 wks (S.D.) 7.6 (0.60) 7.3 (0.66) 7.4 (0.66) 7.1 (0.69) 7.3 (0.51)
   18-21 wks (S.D.) 7.3 (0.64) 6.9 (0.74) 7.1 (0.99) 6.7 (0.59) 7.1 (0.23)
booking
Hb< 5th 
percentile n (%) 30 (7.4%) 82 (19.4%) 31 (19.3%) 12 (6.9%) 13 (15.3%)
Anaemia n (%)  
(Hb<p5/MCV<80fL) 4 (1.0%) 24 (5.7%) 11 (6.8%) 7 (4.5%) 6 (7.1%)
Unknown n (%) 22 (5.4%) 31 (7.3%) 18 (11.2%) 8 (4.5%) 5 (5.9%)
Hb < 6 mmol/l n (%) 1 (0.2%) 13 (3.1 %) 6 (3.7%) 6 (3.4%) 1 (1.2%)
hb at +/- 30 wks
Mean Hb  
mmol/l (S.D.) 7.2 (0.52) 6.7 (0.70) 6.8 (0.68) 6.7 (0.69) 6.6 (0.73)
Hb < 5th 
percentile n (%) 12 (3.0%) 63 (14.9%) 23 (14.3%) 18 (10.2%) 22 (25.9%)
Anaemia n (%)  
(Hb<p5/MCV<80fL) 0 (0) 22 (5.2%) 7 (4.3%) 5 (2.8%) 10 (11.8%)
Unknown n (%) 5 (1.2%) 20 (4.7%) 8 (5.0%) 5 (2.8%) 7 (8.2%)
Hb < 6 mmol/l n (%) 2 (0.5%) 54 (12.8%) 15 (9.3%) 25 (14.1) 14 (16.5%)
Hb: Haemoglobin, MCV: Mean Corposcular Volume, S.D.: Standard Deviation
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significantly higher risk for anaemia (RR 22.0, 95% CI 3–162) and an Hb below 
6.0 mmol/l (RR 25.8, 95% CI 6.3–105.3) at approximately 30 weeks of gestation. 
Mediterranean women had a higher risk for an Hb below the 5th percentile at around 
30 weeks of gestation compared with Northern European women (RR 4.8, 95%  CI 
2.5–9.5). They also had a higher risk of anaemia (RR 20.8, 95% CI 2.6–165.2), and an Hb 
below 6.0 mmol/l (RR 18.9, 95% CI 4.4–81.6) at approximately 30 weeks of gestation.
Black women had a higher risk for an Hb below the 5th percentile compared with 
Northern European women (RR 3.4, 95% CI 1.7–7.0). They also had a higher risk for 
anaemia (RR 13.9, 95% CI 1.7–114.9), and an Hb below 6.0 mmol/l (RR 28.6, 95% CI 
6.8–119.4) at approximately 30 weeks of gestation.
Other ethnic groups had a significantly higher risk of an Hb below the 5th 
percentile compared with Northern European Women (RR 8.7, 95% CI 4.5–17.0). 
They also had a higher risk for anaemia (RR 55.3, 95% CI 7.2–422.2), and an Hb below 
6.0 mmol/l (RR 33.4, 95% CI 7.7–144.1) at approximately 30 weeks of gestation.
transferred home delivery (thd)
According to local policy women with an Hb below 6 mmol/l were scheduled for a 
THD. This occurred in 26 women (3.1%): one was Northern European, seven were 
Mediterranean, 14 were Black and four were of other origins. 
The RR for a THD for non-Northern Europeans was high when compared to 
Northern Europeans (RR 24.1 95% CI 3.3–176.7). Within the group of non-Northern 
Europeans the RR for THD in Mediterranean women was 17.6 (95% CI 2.2–142.0), 
the RR for THD in Black women was 32.0 (95% CI 4.2–241.7), and the RR for THD in 
women of other origins was 19.5 (95% CI 2.2–172.4).
haemoglobinopathies
Due to the multicultural population in the practices studied, some women were 
investigated for HbPs regardless of the findings that were obtained following the 
guideline. Twenty-four women were found to have sickle cell trait and five women were 
found to be positive for thalassaemia, none of which were major. The blood results of 
six of these women warranted an investigation into HbPs because of uncorrected or 
unexplained anaemia. The MCV of three women with an Hb below the 5th percentile 
was not determined; nevertheless, they were investigated for HbPs and found to be 
positive. In total 234 women were investigated for HbPs.
discussion
This study confirms the impression held by midwives that Women of non-Northern 
European descent are a specific group in terms of anaemia, and that they are at 
high risk of a low Hb for all cut-off values. They have a higher chance of becoming 
anaemic in pregnancy, and this can result in different care due to the higher risk 
of THD for this group. This study clearly shows that this group warrants further 
attention when it comes to anaemia during pregnancy.
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methodological issues
Before interpreting the findings, the methodological issues of this study will be 
addressed. The study population was a representative sample of the population in 
highly urbanised areas in the Netherlands in terms of age and parity. The overall 
mean age of pregnant women living in highly urbanised areas is 29.9 years, whereas 
the mean age of the women in the study was 30.5 years (S.D. 5.8). Of all singleton 
pregnancies in the Netherlands, 47% are primiparous women.10 
The ethnic background of the population of pregnant women depends very much on 
the degree of urbanisation. In highly urbanised areas in the Netherlands, the percentage 
of Dutch pregnant women is 57%.10 The practices studied were all situated in highly 
urbanised areas. One area is specifically known for its population of African and Surinam 
origin. This explains the large numbers of pregnant Black women in the study.
The study population was divided into women of Northern European descent 
and women of Non-Northern European descent. The group of women of Non-
Northern European descent was a heterogeneous group. Therefore a stratified 
analysis for three subgroups was undertaken. The subgroup ‘others’ was also in 
itself heterogeneous. However this group was too small for further statistical testing, 
while omitting the group would have resulted in loss of information. The findings of 
this latter group should therefore be treated with some caution. 
Due to the retrospective nature of the study, it was difficult to complete all data 
which sometimes made it difficult to deduct the management of anaemia and actions 
taken from the records. One fifth of the women were excluded. This group consisted 
mainly of late bookers and women with a medical indication for secondary care. One 
practice had more exclusions than the other two practices. This practice is situated 
in an area of Amsterdam which is known for its large multicultural population as well 
as for its poverty. It is possible that a low SES played a role and may have introduced 
some selection bias, as it could very well be argued that women with a low SES are 
more likely to be anaemic. Recently Alderliesten (2006) confirmed that, amongst other 
factors, low levels of education and communication problems beyond language, such 
as cultural difference, are related to a late start of antenatal care.11 However due to the 
retrospective nature of the study, the presence of selection bias remains speculative.
The overall rate for anaemia was 3.4% at booking and 2.7% at approximately 30 
weeks of gestation. The difference between these values and the prevalence suggested 
by the guideline may be explained by the fact that there were insufficient data for 78 
women (9.4%) to determine whether or not they were anaemic. Insufficient data meant 
that either the MCV was missing or the Hb was not investigated further, despite being 
extremely low. If all of these 78 women with missing data were anaemic, the prevalences 
would be 9.1% at booking and 5.7% at approximately 30 weeks of gestation.
When antenatal care was started late, no significant difference was found in 
anaemia at booking. A possible explanation may be the low SES pathway described 
above. A late start for antenatal care is not just due to differences in ethnicity but is 
also related to education, age and communication problems with language barriers.11 
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transferred home delivery
The significantly higher risk for anaemia in women of non-Northern European 
descent was also reflected in their much higher risk for THD (RR 24.1, 95%CI 
3.3-176.7). These women were not able to choose their place of confinement; 
however, the numbers in this group are small, and this is reflected in the large CI. 
Of the 26 women who should have been scheduled for THD, the guideline was 
not properly used for 14 women. These cases might have been prevented. In most 
cases the risk factor for anaemia as specified in the guideline was not identified. 
If ethnic background was added to the guideline as a risk factor, this part of the 
guideline would need the attention of midwives. 
It is difficult to determine the consequences, if indeed there are any, of missing 
a risk factor with regard to the health of pregnant women and the management of 
labour. This should be further investigated. 
haemoglobinopathy
It has never been one of the aims of the guideline to screen and find all HbPs. 
However, they are found occasionally when pregnant women are anaemic and do 
not respond to treatment. It could be argued that in a multicultural population 
with a large percentage of women of Non-Northern European descent, (extreme) 
anaemias could be caused by HbPs. However, this study only found six women 
who were positive for HbPs on account of anaemia found during pregnancy. Three 
women had incomplete data, and the 20 women who were found to be positive for 
HbPs were investigated regardless of anaemia.
The risk of harm to the baby is obvious if both parents are HbP carriers4,5, and 
the clinical relevance of sickle cell disease or thalassaemia major is also evident. 
However, the clinical relevance for pregnant women of being an HbP carrier is 
not immediately obvious, as not all carriers develop anaemia in pregnancy. If a 
non-Northern European pregnant woman has an adequate Hb, the question arises 
whether or not there is any harm in not knowing her HbP status? 
It could be argued that if the HbP status of pregnant women was known at an 
early stage in pregnancy, couples could receive adequate counselling and certain 
anaemias could be better managed. Women could circumvent an unnecessary long 
route of finding out the cause of an extreme low Hb that has been allowed to 
develop in pregnancy, which may have been prevented by timely investigations and 
simple folate supplements. However, further research is necessary to substantiate 
this theory.
Key conclusions and implications for practice
In view of the substantial differences found for pregnant women of non-Northern 
European descent with regard to low Hb and anaemia, special attention should be 
given to ethnicity when the guideline is revised. 
Although the clinical relevance of knowing HbP carrier status in pregnant women 
is not clear, this can cloud the management of anaemia. Therefore midwives need 
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to give this issue more attention and should be more aware of its influence on the 
reproductive lives of women. 
The guideline should be revised to enable midwives to give adequate and 
customised care to women of non-Northern European descent. It is evident from 
this study that women of non-Northern European descent have a higher risk for 
anaemia in pregnancy and there for need extra attention with regard to this issue.
Knowledge of HbP status at an early stage in pregnancy could be an advantage 
in the outcome of pregnancy in several ways. Earlier attention to the possibility of 
anaemia in pregnancy can prevent extreme low Hb levels in this group, and give 
these women equal opportunities in their choice of place of birth.
However the true background behind the fact that women of non-Northern 
European descent have a higher risk of anaemia in pregnancy is not only determined 
by knowing the HbP status. Further research by midwives into the reasons behind 
this higher risk is necessary.
Being of non-Northern European descent should be added as a risk factor for 
anaemia in pregnancy until more is known about the background of this risk-factor.
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abstract
With the introduction of screening programmes for haemoglobinopathies (HbP), 
more women will be aware of their HbP status. The genetic risk for women who 
are carriers of HbP is well known. However, midwives and obstetricians need to 
know whether there are other risks involved in the pregnancies of women who are 
carriers of HbP. The objective of this study was to investigate the hypothesis that 
being a carrier of HbP has no consequences for the health of pregnant women 
and the outcome of their pregnancies. A systematic search was carried out until 
August 2008 in the Cochrane Library, Medline, EMBASE and CINAHL databases. 
All references were inspected to identify further studies. The authors of key 
publications were contacted for any unpublished research. Selection of studies 
was made on the basis of the following criteria: Cohort and case-control studies, 
pregnant women with a singleton pregnancy, exposure: HbAS or thalassaemia minor 
and the following outcomes: urinary tract infection (UTI), anaemia, (pre-)eclampsia, 
gestational diabetes, premature labour, low birth weight, intrauterine growth 
retardation, miscarriage, neonatal death, low Apgar score, neural tube defects. 
Quality assessment and data extraction were carried out by two researchers. A 
total of 780 subjects were identified of which nine were included in the study. A 
protective effect of sickle cell trait was found for premature birth, low Apgar score 
and perinatal mortality rate. No significant effect was found for low birth weight, 
growth retardation, UTI or high blood pressure. The risk of anaemia and bacteriuria 
was increased. In conclusion, the risks amongst pregnant HbP carriers are low. 
Midwives and obstetricians need to be aware of the risk of anaemia and UTI.
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introduction
It is generally accepted that the pregnancy of a woman with homozygotic 
haemoglobinopathy (HbP) disease and some double heterozygous conditions, 
such as HbSC and HbS-β-thalassaemia, carries a higher risk. While the genetic 
implications of HbP carrier status are clear, the effect if any, on the outcome of 
pregnancy remains subject to debate. 
Thalassaemia minor (carriers) constitutes of alpha and beta defects and some 
rare exceptions.1 The most well known of the structural defects is HbS, like beta 
thalassaemia this is a beta gene defect that is non-active in the fetus until birth.
 Over the years, several studies on the effect on pregnancy have been published 
but provide inconsistent conclusions. Some studies suggest an increased risk for 
adverse perinatal outcomes2-4 whereas others cannot confirm this risk.5-9 Pregnant 
women with homozygotic HbP disease need to be referred to a tertiary care centre. 
Pregnant women who are (known) HbP carriers are usually considered low risk as no 
risks for their health or the outcome of their pregnancies are assumed. However, it 
remains unclear whether these women have special needs during pregnancy. As far 
as we are aware, no systematic review has been conducted on this subject. 
Screening for sickle cell disease has been added to the existing neonatal 
screening program in several countries, such as the Netherlands and England. If 
a baby has been diagnosed with sickle cell disease or thalassaemia major or is a 
carrier, the parents will be offered genetic screening tests to confirm their carrier 
status which will then enable them to make appropriate reproductive choices 
concerning any subsequent pregnancies. Midwives and obstetricians will therefore 
increasingly encounter women who are aware of their HbP carrier status. The 
prevalence of an HbP carrier status is currently estimated to be 4-14% amongst 
people with non-Northern European background in the Netherlands10 and according 
to the World Health Organisation approximately 5% of the world population is a 
carrier of a significant variant of haemoglobin disorders such as sickle cell disorders 
or thalassaemias with as many as 40% carriers in some regions.11 It is therefore 
important that midwives and obstetricians are aware of any potential risks among 
HbP carriers during pregnancy.
In this systematic review we will address the possible risks for pregnant HbP 
carriers and investigate the hypothesis that being an HbP carrier has no consequences 
for the health of pregnant women and the outcome of their pregnancies. 
Methods
With the aid of a librarian, we searched the Cochrane Library; Medline; EMBASE 
and CINAHL databases for publications in English, French, German, Spanish and 
Dutch, examining the effect of sickle cell trait (SCT) and/or thalassaemia minor on 
maternal morbidity or perinatal morbidity and mortality. 
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The search was not restricted by publication date and was carried out until 
august 2008. We only searched for (prospective and retrospective) cohort studies 
and case control studies.
Keywords used were: Pregnant women, sickle cell, sickle cell trait, sickle cell anaemia, 
sickle cell disease, thalassaemia, heterozygote thalassaemia, haemoglobinopathy, 
abnormal haemoglobines, pregnancy outcome, complications of pregnancy, urinary 
tract infections, iron deficiency anaemia (IDA), folic acid deficiency anaemia, (pre-)
eclampsia, gestational diabetes, premature labour, low birth weight, miscarriage, 
fetal / neonatal death, low Apgar score and neural tube defects.
We inspected the references of all studies found to identify any further studies. 
The authors of key-publications were contacted for any unpublished research.
The initial selection of studies by title and abstract was carried out by one reviewer 
(SJ) based on its relevance to the research question and, if possible, by the inclusion 
criteria (Table 1). The studies found were assessed and scored by two independent 
reviewers (SJ and AdJ). Details of authors, affiliated institutions, journal name, and 
year of publication were removed for the second reviewer. 
Selection for inclusion into the review was made on the basis of in- and exclusion 
criteria and quality assessment. The use of checklists is disputed by some.12 Sanderson 
et al.13 highlighted the lack of existence of an adequate tool, but he nevertheless 
table 1. Inclusion criteria
inclusion criteria
types of studies
All observational (prospective and retrospective) cohort studies and case control studies 
examining the effect of sickle cell trait and/or thalassaemia minor on maternal morbidity 
and neonatal morbidity and mortality.
types of participants
Pregnant women with singleton pregnancy.
types of exposure
Sickle cell trait or heterozygous α-/β-thalassaemia or homozygous α+ thalassaemia 
versus no trait or no thalassaemia. Sickle cell trait is defined as the presence of HbAS. 
Carrier ship of thalassaemia is defined as α+-thalassaemia heterozygote; α0-thalassaemia 
heterozygote; α+-thalassaemia homozygote or β-thalassaemia heterozygote. 
types of outcome measures
Urinary tract infections
Iron deficiency anaemia 
Folic acid deficiency anaemia
(Pre-) eclampsia 
Gestational diabetes 
Premature labour
Low birth weight 
Intra uterine growth retardation
Spontaneous abortion 
Fetal / neonatal death 
Low Apgar score 
Neural tube defects
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advised to use a simple checklist rather than a scale and concluded that it is 
important to use a small number of key domains for quality assessment. We decided 
to use the guidelines for assessing the quality of observational and case control 
studies as defined by the Dutch Institute for Healthcare Improvement to support 
our quality assessment.14 These include all the elements mentioned by Sanderson 
et al.13, and have been carefully developed by the institute in collaboration with the 
Dutch Cochrane Centre and are generally accepted as adequate in the Netherlands 
(Table 2). We awarded a maximum of two points for each item on the list, meaning 
that each study could score a maximum of 16 points. We excluded any study which 
obtained a score of < 12 points. This high cut-off point was chosen because almost 
all studies automatically scored high on ‘adequate follow-up’ and ‘selective loss-
to-follow-up’. Some authors were contacted for clarification of the study methods. 
Data were extracted independently from the included studies by two 
investigators (SJ and AdJ) on study design, population and setting, screening 
method, exposition, outcome variables, confounders and point estimates. 
Differences were resolved by discussion.
table 2. Quality assessment
Quality assessment criteria
(The Dutch Institute for Healthcare Improvement (CBO) www.cbo.nl) 
Each item scores 0 to 2 points:
- Were the groups that were compared clearly identified?
- Could selection bias be sufficiently excluded?
- Was the exposure factor clearly identified and was the method for assessing the 
exposure factor adequate?
- Was the outcome clearly identified and was the method for assessing the outcome
 adequate?
- Was the outcome assessed blinded for the exposure factor?
- Was the follow-up adequate?
- Could selective loss-to-follow-up be excluded?
- Were the most important confounders identified and was correction for the 
 confounders carried out?
(Statistical) analysis
We used population (ethnicity), exposition, screening method and (definition of) 
outcome variables to assess clinical heterogeneity. Study design, confounders and 
point estimates were used to assess methodological heterogeneity. Confounders 
were assessed for all separate outcomes. 
Both clinical and methodological homogeneity could not be established; 
therefore after consultation with a statistician, we decided not to pool the results.
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resuLts
We initially identified 780 studies from which we selected 91 titles (fig.1). After 
screening the abstracts, we read 36 papers. By inspecting the references of these 
papers, we identified a further 30 studies of which nine studies were read and 
assessed. Contact with the authors provided one additional study which was only 
available as a (PhD-) thesis.15 In total 46 studies were assessed for methodological 
quality. The two reviewers disagreed on six out of 46 studies (13%). Consensus was 
reached by discussion. 
Fig. 1 Flowchart of search 
  
 
 
 
 
 
 
 
 
 
 
 
 
 780 titles identified 
Initial selection by first author 
689 titles excluded for following reasons: 
Study not related to pregnancy or research 
design did not match inclusion criteria in 
research protocol 
 91 abstracts were assessed 
 Snowball method of references and 
author contact yielded another 31 
titles  
37 studies excluded: did not 
match inclusion criteria as per 
protocol or failed quality 
assessment 
 
In Total 36 + 9+1 full studies 
assessed by two researchers  
55 abstracts excluded for following reasons: 
Not related to pregnancy or not according to 
inclusion criteria as per protocol. 
9 studies included into the review 
21 abstracts excluded 
Taylor 20064, Switzer and Fouche 194836, Whalley 19639, Roopnarinesingh 19863, Hoff 198337, Lam 199938, 
Landman 198539, Miller 198340, Okunofua 199041, Thurman 200642, White 198543, Lao 200144, Abrahams 195945, 
Balgir 199746, Tuck 198347, Whalley 196448, Ssebabi 197749, Roopnarinesingh 198650, Rimer 197551, Ibba 200352, 
Hamdi 200253, Cooley 198454, Brown 197255, Blattner 197756, Pearson 196957, Pritchard 197358, McCurdy 196459, 
Morrison 197960, Pakes 197061, Pastore 199962, Whiteside 197363, Pastore 199964, Hoff 200165, Sheiner 200466, 
Lewis 1982 67, White 198668.  
 
fig. 1 Flowchart of search
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Nine studies on HbAS met the inclusion criteria and scored 12 points or more and 
therefore were of sufficient methodological quality to be included in the review. Only 
one of these studies investigated the effect of thalassaemia minor on pregnancy.15 
premature birth/(low)birth weight (lbW)/intra uterine growth retardation 
(iugr)
None of the studies into premature birth stated whether the expected date of delivery 
was confirmed by ultrasound scan (Table 3). Bryant et al.16 showed a significant protective 
effect for delivery before 32 weeks in women with SCT, whereas Tita et al.8 showed 
a protective effect for deliveries at < 37 weeks gestation. Stamilio et al.7 showed no 
difference between the two groups. The prospective cohort study of Landman15 found 
that HbP carriers had a smaller but non-significant risk of a premature delivery.
The prospective cohort study by Larrabee and Monga17 only looked at the mean 
gestational age and showed a significant reduction in the length of gestation by 1 
week in women with SCT. 
None of the four studies examining the risk of low birth weight in infants of 
women with SCT showed a significant effect2,5,7,8 (Table 3).
Four studies5,8,15,18 looked at IUGR (Table 3). Two studies stated that dates were 
confirmed by ultrasound scan and only Tan et al.18 and Landman15 gave a clear 
definition of IUGR. Tita et al.8 supplied the definition of IUGR and Landman15 
confirmed dating by ultrasound scan when contacted. None of the studies found 
any effect of HbP carrier status on the risk of IUGR.
risk of urinary tract infection (uti) and pyelonephritis:
None of the three studies into the risk of UTI in pregnant women with SCT showed 
an increased risk2,5,15 (Table 4). In only one study, a definition of UTI was given15. 
Two studies showed a small but statistically significant increased risk for bacteriuria 
in pregnant women with SCT8,19 and in one of them the risk of pyelonephritis was 
also increased.19
iron deficiency anaemia and folate deficiency
Only three included studies looked at anaemia in pregnant HbP carriers2,5,15 (Table 4). 
None of them took physiological haemodilution into account. Adeyemi et al.5 did not 
give a definition of IDA and found no statistically significant difference between groups. 
Abdulsalaam et al.2 found significantly more anaemia in the HbAS group. Landman15 
found a difference between groups when IDA was found in combination with folate 
deficiency. A significantly higher percentage of anaemia with an Hb ≤ 90 g/l was found 
in the HbAS group (5.5% vs. 3.6%, p=≤0.05). Looking at the specific causes of anaemia, 
IDA occurred more often in the control group but this difference was not statistically 
significant. A combined iron and folate deficiency occurred significantly more frequently 
in the HbAS group. The group with thalassaemia trait had less IDA but this was not 
statistically significant. Folate deficiency and combined iron and folate deficiency 
occurred more in the thalassaemia group but this was not statistically significant. 
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table 4. Urinary Tract Infection / anaemia
first author
country
Study design
year of 
publication
n
population
Setting
definition of 
outcome exposure
uti
point estimate
(ci / p-value)
anaemia
point estimate
(ci / p-value)
Adeyemi5
Nigeria
Prospective 
cohort study
2006
420
African
University 
hospital
No definition 
given
HbAS (210)  
vs HbAA(210)
9(4.3) vs 9(4.3)
p: 1.00
6(2.9%) vs 
9(4.3%) 
(p: 0.61)
Abdulsalaam2
Syria
Prospective 
cohort study
2003
500
Palestinian 
refugees
Health clinics 
(primary care 
setting)
No definition 
given
HbAS (98)  
vs HbAA(402)
RR = 1.03
(CI:  0.3 – 3.6)
7(7.1) vs 9(2.2)
(p: 0.022)
Tita8
USA 
Retrospective 
cohort study
2007
35743
African 
American
Univ hosp
Bacteriuria: 
Positive urine 
culture at 
booking
HbAS (3019)  
vs HbAA 
(32724
AOR = 1.4
(CI: 1.2 – 1.5)
Bail19
USA
Retrospective 
cohort study
1990
1828
No information 
on ethnicity 
given
University 
hospital
Bacteriuria: 
>100.000 / 
ml MSU
HbAS (914)  
vs HbAA (914)
OR 1.4
(p: 0.011)
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Landman15
Netherlands
Prospective 
cohort study
1988
1662
Blacks
Asians
Mediterraneans 
2 University 
hospitals
2 Peripheral 
hospitals
Iron 
Deficiency 
Anaemia
Hb < 110 g/l 
and Serum 
ferritine 
<15μg/l
Or
Hb<110g/l 
and low 
serum iron 
level and 
responsive to 
iron therapy
Or
Hb< 
110g/l and 
reduction 
in MCV and 
responsive to 
iron therapy
Combined 
folate and 
IDA
HbAS (73)  
vs HbAA (83)
ß-thal 
heterozygote 
(40)
vs controls 
(160)
α-thal trait 
(8) vs Asian 
controls (77)
Homozygote 
α-thal.2 (8) vs 
Black controls 
(83)
HbAS (73) vs 
HbAA (83)
ß-thal 
heterozygote 
(40)
vs controls 
(160)
α-thal trait 
(8) vs Asian 
controls (77)
Homozygote 
α-thal.2 (8) vs 
Black
controls (83)
9.6% vs 7.2%
(ns)
7.5% vs 9.4%
(ns)
- vs 11.7%
12.5% vs 7.2%
(ns)
30.2% vs 
54.2% 
(ns)
15%  vs 53.8% 
(ns)
25.0% vs 
53.2%
(ns)
37.5% vs 
54.2%
(ns)
20.6 %  vs 
4.8 % 
(ns)
12.5 % vs 5.0% 
(p: <0.05)
- vs 5.2%
(ns)
25.0% vs 2.4%
(ns)
SCT: sickle cell trait, OR: odds ratio, AOR: adjusted odds ratio, RR: relative risk, CI: confidence interval, 
p-value significant if <0.05, ns: not significant, UTI: urinary tract infection, MSU: mid stream specimen 
of urine.
high blood pressure: pregnancy induced hypertension (pih) and pre-
eclampsia (pe)
Three studies5,8,15 investigated the relationship between being an HbP carrier and 
PIH of which two8,15 gave a definition of PIH (Table 5). None of the three studies was 
able to demonstrate a significant effect.
Four studies2,7,8,17 looked at pre-eclampsia of which only one17 found a significantly 
increased risk for PE in women with SCT.
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miscarriage, fetal and neonatal death 
Three studies into the risk of fetal and neonatal death found opposite effects but 
none of these were significant2,5,8 (Table 5). Another study15 found only one case in 
the control group (results not in table).
Two studies investigated the effect of SCT on stillbirths alone.5,8 These studies 
showed a protective effect but in one this was not significant.5 
Tita et al.8 found a very small non-significant reduction in fetal death. No studies 
examined the risk of miscarriage.
low apgar score
Two studies looked at the Apgar score (Table 5).5,15 One study showed a decreased 
incidence of low Apgar scores among women with HbAS5 and another study showed 
an insignificantly increased risk15. 
gestational diabetes and neural tube defects
None of the included studies examined the effect of HbP carrier status on 
gestational diabetes or neural tube defects.
discussion
As far as we know, this is the first systematic review that examines possible risks 
of pregnant women who are HbP carriers. Besides the obvious need for genetic 
counselling, it is important for midwives and obstetricians to be aware of any risk 
factors if these do exist. 
Some studies showed a protective effect of SCT for premature birth, low Apgar 
score and stillbirth: there was some evidence of an increased risk of anaemia and 
bacteriuria. No significant effect of HbP carrier status was found on low birth weight, 
growth retardation, UTI or high blood pressure. 
These results should be interpreted with caution because of several 
methodological problems. All studies gave adequate definitions of the exposure 
factor and of the population under investigation; however, many authors failed 
to give adequate definitions of the outcomes assessed in their studies and they 
often did not control for confounders such as socio-economic status (SES). In some 
studies7,8,16,20 it was not clear how the expected date of delivery was calculated 
and if this was confirmed by ultrasound scan. Nevertheless, considering the time 
frame and the setting in which the studies took place (academic hospitals), it could 
be assumed that women had an ultrasound scan to assess the expected date of 
delivery. However, in view of the fact that only one author8 was able to confirm this 
when contacted, we need to be cautious with the overall conclusion.
In some studies7,17 ethnicity was poorly defined and SCT may therefore have 
been underreported resulting in considerable bias.
The testing method to confirm carrier status was a problem in most studies. Only 
two studies used adequate methods that identified the presence of thalassaemia.15,18 
Outcomes amongst pregnant HbP carriers
3
61
The other studies used a sickle cell test and / or electrophoresis to establish HbP 
status of pregnant women. Two studies tested all women with a sickle test and 
confirmed only the positive women with electrophoresis.7,17 According to The British 
Committee for Standards in Haematology (BCSH) a sickle test may not detect low 
levels of HbS and should only be used in an emergency (http://www.bcshguidelines.
com). Carriers may have been missed in these studies giving rise to further bias. 
According to the BCSH, electrophoresis is not recommended for the quantification 
of HbA2 necessary to establish carrier status of thalassaemia: HPLC or micro column 
chromatography should be used.21 Most studies did not specifically state whether 
other fractions such as HbAC, HbAE or any of the thalassaemias were found and 
whether or not they were excluded. With the exception of two studies15,18 none of 
the studies gave any information on the co-existence of HbS and thalassaemia. 
Many people of Afro-Caribbean descent with HbAS have a combination of HbAS 
and α-thalassaemia. High HbA2 β-thalassaemia or any other trait found in early 
pregnancy and suspected to be associated with thalassaemia major, sickle cell 
disease or with other severe pathologies, should be confirmed at DNA level in 
particular when a couple at risk is suspected.22 
protective effect
A protective effect was found for preterm labour in carriers of HbP. However in view of 
the many methodological pitfalls, the conclusion of a protective effect is only tentative. 
Besides, the patho-physiological pathways underlying these results are unclear. 
In order to find a significant effect on stillbirth or perinatal mortality, a large 
population needs to be studied. Only Tita et al.8 investigated a large group of 
women and found a small reduction in perinatal mortality and stillbirth which was 
borderline significant. Apart from chance playing a role in this study, the antenatal 
policy of serial urine culture and the reduction in premature labour may also have 
had an effect on the rate of perinatal mortality. 
Two studies found opposite effects on stillbirth.2,5 Consanguinity may have 
played a role in the study which found an increased risk.2 Bittles23 showed that 
consanguinity is responsible for 4,4% of deaths between 6 months of pregnancy 
and 10 years of age. The other studies did not take consanguinity into account. The 
effect may be particularly important in studies carried out in the Middle East where 
the incidence of consanguine marriages is relatively high.24
HbP carrier status appears to offer a small protective effect on perinatal mortality. 
However the patho-physiological mechanism behind this remains unclear and in 
view of the methodological flaws, the results remain questionable.
no effect
No statistically significant difference was found for the risk of low birth weight (as a 
result of prematurity or growth retardation). Two of the studies were carried out in 
developing countries where both the health care standards can differ considerably 
and the population may have different needs than those in developed countries.25 
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As both a poor nutritional status and anaemia increase the risk of low birth weight26, 
a difference based on HbP status may not have been detected. On the basis of 
these studies, it cannot be concluded that HbAS has any effect on the risk of low 
birth weight. We found no increased risk of intra uterine growth retardation among 
women with a positive carrier status for HbP. 
Only Larrabee and Monga17 found a significantly higher risk of both (pre-) 
eclampsia and pregnancy induced hypertension in women who are a carrier of 
SCT. Other studies found no significant differences.2,5,7,8,15 This could be due to 
methodological problems as discussed earlier. None of the authors corrected 
for maternal weight in their study. We conclude that the relation between HbP 
carrier status and the risk of (pre-) eclampsia or pregnancy induced hypertension 
is inconclusive. Further studies are urgently needed to shed light on this issue. 
Especially since hypertensive disorders in pregnancy are the leading cause of 
maternal death in the Netherlands27, rank fourth place in the United Kingdom28 
and are the second direct cause of maternal death in the United States of America 
(http://www.mchb.hrsa.gov). Moreover, a recent study carried out in the Netherlands 
showed that non-Western immigrant women had a 1.3-fold increased risk of severe 
maternal morbidity, including PIH, when compared with Western women.29
increased risk
The generally accepted claim that pregnant sickle cell carriers have a higher 
risk of UTI in pregnancy30,31 could not be substantiated in this review. Two of the 
three included studies2,5,15 failed to give a definition of UTI which may have led to 
classification bias. 
Although we could not confirm an increased risk for UTI in the pregnancies of 
HbP carriers, we did find an association between sickle cell trait and an increased 
risk of bacteriuria in two studies.8,19 Treatment of asymptomatic bacteriuria reduces 
the risk of pyelonephritis in pregnancy.32 
Surprisingly, only three studies were included which investigated the risk of 
anaemia amongst pregnant women with an HbP-trait. It is generally accepted that 
a positive carrier status for HbP can give rise to anaemia in pregnancy32; however 
this has not been very well investigated. Although the overall consensus seems to 
be that SCT is asymptomatic and thalassaemia minor may cause mild microcytic or 
hypochromic anaemia in the general population at risk33 (http://www.thalassaemia.
org.cy), this systematic review shows that few investigators have adequately studied 
the effect of HbP carrier status on anaemia in pregnancy. Small numbers in all three 
studies may be the reason that little or no effect was found. 
Despite the limited power, Landman15 found that women with HbAS or 
ß-thalassaemia trait have a higher chance of having a combined iron and folate 
deficiency anaemia. This study did not take confounders for anaemia into account, 
such as twin-pregnancy, poor dietary habits or a low socio-economic status (SES) 
and the study was carried out amongst a high risk population which may have 
included women that were already referred because of an increased risk of anaemia.
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Abdulsalaam et al.2 did not use anaemia as an outcome measure but instead 
used it as a risk factor for the outcomes to be studied and subsequently found 
a significantly increased percentage of women with HbAS that were anaemic. 
Whether this is due to iron and/or folate deficiency was not clarified in this study. It 
is possible that women who were sickle cell carriers had in fact a combination of SCT 
and α-thalassaemia which was not investigated. It is very likely that a higher risk of 
anaemia amongst HbP carriers is caused by the (combined) effect of thalassaemias 
as these are known for ineffective erythropoiesis which in pregnancy because of 
the increase in blood volume, could result in more pronounced anaemia especially 
in the second trimester. Because of the disturbed Hb synthesis in HbP carriers, it is 
very likely that extra folic acid is needed. This may very well be the reason that most 
textbooks30,31,34 recommend supplementing these pregnant women with folic acid. 
However we found no study that investigated and confirmed this theory.
Besides this, a recent study found that women of Non-Northern European 
descent had a significantly increased risk of becoming anaemic in pregnancy.35 The 
researchers were not able to identify the cause of this increased risk. In view of the 
evidence found in this systematic review the increased risk could partly be explained 
by women who are a carrier of HbP. 
concLusion
In conclusion, the findings of this study show that pregnant women who are HbP 
carriers have a low risk of adverse outcomes of pregnancy. In expectation of 
further research on this subject, midwives and obstetricians should be aware of 
the possibility of anaemia, asymptomatic bacteriuria and the subsequent risk of 
pyelonephritis and investigate pregnant women who are known HbP carriers more 
frequently for these conditions. 
If carrier status of these women is known and anaemia is present, the cause 
of it should be investigated further before any treatment is started. Each woman 
should be correctly diagnosed and be offered partner testing if necessary so that 
she can make a well informed reproductive choice in order to avoid unexpected 
outcomes. It also remains important that women with SCT or thalassaemia minor 
are given correct advice on how this will affect their pregnancy and be reassured 
that it will not increase their risk of developing complications during pregnancy or 
shortly thereafter. We found no reason at present to refer pregnant women who are 
a carrier of HbP to a high risk setting. 
This study highlights the lack of evidence of the effect of a positive HbP status 
on the outcome of pregnancy and the need for large, well controlled prospective 
studies. With routine investigations into HbP becoming more standard in many 
countries, it will become easier to conduct further research to thoroughly investigate 
any possible effect that this may have on pregnancy.
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abstract
objectives: In 2007 neonatal screening was expanded to include screening for sickle 
cell disease and beta-thalassaemia. Up until that year no formal recommendations for 
haemoglobinopathy (carrier) screening existed in the Netherlands. Although it has 
been subject to debate in the past, preconceptional and prenatal haemoglobinopathy 
carrier screening are not part of routine health care in the Netherlands.
This study aimed to explore the decision-making process of the past: why was 
the introduction of a screening programme for haemoglobinopathy considered 
to be untimely and did ethnicity play a role given the history in other countries 
surrounding the introduction of haemoglobinopathy screening.
design: A witness seminar was organised, inviting key figures to discuss the decision 
making process concerning haemoglobinopathy screening in the Netherlands, 
thereby adding new perspectives on past events. The transcript was content analyzed.
results: The subject of haemoglobinopathy screening first appeared in the 1970’s. 
As opposed to a long history of neglect of African-American health in the United 
States, the heritage of World War II influenced the decision-making process in the 
Netherlands. As a consequence, registration of ethnicity surfaced as an impeding 
factor. However overall, official Dutch screening policy was restrained regarding 
reproductive issues caused by fear of eugenics. In the 1990’s haemoglobinopathy 
screening was found to be “not opportune” due to low prevalence, lack of 
knowledge and fear of stigmatisation. Currently the registration of ethnicity remains 
on the political agenda, but still proves to be a sensitive subject. 
discussion: Carrier screening in general never appeared high on the policy agenda. 
Registration of ethnicity remains sensitive caused by the current political climate. 
Complexities related to carrier screening are a challenge in Dutch health care. 
Whether carrier screening will be considered a valuable complementary strategy 
in the Netherlands, depends partly on participation of representatives of high-risk 
groups in policy making.
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introduction
Haemoglobinopathies (HbP), such as sickle cell disease (SCD) and thalassaemia, are 
serious autosomal recessive disorders characterised by severe anaemia, variable 
but severe and debilitating morbidity and a shortened lifespan. In the past HbPs 
occured more frequently in areas where malaria is or was endemic, such as Africa, the 
Mediterranean area, the Middle East and South-East Asia, but they are now common 
in most countries worldwide due to increasing migration.1 Globally approximately 
5% of the population is a carrier of a significant variant of haemoglobin disorders 
with as many as 40% carriers in some regional populations.2 The prevalence of a 
positive carrier status of HbP in the Netherlands has been estimated at 4-13.6% 
depending on ethnic background.3 The birth prevalence of severe hereditary HbP in 
the Netherlands was 64 infants in 2007 among 182.000 total births.4 
Parents who are both carriers of HbP, have a one in four chance in each 
pregnancy of giving birth to a child affected with the disease. Carriers can be 
identified by simple blood tests (Hb-electrophoresis or High Performance Liquid 
Chromatography (HPLC)). Couples could then be informed about their risk, 
preferably before pregnancy. 
The first HbP screening programmes were developed during the 1970’s in 
Mediterranean countries such as Italy, Cyprus and Greece and were aimed at 
thalassaemia. The United States (US) introduced SCD in neonatal screening 
programmes in some states in the 1970’s but screening became more widespread 
after publication of the consensus document of the National Institutes of Health 
(NIH) in 1987.5 In the United Kingdom (UK) the NHS Sickle Cell and Thalassaemia 
Screening Programme was the first service in the world aiming to link antenatal 
and neonatal screening. The programme was officially launched in 2001 (http://sct.
screening.nhs.uk/accessed 26 May 2011). 
In 2006 the WHO urged member states to increase the awareness of sickle 
cell anaemia and to develop systematic and comprehensive programmes for 
the screening of (the carrier status of) SCD.6 HbP programmes based on these 
recommendations have been developed in several other countries both in and 
outside Europe and in low, middle and high income countries.7 
In the Netherlands HbP screening did not attract much attention on a national 
level until 1994 when a report was commissioned by the Consultative Committee 
Minorities of the Department of Health investigating the possibility of introducing 
a screening programme for HbP.8 On the basis of a low prevalence of HbP, fear of 
stigmatisation of carriers, lack of knowledge amongst both professionals and those 
at risk the authors concluded that introducing a screening programme was “not 
opportune” at that time.9 
Carrier screening in general never appeared high on the policy agenda in the 
Netherlands. At the moment of performing the Witness Seminar (July 2009) the 
National Screening Programme in the Netherlands did not include carrier screening 
of any type of genetic disorder and public discussion on the subject was also absent. 
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The programme does include cascade screening for familial hypercholesterolaemia 
(FH), screening for neural tube defects in pregnancy (since 2007) as well as trisomy 
21 for women above the age of 36 and neonatal screening (NNS). In contrast to 
SCD, cystic fibrosis (CF) was not included in the NNS until 2011. The discussion 
about CF has mainly been dominated by the suboptimal specificity and the fact 
that the mutation panel has a different sensitivity for amongst others the Turkish 
population as compared to western Europeans. 
As a result of the discussions on HbP in the 1990’s and in the absence of 
community pressure or sufficient patient demand, no public information on testing 
for HbP (or the carier status) has been available in the Netherlands before 2007. 
Until that time testing was only carried out on the basis of unresolved anaemia or 
established familial risk.10-13 
Information was only available through non-governmental patient organisations. 
Following a 2005 Health Council report, the NNS programme was expanded in 2007 
including screening for SCD.14 The primary aim of this screening was to identify SCD 
patients so that early complications of this disease could be prevented. As a result of 
discussion at the start of the expanded NNS programme it was decided to report on 
alpha- and beta-thalassaemia as well. For beta-thalassaemia, optimal sensitivity in the 
laboratory is pursued. Identifying other HbP is not official policy but remains subject 
of debate. If a case of HbH disease or other relevant HbP is diagnosed in the NNS 
programme, the result is reported to the parents because it is clinically relevant, although 
unintentionally found. Screening also leads to unsought identification of carriers. Parents 
may opt out from receiving information on carrier status of their child by ticking a box 
on the test card. In a survey 62 out of 3200 parents (1.9%) indicated to have opted 
out.15 Those parents whose child is found to be a carrier of HbS (other carrier states are 
not communicated) are invited by their family doctor to be tested to allow for possible 
reproductive choices in subsequent pregnancies. However in 2007 only 20 parents of 
the 806 children with HbS carrier status were referred for genetic counselling, whereas 
based on a carrier prevalence of 10%, 80 carrier couples were expected.16 
In 2007 the Health Council of the Netherlands published a report on the subject 
of preconception care17 recommending a pilot study on carrier screening for HbP 
(and Cystic Fibrosis); however, to date no governmental advice has been issued to 
introduce a broad preconceptional screening programme for HbP.
In the US, social activism surrounding race relations and disease dramatically 
altered the issues of race and health because affected minority groups came together 
themselves to challenge many mainstream assumptions.18 Previously the top-down 
implementation of a screening programme met with opposition; the racial identity of 
white patients was questioned, social concerns about the interbreeding of races were 
voiced.19 The community of African Americans viewed screening with suspicion and 
as part of the long history of interference with self-determination.20 Indeed according 
to Wailoo and Pemberton “(…) every aspect of SCD in the United States speaks 
to the problem of race and the social condition of African Americans”.20 Although 
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screening for SCD has been accepted since the 1980’s, screening for carrier status 
has been the cause of ongoing controversy. Most recently marked by discussion of 
the testing of recruits to the US Armed Forces and professional athletes.21-23 
In the UK it took considerable effort by the community and health professionals to 
attract policy interest. They had to overcome barriers of inequality and (institutionalised) 
discrimination before positive results were achieved by exerting political pressure on 
the relevant agencies.24 Given the history in the US and the UK, it was questioned 
whether Dutch policymakers and (health) professionals were aware of the issues of 
discrimination and stigmatisation thus causing hesitation about the introduction of 
a screening programme in the Netherlands. It is not apparent whether elements of 
the history and discussions in both the US and UK had any (indirect) influence on the 
Dutch discussion in the 1980’s and 1990’s. It would be interesting to perform a case 
study focussing on a country other than either the US or the UK to investigate the 
agenda setting of a disorder with differential sensitivities in different ethnic groups 
and with a growing prevalence due to a still increasing group of immigrants and their 
descendants. This is especially relevant in the light of the fact that the 2007 expansion 
of the neonatal screening programme has raised the discussion whether or not a 
carrier screening programme should be introduced in the Netherlands, renewing the 
discussion which followed the publication of the report in 1994.25-28 
While it would be interesting to make a comparison with the history of the US 
and the UK, to do so would go far beyond the scope of this study. Attention often 
focuses on the experience of these two countries whereas the Dutch situation is 
essentially different. Because programmes such as the ones in the US and the UK 
cannot automatically be transposed to other countries, we prefer to concentrate on 
the case history of the Netherlands. Although references are made to the history and 
situation of these two countries, we explicitly did not aim to carry out a comparative 
study. The aim of this study was to explore why and when the issue of preconception, 
antenatal or neonatal testing of asymptomatic persons at risk of HbP did or did not 
receive any attention on the agenda of the Dutch public health authorities. To what 
extent was this influenced by the political climate at the time and potentially deep-
seated concerns about the role of ethnicity and the fear of discrimination? 
Methods
Witness seminar
The formulated research questions were investigated using a witness seminar. This 
method was developed by the Institute of Contemporary British History (ICBH) as a 
special form of oral history, in which several experts, researchers and policymakers 
who each have been associated with a particular set of circumstances or events, are 
invited to meet in order to explain and debate their recollections of a certain time 
period and subject (www.ccbh.ac.uk/witnessseminars.php, accessed 11 Oct. 2010). 
This enables researchers to elaborate on developments in the past and on traditional 
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sources of historical research such as the existing literature. The advantage of using 
this method to investigate the subject of (the absence of) HbP screening in the 
Netherlands is that it may generate a better understanding of the original definition 
of the problem, the collaborative relationships and the controversies. Apart from 
supporting the current discussion with new background material, this method 
further enables exploration of possible barriers against the introduction of a broader 
screening programme for HbP and other ethnicity related disorders. 
preparations
The Dutch literature, both scientific and grey literature (information produced on 
all levels in electronic and print formats not controlled by commercial publishing: 
www.greynet.org, accessed 14 June 2010), was scrutinized to identify Dutch articles 
concerned with HbP, both research and otherwise, and to identify those involved 
in the decision-making process and the discussion about the introduction of a 
screening programme for HbP.
The search was carried out in the most important Dutch medical journals such 
as the Dutch Journal of Medicine, General Practitioner & Science, Dutch Journal of 
Obstetrics and Gynaecology, Journal of Health Science and The Midwives’ Journal. 
All articles identified were scrutinized for further literature by snow-ball method. 
Authors, the Ministry of Health archives and non-governmental organizations 
which were possibly involved in the decision making process (such as the patient 
organization for HbP (OSCAR) and the VSOP (Dutch Genetic Alliance)) were 
contacted for further documentation, information and correspondence.
Key figures e.g. clinicians, scientists and policymakers were contacted and 
interviewed by telephone.
The collected material was used to identify themes and to construct a discussion 
guide for the witness seminar (Box 1) which lasted a full day and was divided into 
three sessions. Key witnesses were invited to attend the seminar. 
The study was approved by the Medical Ethics Committee of the VU University 
Medical Center, Amsterdam.
Study sample
Fourteen witnesses who were involved in the past discussions or decision making 
process in the past were invited to participate. They were either active in the 
field of obstetrics, haematology, paediatrics, genetics, epidemiology, ethics, 
clinical chemistry, or were working as officials for the Health Inspectorate or the 
Department of Health. All members of the original advisory committee to the 
National Investigation into Sickle cell anaemia and Thalassaemia8 were contacted 
and invited to attend the witness seminar (all were able to attend apart from one 
who was subsequently replaced by a colleague).
The meeting was chaired and facilitated by a medical historian (EH). An 
introduction to the meeting was presented outlining the historical context of the 
topic in order to activate the memory of those attending the seminar. 
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box 1. discussion program
discussion program of witness seminar
The meeting was divided into three sessions, each addressing a specific period in time. In 
each session issues relevant for that particular period were discussed and explored:
Session one
The period after World War II until the eighties: First appearance of studies and articles in the 
medical press investigating the prevalence and aetiology of HbP and the start of an initial debate. 
  Were opinions expressed about screening for HbP? 
What were local practices of HbP screening? 
Was fear of stigmatisation and discrimination present?
Session two
The nineties: Structured around the publication of the report of the National Investigation into 
Sickle cell anaemia and Thalassaemia.8
  Why and how was the report initiated?  
What was the role and policy of the public health authorities? 
Does a comparison to CF elucidate the discussion?
Session three
The new millennium: Transformation of opinions, the introduction of sickle cell disease in 
neonatal screening and discussion on preconceptional and antenatal screening.
  Was a transformation really apparent? 
What was the background of the decision to limit neonatal screening to SCD? 
What possibilities and limits are there to introduce a broad (carrier) screening 
program in the future? If so, does ethnicity play a role in this?
analysis
Socio-technical analysis
For the analysis of our results we used a study which was carried out to obtain more 
insight into the process of the potential implementation of a screening programme 
identifying carriers of cystic fibrosis and haemoglobinopathies before pregnancy.29 
The study was based on the model of co-evolution between technology and 
society74 and helps to identify constraining and enabling factors factors intrinsic 
to the introduction of a screening programme for HbP carrier status. For the 
successful introduction of new technological options, such as screening, attunement 
between stakeholders on various issues is necessary.29 These issues range from the 
technological options necessary to carry out such a screening programme to the 
necessary facilities and services, the demand particularly by the population at risk, 
and the political and cultural acceptability of a screening programme for HbP.
We used this model to compare the past to the present situation and to 
understand why the introduction of a screening programme may or may not have 
been possible in the past. Including what kind of interactions should be facilitated 
before the introduction of a screening programme can be possible in the future. 
Further Analysis
The meeting was fully recorded and the entire discussion was transcribed verbatim 
and three researchers (SJ, CvE and AMP) were present to take notes.
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A full copy of the transcript was sent to all participants for approval and corrections. 
Such amendments were only allowed to be stylistic or mistakenly remembered facts 
such as names or dates. The transcript was independently content-analyzed and relevant 
themes were identified and categorized by four researchers (SJ, CvE, AMP and EH). 
The result of the literature search and additional sources of information, such 
as correspondence and interviews, were used to resolve any disagreements in the 
discussion. 
The central themes identified are discussed in this article and are illustrated with 
quotations.
resuLts and discussion
Session one: from World War ii until the 1980’s
Isolated scientists and doctors
Following World War II and prior to the 1980’s, scientists and doctors began to 
show an interest in (screening for) HbP. Gradually (research) articles began to 
appear in the Dutch medical press, originating from a few academic centres in the 
Netherlands.30-32 Initial policy was ad hoc and local, influenced by the interest of 
specific clinicians. The interest of scientists in the northern city of Groningen, with 
few inhabitants of immigrant descent, was generated by a professor of paediatrics 
who had a specific interest in blood group antagonisms. He created a research 
collaboration with colleagues from the Dutch Caribbean island of Curaçao which 
originally generated his interest in HbP.33 This resulted in the thesis of a gynaecologist 
entitled Haemoglobinopathy Screening in Pregnancy34 which focused primarily 
on antenatal screening and investigated the influence of HbP on the outcome of 
pregnancy. An investigation into the HbP status of the child was also included. In 
the 1960’s, the University of Leiden in the western part of the Netherlands attracted 
a human geneticist, who subsequently developed what would become a well-known 
reference laboratory for HbP.
Meanwhile an interest in HbP in Amsterdam had also been generated due to 
a large population of immigrants in the city and the specific interest of doctors 
specialised in tropical medicine. High risk individuals who attended the local out-
patient clinic for tropical medicine, were offered ad hoc (preconception) screening 
which would inform them of their carrier status. This was carried out as an extra 
service. Whether this resulted in any further action being taken remains unclear:
We didn’t screen just because it was interesting and it wasn’t done for 
research purposes either. It was probably meant to offer people the 
possibility of [reproductive] choice so that they could take this into 
account when thinking about their [future] offspring.
(Professor of tropical medicine)
76
However, doctors and scientists had little or no contact with each other and 
there was no collaboration between universities and their departments on this 
subject. An explanation for this may be that one department was self-supporting in 
terms of diagnostic capacity and another centre was isolated because of geographic 
location. A sense of urgency was not yet perceived by any of the experts:
I think the impact of the research in Groningen has been limited because 
it was situated in Groningen [and therefore geographically relatively 
isolated]. The research [on HbP] clearly identified the problems and 
gave excellent [clinical] advice. But because we were so remotely 
situated from most of these problems, the results and conclusions 
weren’t picked up by other professionals in the country. No issues of 
discrimination by colour or anything like that played a part here.
(Prof. of obstetrics, formerly assigned to the University of Groningen 
in the north of the Netherlands)
In 1985 a thesis was published in Amsterdam entitled Sickle Cell Disease in 
the Netherlands35 that primarily investigated the prevalence of HbP, haematological 
and clinical variables and treatment in the Netherlands. The author touches on the 
subject of HbP screening with a singular closing statement. “To omit the performance 
of Hb electrophoresis in a patient with a Mediterranean or “negroid” background 
should be considered malpractice”.35
Start of the debate
Before 1980 the population at risk was still relatively small; therefore, HbP received little 
or no attention. However, due to an increasing influx of migrant workers, the population 
at risk increased dramatically during the 1980’s (www.cbs.nl, accessed 11 Oct. 2010). This 
resulted in an attempt to supply immigrant minorities with extra support:
… It wasn’t until the end of the 80’s, now over twenty years ago, that 
the Ministry of Health had the idea that we should do something 
coordinated for migrant minorities. We should at least do something 
about the access to health care for migrant minorities. All the 
departments within the Ministry of Health put together a budget of 
three million guilders per year [less than one million English pounds]. 
They appointed a coordinator, a new job function, which was me.
(Civil servant of Dept. of Health)
In comparison to the US and the UK, it is interesting to note that the initiative for 
specific health needs for immigrant workers was initiated by the government and 
not by societal organisations representing the population at risk. 
A case study of haemoglobinopathy screening
4
77
In terms of policy context it is relevant to point out that both in the Dutch 
Parliament and in society a public debate ensued during the second half of the 
1980’s when new possibilities for genetic testing and screening became increasingly 
clear.36 A documentary series discussing both the possibility of selecting foetuses 
and the offer of antenatal testing37 was broadcast in 1987 and stirred alarm about the 
social and ethical consequences of genetic testing. At the end of that same year, the 
Ministry of Health produced a report on the prevention of congenital anomalies.38 
By including genetic testing as a means to prevent congenital anomalies and to 
enact “responsible parenthood”, the suggestion was raised unintentionally that the 
government would favour a eugenic population policy, stimulating prenatal testing 
and abortion reminiscent of World War II. In the ensuing debate39, it was made clear 
that the goal of genetic counselling should be to inform people, to help them cope 
with genetic conditions and to support them to choose a course of action appropriate 
to their individual risk, their family planning, and their ethical and religious standards 
and then to act in accordance with that decision.40 The general consensus was that 
governmental prevention policy should refrain from interference with reproductive 
genetic issues. At this point in time the term “prevention” could no longer be used 
in context with reproductive genetic screening in the Netherlands. Whereas in other 
countries, “prevention” is more readily associated with (HbP) screening, “offering a 
reproductive choice” would be the optimal preferred terminology in the Netherlands 
(Health Council of The Netherlands 1989).41 Reproductive choice refers to options 
parents have available to them when they are both carriers: adoption, remaining 
childless, change of partner, accept the risk of a possibly affected child, use of donor 
gametes, or use of prenatal diagnosis and termination of affected pregnancies. Pre-
implantation Diagnostics (PID) was not yet available at this time. Concern for the 
expectations of the at-risk community was not apparent until later on.
In the wake of these debates, governmental policy regarding genetics and 
reproductive issues became restrained. This probably influenced the 1989 
governmental decision led by Christian Democrats and with full support of 
Parliament not to implement prenatal screening for neural tube defects.42;43
Carrier screening for haemoglobinopathies was not discussed until the second 
half of the 1980’s, when a book entitled Can I Have Your GenePassport? was 
published exploring the ethical issues related to carrier screening in reproductive 
health care.44 The book resulted from a report that was commissioned by the 
Department of Health and presented in 1988:
Our first conclusion was that carrier screening could be defended from 
an ethical point of view given certain conditions. One of the important 
conditions is the aim of the screening: Is this to maximise prevention 
or to maximise selective abortion, is it about population eugenics or 
does it facilitate informed choice. We opted for the last one.
(Professor of ethics, author of the book)
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The above statement also illustrates the importance of terminology used at the time 
and how it also generated some discussion: Some people preferred to use the term 
“prevention” whereas “informed choice” was the concept that came to be preferred:
The professor of my department was like a lion in his cage: he was 
roaring (with me) in the department that prevention [of HbP] should 
be implemented. But when he had to explain this in public, he was a 
lot more careful and said that we were the researchers and prevention 
was the responsibility of the doctors. But they didn’t do very much, so 
the word “prevention” came from us.
(Clinical chemist and head of reference laboratory for HbP)
Besides the more general restraint towards screening for reproductive options, 
another sensitive issue, the registration of ethnicity also became part of the HbP 
screening debate. Since the 1970’s a law on the registration of personal data, was in 
preparation. The law itself was a result of societal commotion starting in 1970 when 
organisations and journalists stirred up a public protest against the national census. 
Intellectuals warned against the danger of a government being able to register 
religion or ethnicity referring to the misuse of personal data resulting in the mass 
deportation of Jewish citizens in World War II. In the proposed law, it was explicitly 
stated that registration of ethnicity is prohibited.45 This debate continued into the 
1980’s when the Council of the Sick Fund sent a letter to the State Secretary of 
Health concerning its statement on the registration of ethnicity:
On November 7 1984 the chairman [of the Council of the Sick Fund] 
received a telex … in which both national trade unions expressed their 
opinion of not supporting ethnic registration according to nationality. 
This accurately reflects the mood at that time.
(Former officer of the Health Inspectorate)
Both researchers and other professionals were aware of these issues which 
influenced their decision making:
I was involved with the introduction of hepatitis B screening in 1989 
and this discussion was very relevant, who do you screen: certain 
ethnicities at risk or the entire Dutch population? It was said at the 
time that it is impossible to ask women about their ethnicity, the 
midwives don’t want this, nobody wants this. So we subsequently 
opted for universal hepatitis screening.
(Head of central screening laboratory)
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In the US the debate on sickle cell screening was influenced by suspicions in the 
Black community that screening was being used to determine racial purity in order to 
secure white supremacy and specifically Black inferiority.19 Scientists, policymakers 
and politicians in the Netherlands seemed to have been oblivious to this debate. 
Although the authors of the aforementioned book Can I Have Your Gene Passport? 
referred to the situation in the United States:
When we focus on sickle cell disease: the classic example of bad 
management was the United States. This had much to do with failing 
technology, miscommunication, confusing the disease with carrier status 
and in our view specifically because it was introduced in a top-down 
fashion without any interaction with or involvement of the population at 
risk. This resulted in our recommendation that (…) you need to create 
support by involving the population at risk. Without support from the 
population at risk, invariably you will be accused of racism et cetera.
(Professor of ethics)
Session two: the 1990’s: introduction of a new law and two reports
This decade was marked by political influence on screening in general and the 
National Investigation Sickle Cell Disease and Thalassaemia.8 The strained attitude 
regarding genetic screening for reproductive issues that was rooted in the 1980’s 
continued in the 1990’s. Although this attitude was supported by a broad range of 
political parties, the leading influence of the Christian Democratic Party (CDA) is 
relevant to note, because they were part of the government during many years.46 
Their view on genetics was elaborated in a 1992 report called Genes and Limits47 
which was motivated by the introduction of new technology and possibilities in 
reproductive health care. In the report both prenatal screening and preconceptional 
carrier screening were described as undesirable developments because of both the 
need to protect the foetus and the psychological burden imposed upon people 
when knowing their future child may have a serious untreatable condition. The 
report was to influence the general screening debate for years to come:
Genetics is scary, genetics is dirty (…) it [the report of the Christian 
Democratic Party] was full of a ‘German’ [based on WW II] aversion 
against eugenics in the past. It is the additional sum of only negative 
possibilities. The possibility of empowerment did not occur to them.
(Professor of ethics)
Shortly after the publication of Genes and Limits the final report of the National 
Investigation Sickle Cell Disease and Thalassaemia was published by Rengelink-van der 
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Lee in 1994.8 This report was not initiated by the Department of Health itself but instead, 
was commissioned by the Consultative Committee Minorities of the Department of 
Health. The conclusions were based on the prevalence of HbP disease (which was mainly 
found amongst adopted children born outside the Netherlands) and the results of an 
anthropological study. The latter concluded that only very limited knowledge amongst 
both the population at risk and professionals existed. The researchers, who were also 
concerned about stigmatisation, concluded that introduction of a screening programme 
for HbP was not “opportune” at this point in time:
Yes, that was the main question [whether the prevalence of HbP in 
the Netherlands was high enough to warrant the introduction of a 
screening programme] and the idea of having preconceptional or 
antenatal screening. We thought that that would be the best scenario 
but it didn’t seem feasible. 
Preconceptionally because the knowledge was far too limited and you 
would have to be able to reach people at a very early stage (…)…and 
specifically at that time in the 1990’s, the knowledge about inheritable 
diseases was very limited, both with the older immigrants [those who 
immigrated to the Netherlands a long time ago], e.g. the people from 
Surinam, as with more recent immigrants. There was no basis on which 
a screening programme could be introduced. People felt stigmatized 
which was a very important feeling (…) the fact is that many parents 
said: I don’t want to know if my child is a carrier of a certain disease 
because I won’t be able to find my daughter a suitable wedding 
partner.
(Professor of paediatrics & co-author of report)
The report fuelled the discussion and generated opposition among some 
professionals who were clearly disappointed with the report’s conclusion.48;49 Some 
argued that developing a neonatal screening programme for SCD would be a first 
step in the right direction50 as was alluded to by the report itself.
In the end the result was a negative advice, it can easily be said that 
this was a heavy blow for us and which determined the future for the 
next ten years. 
(Clinical chemist and head of reference laboratory for HbP)
The criteria of Wilson & Jungner51 were not explicitly mentioned in the final 
report of the National Investigation into Sickle Cell Disease and Thalassaemia8 nor 
did they surface in the discussion that followed the report’s publication. However, 
the research that was part of the report, investigated the attitude of the target 
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population which was (unintentionally) an elaboration of one of the criteria of Wilson 
and Jungner in so far that the test should be acceptable to the target population. 
Although the (problematic) registration of ethnicity is not given any attention in 
this report, it does seem to have influenced the discussion: 
And of course even then we weren’t allowed to screen on the basis of 
ethnicity. It was unheard of to pick out all the Black kids and submit 
them to heel prick screening [to investigate for HbP]. That would be 
ethically impossible […] The Department of Health said to us: well 
thank you very much, we don’t need to implement any policy on this 
subject. We will put it in a drawer somewhere.
(Professor of paediatrics & co-author of report)
A professor of preventative and curative health care for children who was 
interviewed by telephone, confirms this:
We talked about screening the population at risk but this was such a 
sensitive subject: it was considered discrimination and was seen as 
politically very incorrect, even if it was used as positive discrimination.
The constraining influence of the existing political climate is further illustrated when 
researchers and clinicians were clearly relieved with a change in government (1994):
I believe the change in government in 1994/5 when the Christian 
Democrats were no longer in office, was very important. I remember 
this very clearly. We had a very broad discussion with the Department 
of Health, including the discussion whether or not to screen for 
Down syndrome which was of course impossible. When the Christian 
Democrats left office we were all very relieved.
(Clinical chemist)
In 1996 a new law was introduced (Population Screening Act, in Dutch: WBO) 
based on the criteria of Wilson and Jungner, aimed at protecting the general public 
against the possible hazards of population screening programmes. The sensitivity 
towards reproductive issues is illustrated by the fact that this law requires a special 
licence for certain types of screening such as screening for disorders for which no 
treatment is available, complicating the introduction of prenatal screening.36
Despite a change in the political climate, policy towards HbP carrier screening did 
not change. Although researchers felt more comfortable investigating the subjects 
surrounding screening and the fact that the population at risk doubled in size during 
82
the 1990’s (www.cbs.nl, accessed 2 March 2010), no screening programme for carrier 
status of HbP has been introduced to date.
Session three: a new millennium: a change in direction
Turning into a new millennium attitudes change and eventually more attention is 
given to the health needs of the different populations in the Netherlands. 
Though at the end of the 1990’s attention to the debate on HbP screening 
decreased, at the turn of the century the debate resurfaced under the influence of 
an enthusiastic and very driven molecular geneticist.52
The Netherland’s population had changed dramatically in the previous decades 
(www.cbs.nl, accessed 6 Oct. 2010); there were now a vast variety of immigrants 
and their descendants from all over the world e.g. not only from Turkey, Morocco, 
Surinam and the Dutch Antilles but also from Africa, South-East Asia and the 
Middle East. Certain ethnic groups had organized themselves (www.ocan.nl 
accessed 26 Nov. 2010) and SCD and thalassaemia patients had founded their own 
organisation (OSCAR) in 1989, although the organisation did not become publicly 
visible until 1998 (www.sikkelcel.nl accessed 26 Nov. 2010).
Certain professionals began to realise that by not specifically tailoring health 
care needs to certain groups that this in fact is discriminatory, for example by not 
offering HbP screening to groups at risk: 
[during the nineties] where I spoke to Elizabeth Anionwu [see: Anionwu 
and Atkin 2001] … she said you might be worried about discrimination 
if you start screening for HbP, but the discrimination you create by not 
screening is probably far greater.
(Em. Professor of clinical genetics)
I was in London at the conference of the European Society of Human Genetics 
The debate on the registration of ethnicity was renewed and this time it was 
approached from a different angle; socioeconomic influences in health were being 
investigated as well as possibilities to reduce them.53-55 Both education level and 
ethnicity are analysed to look for possibilities to reduce inequalities in health. In 
order to use ethnicity and risk factors more constructively and to avoid any negative 
connotations, some researchers explored the possibility of combining screening for 
several groups at risk for different disorders.56 The Netherlands Organisation for 
Health Care Research and Development funded several projects on HbP screening 
after 2000.57-59 Results of these projects have contributed to the debate on potential 
implementation of HbP (carrier) screening. 
In 2005 the Health Council of the Netherlands published a report on neonatal 
screening which stated that the prevalence of certain disorders is changing, influenced 
by the composition of the population in the Netherlands.14 This report resulted in 
the expansion of the neonatal screening programme when fourteen diseases were 
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rapidly added to the programme, one of which was SCD. It was the first time since the 
previous debate that an official report put the issue of an ethnicity related disorder on 
the (public and political) agenda. The possibility of ethnically targeted screening was 
dismissed in the report, and universal screening proposed instead. The 2007 Health 
Council report on preconception care17 subsequently explicitly mentioned ethnic 
background as a risk factor, specifically calling attention to HbP, CF and Tay Sachs 
disease. Comments published in a national newspaper60 contributed to the debate 
which led to discussions in Dutch Parliament and official queries at the address of the 
Minister of Health. In his reply the Minister of Health made the following statement: 
“However the question is if offering screening to certain preselected groups on the 
basis of ethnicity is desirable and acceptable in our society”.61
The issue of screening and ethnicity therefore remains difficult to fathom. The 
Parliamentary discussion is referred to during the witness seminar:
The minister thinks it should be possible to screen by indication but 
doesn’t mention whether pregnancy is seen as an indication. Whether 
a woman with ancestors from another country wishes to be pregnant is 
an indication for screening, is not mentioned either. But he does want 
carrier testing to be carried out in a genetic centre.
(Professor of community genetics) 
Clearly the registration of ethnicity has returned to the current (political) agenda. In 
January 2008 the Dutch Society of Clinical Geneticists (VKGN) gave the State Secretary 
of Health positive advice in response to questions of the department regarding the 
relevance of the registration of ethnicity related to care in clinical genetics.62 However 
hospitals and health professionals are reluctant; it is against hospital policy to register 
the ethnicity of a patient for the benefit of adequate care and the Dutch Federation 
of Medical Specialists (KNMG) advises restraint in the matter.63
Subsequently a report has been published by the Netherlands Organisation for 
Health Care Research and Development recommending the registration of ethnicity 
in the health care sector to facilitate further research in order to reduce differences 
in health outcomes amongst different ethnic groups in Dutch society.64 
Despite being back on the agenda, the registration of ethnicity still proves to be 
a sensitive issue when, although not health related, a minister lost her post over this 
debate in 2008 suggesting ethnic registration as a means to monitor young offenders. 
The late 1990’s have been politically dominated by a joint Labour and Liberal 
government but the new millennium is once again marked by religiously influenced 
political parties. Recently this has led to a renewed discussion concerning the late 
termination of pregnancies following prenatal screening whereby specifically religious 
parties but also the right wing Party for Freedom argue against late terminations of 
pregnancy reducing the options available to parents.65 The expectation is that the 
liberal yet right wing government which was installed in October 2010 will not be 
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very forthcoming. Moreover, preconception care in general suffered a setback as 
the Minister of Health recently denounced any further commitment to this subject.66 
Sociotechnical analysis
After having discussed the findings of the witness seminar and the context of 
discussions on screening for HbP, we will now address the sociotechnical analysis. 
The witness seminar and the preceding literature search have identified the actors 
and stakeholders involved in the former discussions and decision making process 
about whether or not a screening programme for HbP should be introduced in the 
Netherlands. These individuals can be categorised into four groups: 1) Scientists 
in the field, 2) Healthcare professionals, 3) Policymakers and 4) The patients and 
population at risk (fig.1). We looked at attunement between these stakeholders both 
in the past and the present on technical options, facilities and services, demand and 
issues of political and cultural acceptability. Thus more insight was gained into why 
it was not possible to implement a screening programme in the past and compare 
this to the current situation. 
Technological options
In the 1990’s, technological options were acceptable as simple and reliable tests 
were available. HPLC testing for HbP might not yet have been available in all 
laboratories, however, electrophoresis was a test available to clinicians.8 Availability 
and standardisation of testing methods has only improved since this period.14;67 
Demand
In the past, limited knowledge amongst the groups at risk also made demand for screening low or non-
existent (Rengelink-van der Lee et al. 1994).8 Recent research has shown that screening is acceptable 
amongst the groups at risk71;72 although cascade screening following a positive carrier status found 
during the neonatal screening is still limited.16 After 2000, the patient organisation becomes more 
established and expresses the need for implementation of screening services, however, it does not 
feel as if its voice is being heard (OSCAR personal communication 2011).
HbP carrier screening 
program
Regulatory advisory and 
governmental agencies
Scientists in 
laboratories and 
clinics
Population at risk,
patients
Professionals
in (primary) healthcare such as 
general practitioners, midwives
fig. 1 Network of stakeholders & actors involved
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Facilities and services
Facilities and services were clearly limited at the time because preconception care 
was unavailable to the public. Currently preconception services are being offered in 
most regions, however; this type of care only reaches a very small part of the target 
population.68 Although preconception services have recently been endorsed by the 
Dutch Steering Committee on Pregnancy and Childbirth69, the Minister of Health 
has refused to financially support further policy development regarding this issue.66 
The National Investigation showed that knowledge amongst professionals was 
very limited in the early 1990’s.8 Although more attention to the subject has been 
given since, i.e. neonatal screening has been expanded to include SCD14, knowledge 
about these kinds of genetic disorders is still insufficient amongst professionals.70;71
Besides this, carrier diagnosis is indicated for certain groups of people in case 
of (unresolved) anaemia as part of the anaemia guideline of both the midwives and 
the GPs.12;13
Demand
In the past, limited knowledge amongst the groups at risk also made demand for 
screening low or non-existent (Rengelink-van der Lee et al. 1994).8 Recent research has 
shown that screening is acceptable amongst the groups at risk71;72 although cascade 
screening following a positive carrier status found during the neonatal screening is 
still limited.16 After 2000, the patient organisation becomes more established and 
expresses the need for implementation of screening services, however, it does not 
feel as if its voice is being heard (OSCAR personal communication 2011).
Political and cultural acceptability
The witness seminar has clearly shown that political and cultural acceptability was non-
existent; this was partly caused by the insurmountable discussion on the registration 
of ethnicity. Moreover, research showed that parents worried about the possible 
stigmatisation of their affected children.8 Furthermore, during the 1980’s and 1990’s 
the discussion on screening was burdened by the fear of eugenics.36 The renewed 
debate seems to be turning in favour of screening25 supported by the realisation 
that ethnicity does play a certain role in health care which needs to be investigated 
further.64 There is international consensus that a screening programme should be 
implemented in those countries where HbP is prevalent6, preferably carried out in a 
primary health care setting.2 Although consensus is still lacking at the national level, 
health professionals seem willing to carry out screening for HbP.25;71 
 Table 1 gives an overview of the various failing processes of attunement in 
the past on several dimensions and clarifies which issues have changed in the last 
decade. This model is helpful in understanding the possibilities and barriers that 
exist for present-day attunement for implementing HbP carrier screening. 
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concLusion
By means of a witness seminar the case history of screening policy in the Netherlands 
was explored and has demonstrated the influence of the heritage of past events on 
general health care policy, even to this date. Although this method allows researchers 
to make a further in-depth analysis and explore hidden and sensitive elements of 
discussions in the past, the method has some weaknesses. The results of the seminar 
are in part dependent on the participants attending and their recollections which 
may be hampered by the passing of time. However by using the group dynamics, 
participants are invited to respond and add to each other’s account, thereby helping 
to reconstruct past events from different perspectives. While being aware of its 
limitations, the study is able to address an important issue that has long been 
neglected by elaborating on traditional and often scarce sources.
Policy makers and healthcare workers have been and still are struggling with 
the challenge of being able to deliver equitable services for an ethnically diverse 
population. 
As opposed to the US where the history of slavery influenced extremely sensitive 
discussions surrounding the introduction of (carrier) screening for HbP, healthcare 
policy in the Netherlands is still burdened by the inheritance of WW II when the mass 
deportations of Jews was supported by a diligent register of the Dutch population 
which causes ethnic registration still to be problematic until today. In addition 
genetic screening for reproductive options proves to be a sensitive subject against 
the same background. Whereas in the US the National Sickle Cell Disease Control 
Act was introduced in 1972, followed by the Genetic diseases Act of 1976 and the 
NIH consensus statement in 19875, the discussion in the Netherlands is still ongoing. 
Difficult and sensitive discussions against a background of collective feelings of guilt 
and penance have influenced the decision making process surrounding screening 
issues, causing extreme apprehension to debate the registration of ethnicity for the 
benefit of equitable health services. The issue of ethnicity and the fear of possible 
discrimination, proved to be a relevant subject but only played a secondary role 
in the decision making process in the end. In the 1990’s the restrained political 
climate regarding genetic screening for reproductive options as illustrated by the 
Christian Democrat Party and the law on population screening prevented any further 
development in the HbP screening discussion. 
In addition, the Research Report National Investigation into Sickle Cell Anaemia 
and Thalassaemia made any initiatives towards the introduction of a screening 
programme by this department superfluous. Although excellent research exploring 
the possibilities of a screening programme for carrier status of HbP has taken place 
over the years both in and outside the Netherlands, the results seem to be “lost 
in translation”.73 To date, preconceptional and prenatal screening programmes for 
HbP carrier status have not been introduced in the Netherlands. Screening is still 
limited to SCD in the neonatal screening programme. The fact that no one, neither 
at governmental level nor in the scientific community, convened a meeting at the 
88
time to debate and clarify the issues at stake with all professionals and policymakers 
involved, exemplifies the lack of attunement at the time.
The discussion in the Netherlands has focused primarily on equality (all persons 
being equal) however the realisation that this may limit health care equity for some 
has only surfaced in recent years. Under the influence of increasing immigration to the 
Netherlands (as elsewhere in Europe), and both departmental and political changes, 
professional opinion concerning the use of information about ethnicity to benefit 
public health, has begun to change but still remains a sensitive discussion. While 
a report on the registration of ethnicity by the Health Council of The Netherlands 
is expected in the near future, a national debate on the introduction of a broader 
screening programme is urgently required; this should include the voice of the 
patient organisation which has been insistently calling for further development on 
this terrain (www.oscarnederland.nl, accessed March 2011).
Key Message
Before 2000 reflecting on the inheritance of World War II, reproductive genetic 
screening and the registration of ethnicity, has been politically unacceptable in 
the Netherlands, causing a barrier for the introduction of HbP carrier screening. It 
is clear that carrier screening based on ethnicity would only be acceptable under 
certain conditions, mainly aimed at a guarantee of informed decision making.
Besides careful analysis of the present situation to resolve existing challenges, 
future decision making on an extended screening programme needs to include 
representatives from groups most at risk of HbP to support the possible 
implementation of such a programme.
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abstract
Haemoglobinopathies are severe autosomal recessive disorders with high prevalence 
amongst certain ethnic groups. WHO advises implementing screening programmes 
for risk groups. Research in the Netherlands has shown that general practitioners 
and midwives do not perceive ethnicity as a risk factor for haemoglobinopathies. 
Moreover, registration of ethnicity is a controversial societal issue which may 
complicate the introduction of a national preconception or antenatal carrier 
screening programme. 
This study investigates attitudes, intention and behaviour of general practitioners 
and midwives towards ethnicity-based haemoglobinopathy carrier screening in general.
A structured questionnaire based on the Theory of Planned Behaviour was sent by 
mail to a random selection of 2100 general practitioners and1800 primary care midwives. 
Response was 35% (midwives 44.2%; GPs 27.6%).
Although 45% of respondents thought that offering a carrier test on the basis 
of ethnicity alone should become national policy, it is currently not carried out. The 
main factor explaining lack of intention towards ethnicity-based haemoglobinopathy 
carrier screening was subjective norm, the perception that their peers do not 
think they should offer screening (52.2% variance explained). If ethnicity-based 
haemoglobinopathy carrier screening would become national policy, most 
professionals report that they would carry this out. Most respondents favoured 
ethnicity registration for health purposes.
Since most practitioners look for role models among peers, debate amongst 
general practitioners and midwives should be encouraged when new policy is 
to be developed articulating the voices of colleagues who already actively offer 
haemoglobinopathy carrier screening. Moreover, primary care professionals and 
professional organisations need support of policy at national level.
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introduction 
Haemoglobinopathies (HbP) such as sickle cell disease (SCD) and thalassaemia are 
autosomal recessive disorders with severe anaemia, variable but life-long morbidity 
and currently with a shortened lifespan due to multi-organ ischaemic damage.1-3 
Couples in which both partners are carriers of HbP have a one-in-four chance in each 
pregnancy of giving birth to an affected child. HbP is one of the world’s main genetic 
disorders but occur more frequently in current or formerly malaria-endemic areas, 
such as Africa, the Mediterranean region, the Middle East and South-East Asia. Due 
to immigration these disorders are now also common in non-endemic countries3 
with an estimated prevalence ranging from 5-40% depending on ancestry.4 The 
prevalence of a positive carrier status of HbP in the Netherlands has been estimated 
at 4-14% depending on ethnic background5 with a birth prevalence of severe HbP 
of about 60 infants among 182.000 total births.6 
In 2006 the World Health Organisation (WHO) urged member states to increase 
the awareness of SCD and to develop services which integrate carrier detection and 
genetic counselling within existing primary healthcare systems, in addition to the 
services of specialists such as clinical geneticists and paediatricians.4,7 Such genetic 
population screening programmes have several social, ethical and technological 
issues which may vary according to the type of screening. Universal neonatal 
screening as offered in the public health setting, generally serves the purpose of 
timely detection of a disorder to prevent further illness. Ethical concerns centre 
primarily on objections to abortion, embryo selection, and concerns on eugenics 
and medicalization of care, and are especially relevant in the context of prenatal and 
preconceptional genetic screening, where prevention is not the primary purpose. 
In the preconceptional or prenatal setting the primary aim of any genetic disorder 
related screening programme is reproductive choice.8 Although preconception carrier 
screening provides prospective parents with the most reproductive choice, antenatal 
carrier screening has practical advantages: it reaches the target population more 
easily. This article is limited to preconception and antenatal HbP carrier screening. 
Although (ethnic) diversity and heterogeneous distribution of HbP may make the 
introduction of such a programme challenging, it is currently thought to be possible 
to develop an appropriate programme that meets the ethical considerations for the 
introduction of genetic screening programmes as agreed upon at European level.9
England is an example of a country where a linked antenatal carrier screening 
(both targeted and universal, depending on prevalence) and neonatal screening 
programme (universal) for HbP is available.10 This policy is supported by the 
National Institute for Health and Clinical Excellence (NICE) which recommends 
(preconception) counselling and carrier testing.11 Carriers can be identified by a 
simple and inexpensive blood test (Hb-electrophoresis or High Performance Liquid 
Chromatography (HPLC)) allowing couples preferably before pregnancy to be 
informed about their risk, giving them a wider scope of reproductive options. 
Primary care attitudes towards HbP carrier screening
5
97
Although universal carrier screening, in which all women regardless of their 
ethnicity who are either pregnant or planning to become pregnant are offered carrier 
screening, may be preferable in equitable terms, this may not always be preferred 
in economic terms because in some geographical areas prevalence may be too low 
to warrant universal screening even though this means some cases may be missed.12 
Even if universal screening would be the goal, women should always be offered the 
choice to opt out. Information on risk based on her ethnic background can be used 
to support women making an informed choice about whether to accept screening 
or not. For example, targeted ethnicity-based screening as advised by the American 
College of Obstetricians and Gynecologists (ACOG), may be more appropriate.13 This 
requires health professionals, such as GPs and midwives to identify couples at risk by 
taking an ethnicity-related history by asking them about their ancestry in conjunction 
with offering them information about HbP carrier screening when women (and their 
partners) enter into care. Initiatives have been undertaken to develop instruments to 
help decide who is eligible for testing and who is not. 10,14,15 Although implemented 
in England, this still awaits further discussion in the Netherlands.
Pregnant women are mostly cared for in primary care by midwives and 
occasionally by GPs and are currently at best offered carrier testing on the basis of 
anaemia, a positive family history or at the personal discretion of midwives and GPs 
in the Netherlands.16-18 However if (primary) healthcare services want to adequately 
meet the needs of the whole population, health professionals should be aware of 
the specific healthcare requirements of certain ethnic groups.
In the past and even still today, ancestry or ethnicity-based HbP screening has 
not been without controversy.19-21 A recent study showed ethnic registration to be 
a controversial issue in the Netherlands because of its relationship with World War 
II and lingering feelings of guilt in Dutch society, causing it to be a barrier for the 
introduction of HbP carrier screening.22 Moreover, in a pilot study primary care 
professionals expressed that although they support HbP carrier screening, they do not 
interpret ethnicity as a risk marker for HbP.23 In order to offer equitable health services 
to all groups in society, health professionals need to be aware of ethnicity-related 
health needs without the fear of raising issues of discrimination or stigmatization. 
Because attitudes of health professionals may influence clinical practice, the specific 
attitudes of such professionals towards ethnic registration are of interest. 
The aim of this study was to investigate the attitude, intention and behaviour 
of midwives and GPs towards ethnic registration and their willingness to undertake 
carrier testing for clients and patients on the basis of ethnicity.
MateriaL and Methods
Questionnaire
A cross sectional study was designed by means of a structured questionnaire based 
on a previous pilot study23 including direct measures of the main constructs of 
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the Theory of Planned Behaviour (TPB) (figure1). TPB interprets the behavioural 
intentions concerning performance as the most immediate and important predictor 
of whether people perform a certain behaviour.24 The behaviour of interest in 
this study was offering patients an HbP carrier test on the basis of their ethnicity 
which was explained to participants in the introduction to the questionnaire. We 
underlined the fact that the amount of patients at risk in their practice and whether 
or not they tested them for (carrier status of) HbP at present was irrelevant to being 
able to answer the questions. 
The relationship between attitudes, subjective norm and perceived behavioural 
control is described by the theory as the underlying foundational belief about the 
intention of performing the behaviour.
Attitude was measured by using multiple word pairs to answer two questions. 
First, What do you think about offering your patients a carrier test for HbP solely on 
the basis of ethnicity (regardless of family history)? A sum-score was then calculated 
from answers scored on a 7-point scale using the following word-pairs: bad-good, 
nonsense-important, tough-easy, undesirable-desirable, harmful-beneficial and 
discriminating-privilege. The results showed good consistency for the total score 
(Cronbach’s alpha 0.86). The one factor model fitted well using exploratory factor 
analysis, all items loaded onto one factor.
Secondly, What do you think about registering the ethnicity of your patients? 
A sum-score was calculated from answers scored on a 7-point scale using the 
following word-pairs: wrong-good, harmful-beneficial, nonsense-appropriate, 
awkward-useful, discriminating-harmless and objectionable-desirable. (Cronbach’s 
alpha 0.89). All items were loaded on one factor using exploratory factor analysis. 
The relationship between attitudes, subjective norm and perceived behavioural control is described by 
the theory as the underlying foundational belief about the intention of performing the behaviour.
Figure 1. Theory of Planned Behaviour23 
Attitude was measured by using multiple word pairs to answer two questions.
First, What do you think about offering your patients a carrier test for HbP solely on the basis of 
ethnicity (regardless of family history)? A sum-score was then calculated from answers scored on a 7-
point scale using the following word-pairs: bad-good, nonsense-important, tough-easy, undesirable-
desirable, harmful-beneficial and discriminating-privilege. The results showed good consistency for the 
total score (Cronbach’s alpha 0.86). The one factor model fitted well using exploratory factor analysis, 
all items loaded onto one factor.
Secondly, What do you think about registering the ethnicity of your patients? A sum-score was 
calculated from answers scored on a 7-point scale using the following word-pairs: wrong-good, 
harmful-beneficial, nonsense-appropriate, awkward-useful, 
discriminating-harmless and objectionable-desirable. (Cronbach’s alpha 0.89).  All items were loaded 
on one factor using exploratory factor analysis. 
Subsequent questions were answered with single word pairs. The question Do you think your 
colleagues believe a carrier test solely on the basis of ethnicity should be offered to patients (certainly 
not [1]-certainly [7])? measured the subjective norm of the professional groups. Behavioural control 
was measured with the following question: Are you currently able to offer your patients a carrier test 
for HbP on the basis of ethnicity alone (certainly not [1]- certainly [7])?
Two questions measured intention: Do you intend to offer your patients a carrier test for HbP 
exclusively on the basis of ethnicity in the future (certainly not [1]- certainly [7])? and: Do you intend to 
offer your patients an HbP carrier test solely on the basis of ethnicity should this become national 
Attitude
Subjective 
Norm
Perceived 
Behavioural 
control
Intention Behaviour
Figure 1. Theory of Planned Behaviour23 
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Subsequent questions were answered with single word pairs. The question Do 
you think your colleagues believe a carrier test solely on the basis of ethnicity should 
be offered to patients (certainly not [1]-certainly [7])? measured the subjective norm 
of the professional groups. Behavioural control was measured with the following 
question: Are you currently able to offer your patients a carrier test for HbP on the 
basis of ethnicity alone (certainly not [1]-certainly [7])?
Two questions measured intention: Do you intend to offer your patients a carrier test 
for HbP exclusively on the basis of ethnicity in the future (certainly not [1]-certainly [7])? 
and: Do you intend to offer your patients an HbP carrier test solely on the basis of 
ethnicity should this become national policy (certainly not [1]-certainly [7])?
Behaviour was measured by asking the following questions: Do you at present 
offer your patients an HbP carrier test solely on the basis of ethnicity (never [1]-
always[7])? and: Do you offer your patients with unresolved anaemia and no familial 
history an HbP carrier test (never [1]-always [7])?
Responders were also asked if they thought that: An HbP carrier test on the basis 
of ethnicity alone should become national policy (binary answer; yes [1] or no [2]). 
Finally, they were asked some basic characteristics (location of practice, estimated 
percentage of population from the group at risk in their practice, work experience).
The final version of the questionnaire was approved by members of an expert group 
which consisted of members of the GP and midwifery professions, a representative 
from the national patient organisation and researchers in the field of HbP.
respondents
The questionnaire was accompanied by a letter of introduction explaining the aim 
of the project i.e. exploring the opinion of health care professionals about offering 
patients an HbP carrier test on the basis of their ethnicity and underlining the fact 
that no specific knowledge about HbP was necessary to be able to answer the 
questions. This was sent by post to 2100 GPs and 1800 primary care midwives 
between November and December 2009. GPs were randomly selected from the 
total population of GPs (roughly 8000) by the Netherlands Institute of Health 
Services research (NIVEL). The total number of midwives is small in the Netherlands; 
therefore, all primary care midwives were sent a questionnaire. No reminders were 
sent out and no incentives were offered to participate in the study. 
analysis
Differences between GPs and midwives were assessed by a two-tailed t-test and 
chi²: p-values <0.05 are reported as statistically significant. 
Direct measures of the main constructs of the TPB (attitude, subjective norm, 
perceived behavioural control and intention) are reported as a mean. Standard linear 
regression analysis was applied analysing data obtained according to the TPB in order to 
explain the behaviour of midwives and GPs towards ethnicity based HbP carrier testing 
(figure 1). Variables were added backwards. Two tailed values for Pearson correlations 
are reported between determinants from the TPB. All data were analysed in SPSS 15.01.
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resuLts 
The questionnaire was returned by 1346 primary health care workers: 795 midwives 
(response rate 44.2%) and 551 GPs (response rate 27.6%) resulting in a total 
response rate of 35%. 
Respondent characteristics are presented in table 1. About half of the 
respondents worked in urban areas. The average working experience was 14 
years. More midwives came from urban areas compared to the GPs and they had a 
significantly longer working experience. The estimated percentage of patients from 
ethnic minorities in the practices showed a wide distribution of 0-95% with a mean 
of 16.6% (SD 18.7%). The midwives reported significantly higher estimates of clients 
from the groups at risk for HbP in their practices. 
Results according to items of the TPB are shown in table 2.
table 1. Characteristics of respondents
 
gps 
n=551
midwives 
n=795
Urban location of practice, n (%)** 255 (46.4)¹ 452 (56.9 )
Estimated average percentage of patients  
from population at risk in practice ** 12.9¹ 19.1 
Years of experience (mean SD)* 11.3 (9.0)¹ 17.3 ( 9.3)
¹Difference between groups significant at p <0.001 *Independent t-test ** Chi2 GP= general 
practitioner
table 2. Constructs of TPB, comparison between GP sand midwives
gps 
mean score (Sd)
midwives 
mean score (Sd)
Attitude towards testing on the basis of 
ethnicity
4.6¹
(1.3)
4.9
(1.3)
Attitude towards the registration of 
ethnicity in daily practice
4.5¹
(1.4)
5.6
(1.2)
Subjective norm 3.6 (1.4) 3.8 (1.7)
Perceived behavioural control 4.4¹ (2.1) 4.0 (2.1)
Intention on the basis of ethnicity 3.4¹ (1.7) 3.9 (1.7)
Intention on the basis of national policy 5.1¹ (1.8) 5.7 (1.7)
Current behaviour 1.9 (1.4) 1.8 (1.6)
Current behaviour on basis of guidelines 4.2¹ (2.1) 5.2 (2.1)
¹ t-test, two tailed significant p <.001 TBP = Theory of Planned behaviour GP = General Practitioner
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attitude
On average primary care providers have a fairly positive attitude towards offering 
a test solely on the basis of ethnicity and regardless of family history, midwives 
being more positive than GPs. The midwives also displayed a more positive attitude 
towards the registration of ethnicity. 
Subjective norm
Both GPs and midwives were less positive about what they thought their colleagues 
opinions were to ds testing on the basis of ethnicity. Most of them thought their 
colleagues would not recommend screening based on ethnicity. 
perceived behavioural control
While in practice the laboratory test is easily available, the responses were close to 
the scale average. GPs felt somewhat more able to actually carry out an HbP carrier 
test compared to midwives.
intention
GPs scored the intention of offering an HbP carrier test to their patients on the basis 
of ethnicity alone more negative compared to midwives, who scored almost neutral. 
However if this were to become national policy, most participants did express the 
intention to offer this to their patients: midwives significantly more so than GPs.
current test behaviour
The scores for the questions on current behaviour showed that both GPs and 
midwives almost never offer a carrier test for HbP on the basis of ethnicity alone 
(mean scores 1.9 and 1.8). On the other hand, specifically midwives were prepared 
to test patients on the basis of unexplained anaemia as instructed by the guidelines 
of their professional organisations (mean score 5.2). GPs however were less inclined 
to do so (mean score 4.2); the difference was significant.
Of all primary care providers, 45% thought that offering a test for carrier status 
on the basis of ethnicity alone should become national policy, GPs thought so 
significantly less often than midwives. 
explaining intention and behaviour
For both midwives and GPs together, the intention of offering patients an HbP 
carrier test on the basis of ethnicity alone was largely explained by three factors: 
the attitude towards offering patients a carrier test for HbP only on the basis of 
ethnicity, subjective norm and control over the ability to effectuate the test. This 
model explained 52.2% of the variance (p< 0.001). The subjective norm, i.e. what 
GPs and midwives perceived their colleagues’ opinion to be, contributed most to 
the model (Beta=0.49 p<0.001).
Variance changed only slightly by adding attitude towards the registration of 
ethnicity to the model (explained variance 52.5% p<0.001). In this model, attitude 
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towards the registration of ethnicity was the second most important contributor 
(Beta = 0.31 p<0.001). Characteristics of the participants, such as percentage of 
population from the group at risk in their practice, work experience and location of 
practice, did not influence intention towards screening for carrier status of HbP on 
the basis of ethnicity. 
discussion
Although at present midwives and GPs in the Netherlands do not carry out HbP 
carrier testing solely on the basis of their patient’s ethnic background, they generally 
have a positive attitude towards ethnicity-based carrier screening. This finding is 
supported by the results of other studies.23,25 According to the TPB, subjective norm 
influences intention and behaviour. Since health care professionals apparently only 
have very few examples of colleagues who carry out this type of testing, they are 
not inclined to do so in their own practice environment. However, they are prepared 
to follow guidance should carrier screening become national policy. Control over 
the ability to administer the test was also part of the model that explained intention 
and behaviour. Midwives especially seemed less than secure in their capability of 
carrying out a test for HbP carrier status as they scored significantly lower on this 
item (personal control) when compared to GPs. Although ordering an HbP carrier 
test is relatively simple, the interpretation of the results is not always straight 
forward. This requires more knowledge than health professionals may have26,27 and 
may explain why health professionals are reluctant in offering carrier testing for HbP. 
Another reason may be that health professionals incorrectly believe they are legally 
restricted to offer carrier screening because of the Dutch Population Act.28
Interestingly the attitude of midwives towards the registration of ethnicity in 
daily practice was much more positive when compared to GPs. One explanation 
may be that midwives are already used to registering the ethnicity of their clients 
and in contrast to GPs also have the possibility to do so in the software they use. 
It is unclear in which manner midwives (and GPs) determine ethnicity; if and what 
questions are asked or whether this is self reported or otherwise determined. This 
important and interesting point needs further investigation in the future.
Since we wanted to know what health professionals thought in general about 
ethnicity related HbP screening, we did not specify when the screening should take 
place; either preconceptionally or antenatally. It is not inconceivable that attitudes 
may differ between the two as reproductive options during the antenatal period are 
limited for a carrier couple. The questionnaire was used in a previous pilot project23 
and discussed in the expert group. Despite this the question An HbP carrier test 
on the basis of ethnicity alone should become national policy could be interpreted 
in several ways and is therefore one of the limitations of the study. It is difficult 
to attribute definitive meanings to the answers with this question: A person who 
answers ‘no’ might do so either because he/she believes that screening should only 
be offered if universal or because they do not believe such screening for HbP should 
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be offered at all in the Netherlands or that it should be an individual decision at 
professional level. This needs further study.
Although the response rate was low in this study (35%); it was reached without 
sending out reminders and the response rate amongst GPs was much lower resulting 
in a lower overall response rate. We expected to receive more questionnaires 
from those GPs and midwives practicing in urban areas with a higher percentage 
of the population at risk. This was not the case, especially in the group of GPs. 
The spread of practice location, however, corresponds with national spread of GPs 
indicating a representative sample.29 Responding GPs estimated only slightly more 
patients from ethnic minorities in their practice (12.9%) compared to the national 
population (11.2% non-western). In 2008, 19.6% of women in Dutch midwifery 
practices were of non-Dutch ethnicity which is comparable to what the midwives in 
the study estimated.30 Other surveys have encountered similar problems in terms of 
response and indicated that a high workload prevented health professionals from 
participating.31 A lack of interest or failure to see the importance of the subject 
and the popularity of GPs as research objects may also have influenced the lack of 
enthusiasm amongst GPs in returning the questionnaire. Although the response rate 
was low; there was no evidence of selection bias. 
Achterberg et al. argued that effective implementation of screening for HbP will 
require changes at both regime (suppliers and users) and landscape level (institutions, 
material social, political and legal infrastructure), but that such change is difficult to 
achieve without an active orchestrating role of the government.32 This contradicts 
present governmental policy which expects the field of health professionals to initiate 
such policies. The fact that similar programmes in the Netherlands have been initiated 
by the government in the past33 makes this all the more curious. Whether or not to 
test for (carrier status of) HbP during reproductive life (ie preconceptional, antenatal 
or neonatal) has been debated since the seventies and eighties. Possibly, previous 
sensitivities surrounding ethnicity and ethnic registration are still applicable today.22 
Since most women in the Netherlands are cared for by midwives when pregnant30 
and most women will probably meet with their GP at some point during their 
reproductive life, they would be the professionals of choice to offer HbP carrier 
screening to women and /or couples. 
Morgan et al.34 showed that fewer than 28% of gynaecologists offered their 
pregnant patients screening for cystic fibrosis (CF), on the basis of all of the criteria 
in the guidelines of the ACOG. One explanation given was that almost 60% did 
not feel familiar enough with genetics to offer screening.35 This lack of knowledge 
displays a need for continuing education in genetics, a problem which probably also 
exists amongst primary healthcare professionals. Vansenne et al. reported a lack 
of HbP knowledge and clinical experience influencing primary care practitioners’ 
behaviour in neonatal screening which confirms the need for further education.26
Besides knowledge development, the use of specific antenatal laboratory forms 
(such as used for the Antenatal Screening Programme for Infectious Diseases and 
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Pregnancy Immunisation, PSIE, programme36) could prompt health professionals to 
initiate HbP carrier testing and may encourage implementation of testing. Since 
the design of this form is not the responsibility of professional organisations such 
as those of GPs and midwives, it would still require some form of governmental or 
laboratory experts’ initiative.
It has been shown that informed choice is less well facilitated for women from 
different ethnic backgrounds in other areas of antenatal screening37, although 
several researchers have shown that both preconception and antenatal screening 
is acceptable amongst the population at risk.38-40 Ethnic diversity poses an extra 
challenge to health care professionals to deliver equitable services.41 The discussion 
in the Netherlands has focused primarily on equality in health care and concerns over 
stigmatisation of certain groups in society; however, the realisation that this may limit 
health care equity for some has only surfaced in recent years.22 If we want to strive to 
provide equitable healthcare services for all, it is important that health professionals 
such as midwives and GPs are aware of these issues and that discussions on equity, 
equality and access are part of (continuing) education programmes to enable them 
to provide women with the care they need. Introduction of HbP carrier screening 
should be a part of meeting these needs, as proposed by the WHO.
Many countries have been hesitant about introducing ethnicity-based HbP carrier 
screening based on negative reports related to discrimination and stigmatization of 
groups at risk. In the past SCD has been wrongly addressed as a “Black disease” 
and care for these patients has been and very often still is shadowed by mistrust 
and health care discrimination.19,42 Associating (carrier status of) HbP with particular 
ethnic groups may undermine the success of a possible screening programme. 
For such a program to be effective, equitable facilities for diagnosis and treatment 
should be available.43 Moreover, the correct determination of ethnicity is important 
but it could also be possible that health professionals and/or their patients find this 
difficult; they may need to be supported by a tool to determine risk or universal 
screening should be considered.15,44
We conclude that most practitioners are willing to offer screening solely on the 
basis of ethnicity should this become national policy, however not all. The fact that 
not all midwives and GPs answered that they are not prepared to implement a 
national guideline for HbP carrier screening, is unusual. The background of this 
result and a more in depth analysis of the possible barriers for ethnicity-based HbP 
carrier screening, warrant further investigation.
 In developing and implementing new policy with regard to HbP carrier screening, 
debate amongst GPs and midwives should be encouraged, articulating the voices 
of colleagues who already actively offer HbP carrier screening. Opinion leaders and 
professional organisations of primary health care professionals should be supported 
by policy at national level when targeting GPs and midwives to implement HbP 
carrier screening.
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abstract
background: The Netherlands does not have a national haemoglobinopathy carrier 
screening program aimed at facilitating informed reproductive choice, even though 
the WHO advises this. HbP carrier testing for those at risk is at best offered on 
the basis of anaemia. Registration of ethnicity has proved controversial and may 
complicate the introduction of a screening programme if ethnicity-based. However, 
other factors may also play a role. 
objective: To explore perceived barriers and attitudes amongst general practitioners 
(GPs) and midwives regarding the registration of ethnicity and ethnicity based 
haemoglobinopathy carrier screening.
methods: Six focus groups in Dutch primary care with a total of 37 GPs and midwives 
were conducted, transcribed and content analysed using Atlas-ti.
results: Both GPs and midwives struggled with correctly identifying ethnicities 
at risk for HbP. Ethical concerns regarding privacy seem to originate from World 
War II experiences when ethnic and religious registration facilitated deportation of 
Jewish citizens, coupled with the current political climate. Some midwives thought 
the ethnicity question might undermine the relationship with their clients. Despite 
this, both groups seemed positive and are familiar with identifying ethnicity and 
use this for individual patient care. Software programs prevent GPs from registering 
ethnicity of patients at risk. Financial implications for patients were also a concern.
conclusion: Although health professionals are generally positive about screening, 
ethical, financial and practical issues surrounding ethnicity-based HbP carrier 
screening need to be clarified before introducing such a programme. Primary care 
professionals can be targeted through professional organisations but need national 
policy support.
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bacKground
Haemoglobinopathies (HbP), such as sickle cell disease and thalassaemia, are 
autosomal recessive disorders with severe anaemia, variable but life-long morbidity 
and with a shortened lifespan due to multi-organ ischaemic damage.1;2 HbP occur 
more frequently in areas such as Africa, the Mediterranean area, the Middle East 
and South-East but are now also common in other countries due to migration 
and population admixture, resulting in a varying carrier prevalence of up to 40% 
depending on the ancestry2;3 making ethnicity an important determinant of risk. 
Carrier couples have a 1-in-4 chance in each pregnancy of giving birth to a diseased 
child. Carrier screening would allow the identification of these couples and give them 
an opportunity to make informed reproductive decisions. Despite the advice of the 
World Health Organisation (WHO)4, the Netherlands, as many other countries, does 
not have a national HbP carrier screening programme. Although national guidelines 
advice HbP carrier testing for (unresolved) anaemia or in case of a positive family 
history5;6, health professionals such as general practitioners (GPs) and midwives 
rarely carry this out to facilitate reproductive choice. Several studies have shown 
that both health professionals and groups at risk support HbP carrier screening.7-10 
One study however showed that primary care professionals do not see ethnicity as a 
risk factor for HbP.8 Another study suggested that because HbP testing is influenced 
by peer behaviour and since colleagues rarely test and official screening policy is 
lacking9 could be one of the explanations why testing rarely happens. Subsequently, 
most carriers remain unidentified, also because recessive disorders are often not 
apparent in families.
In England, where antenatal HbP carrier screening was introduced in 2004, self 
identified ethnicity based on a family origin questionnaire is determined to assess HbP 
risk in both low prevalence areas where targeted screening is practiced, as well as in 
high prevalence areas where universal screening is the norm.11 Although HbP carrier 
status can easily and cheaply be determined by a HPLC test, identification of ethnicity 
might still be necessary not only to investigate mutations but also to inform a couple of 
their risk, regardless of how screening is carried out. Identification of the extent of their 
risk based on ethnicity supports health care professionals to facilitate women and their 
partners to make an informed choice with regard to their (future) pregnancies as HbP 
(carrier) prevalence differs across ethnic groups. Additionally, economic arguments may 
also be used to favour implementation of targeted screening.12
Research by Dyson et al. showed that health care workers struggle with the 
ethnicity question as a screening tool and worry about the sensitivities related to 
ethnicity.13 In the Netherlands, ethnic registration proved to be a controversial issue 
rooted in the history of World War II and linked to the current nationalistic political 
climate and came up as a barrier for the introduction of HbP carrier screening.9;14 In 
order to offer equitable health services to all groups in society, health professionals 
need to be aware of ethnicity-related health needs without the fear of raising issues 
of discrimination or stigmatisation.
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objective
This study’s objective was to explore the present attitudes towards ethnic registration 
by GPs and midwives related to every day practice and in particular to identify risk 
groups for preconceptional or antenatal HbP carrier testing and to explore perceived 
barriers if ethnicity-based HbP carrier screening is implemented in the future.
Methods
design and setting
This qualitative study is part of a broader study examining ethnicity-based HbP 
screening.9;14 
As both ‘ethnicity’ and ‘ancestry’ are shown to be equally complex terms and 
ethnicity is supported by the literature as a proxy for ancestral or ethnic origin15, 
this term was chosen to be used in the study. Moreover, this term is most common 
among health professionals.
A focus group study was designed as this method stimulates debate and 
generates ideas about the topics introduced. 
Focus groups were homogenous with regard to health profession in order to 
generate a sufficient feeling of security among participants. The semi-structured 
topic guide was based on the literature and the questionnaire results. Topics 
included experience with HbP carrier testing; attitudes regarding ethnic registration 
also related to HbP screening and perceived barriers. Prior to the start of the 
focus group participants received a brief HbP fact sheet by post giving disease 
background and information on groups at risk and they were asked to complete 
basic background questions and provide written consent.
The focus group discussions took place at two universities and a midwifery academy; 
they lasted approximately 90 minutes and were facilitated by one of two moderators, 
(LvT, health scientist or CvE, sociologist). The primary researcher (SJ, midwife), was only 
involved in the GP group as note taker to prevent influencing the discussion of her 
colleagues. Another assistant took notes in the midwives group. Midwives received 
professional register credits in return for participation. All participants received a €10,- 
gift voucher but were not informed of this prior to the discussion. 
participant recruitment and data collection
Primary care practitioners were asked to participate by means of a letter included 
in a postal questionnaire (sent to all primary care midwives and a random GP 
sample) on ethnicity-based HbP screening. 9 To this letter 29 GPs and 191 midwives 
responded. We selected a regionally based purposeful sample from the responders, 
on the assumption that rural health professionals would have less experience with 
HbP risk groups. Our sample included six focus groups of about six midwives or GPs 
each, with a total of 37 individuals aged 23-65 years. In the autumn of 2010 four 
focus groups were held with midwives (n=28) and two with GPs (n=9) after which 
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saturation was achieved concerning the midwives. Several attempts were made to 
recruit more GPs but proved unsuccessful. While most midwives were female, the 
mostly male GPs had more working years experience compared to the midwives. 
Even so, midwives were more familiar with preconception care and looked after a 
larger percentage of the population at risk for HbP (table 1). Digital audio recordings 
of the discussions were collected and anonymously transcribed. 
analysis
The transcripts were checked once to ensure accuracy and to gain familiarity with 
the data, and were subsequently content analysed (SJ). Transcripts were searched 
for common themes but also for deviant cases and subsequently indexed as codes. 
The coding frame was developed by the primary researcher (SJ), in consultation 
with two other researchers (LH, health scientist and CvE). SJ coded the transcripts 
and CvE and LH each verified one third of the transcripts as an inter-rater check. The 
codes were grouped together into key themes. Codes and emerging themes were 
compared for coding reliability through a process of discussion and deliberation of 
themes and connections (SJ, LH, CvE). ATLAS.ti software package (version 5.2.0) 
was used to support the analysis of the transcripts. 
resuLts
General attitudes towards HbP carrier screening were mixed. While practitioners 
thought it to be good practice and would fulfil a health need, they also questioned 
cost-effectiveness and necessity because of perceived low prevalence. Data 
analysis identified four themes related to ethnicity-based carrier screening: Defining 
ethnicity; Ethical dilemmas and sensitivities; Ethnic awareness and good practice; 
Practicalities. All are discussed here and illustrated by representative quotations 
from the discussions translated from Dutch. The participants group and type of 
health care professional (GP or midwife) are given in brackets. 
table1. characteristics of participants in the focus groups
characteristics
midwives 
(n=28)
general practitioners 
(n=9)
Mean age (sd) 35.4 (11.3) 51.4 (11.2)
Female gender, n (%) 27 (96) 2 (22)
Dutch, n (%) 27 (96) 9 (100)
Mean years (sd) of practice experience 10.4 (9.2) 22.0 (11.7)
Estimated percentage of population at 
risk in practice 27 20
Urban area of practice, n (%) 18 (64) 4 (44)
Gives preconception care, n (%) 14 (50) 4 (44)
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defining ethnicity: Who is at higher risk?
The issue that generated most discussion in all focus groups was the concern of 
being able to correctly identify those individuals at higher risk for HbP. Participants 
wondered how ethnicities can be defined, and thus how they could correctly identify 
those at risk: by appearance; by name; by country of birth? 
So they might look Hindustani [Surinam people of Indian origin] 
but there might be some black or something, (…) but how strong… 
wouldn’t you need to test them? 
Midwife (group 6)
But no, I believe all those Mediterranean people are Caucasian too and 
that is clearly a different ethnicity. Because I [this GP is of Dutch ancestry] 
don’t have a higher risk of HbP and they do. So yes, the way you define 
ethnicity puts you immediately in a morass of difficult considerations.
GP (group 2)
Participants wondered how far back they would have to look into one’s ancestry 
to determine their risk of being a HbP carrier. 
How strong is HbP in the inheritance? (…) How much white; lets say 
how much percent of something else do you need to take away the 
effect? This is what I don’t know (…). Percentages will drop the more 
mixing there is. But it’s still only a chance and you have a chance of 
one in two that it will be passed on to you and that will always remain 
if your parents have it.
Midwife (group 6)
Both GPs and midwives also struggled with mixed backgrounds of their patients 
and clients which made them feel unsure how to handle this in daily practice, and 
uncertain whom to offer screening:
But what do you do with someone who has an Indonesian mother and 
an Italian father and she is married to a Dutch man, you know, these 
people can also have carrier (…) The fact that people are so intertwined, 
so often, well that is, we see a lot of people with mixed backgrounds 
and what is the limit [cut-off point], with which background? 
Midwife (group 3)
Participants seemed aware that determining ethnic origin with regards to HbP 
carrier screening entails more than identifying someone’s place of birth.
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I mean, they are from Moroccan descent that’s what it’s all about of 
course, the ethnicity on the basis of genetics and not let’s say… the 
ancestors, yes, so the country of birth of their parents counts, but let’s 
say as a person I don’t really have someone in front of me with a lot of 
Moroccan influences, her Dutch influences are much bigger.
Midwife (group 5)
ethical dilemmas and sensitivities
Both midwives and GPs had several, sometimes quite strong ethical opinions 
concerning ethnic registration. Specifically, GPs felt burdened by ethical objections 
that stem from Dutch experiences during World War II, when ethnic and religious 
registration facilitated mass deportation of Jewish citizens.
But if you think a bit further, at the time of Hitler and the Jewish 
people et cetera; they carried out all sorts of scary experiments with 
different ethnic populations, that was on the basis of you know… Jews 
and Gypsies and I don’t know who… And if we would register all of 
that and it would be registered somewhere that you are Caucasian; 
Muslim; African or whatever else: Go ahead think about it, in times 
of, people, well in the craziness of war strange things can happen… 
Midwife (group 5)
One GP said that he would not object to the registration of ethnicity, and that 
it could potentially be useful, but despite this, he still felt distrust and maintains his 
recordkeeping to a minimum:
I register as little as possible. And well, I wouldn’t object [to ethnic 
registration] if it was possible to do this correctly and in a way that’s 
reproducible. I know we have a huge trauma in the Netherlands 
caused by World War II when Jewish people were registered with the 
council and as Dutch citizens we diligently helped the Germans to 
deport them and we pretend to be the best country in the world. (…)
GP (group 1)
Participants coupled this with the current political climate (right wing and 
nationalist) and worried about the misuse of data that could threaten patient 
confidentiality. GPs especially felt very protective of their patients’ privacy and had 
little confidence in digital record keeping: 
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I have no trust whatsoever in that it [electronic patient record] won’t 
be used for anything but patient purposes. The safety and the 
trustworthiness of this still have to be verified and demonstrated in 
my opinion. I believe records can easily be hacked at the moment. 
Besides, I don’t know what governmental authorities will do with this 
in the long run. At the moment we have a government which says they 
will only do the right thing but I am sorry the [Nationalist right wing 
political party] has a very large following and I am not sure what will 
happen in the future.
GP (group 2)
The current political climate in which tolerance regarding ethnic and cultural 
differences is reduced, may also be at the root of midwives’ concerns. Participants 
seemed keen not to be seen as supportive of this and therefore, felt uncomfortable 
asking the ethnicity question. Some seemed to think that clients might interpret this 
as a sign of being less welcoming to them compared to a client of Dutch descent 
and worried that confusion over ethnicity, descent and nationality, might possibly 
cause tension:
Are we just going to ask: ‘Hey where are you from? Where are your 
parents from?’ Because really they are just Dutch, but that’s what I 
find difficult; that I’m emphasizing that they are not Dutch originally. 
Although my impression is that they don’t seem to mind themselves. 
It’s more that it makes me feel uncomfortable.
Midwife (group 5)
In contrast, one midwife said she did not mind at all asking her clients about their 
ethnicity to determine their risk; she felt the ethnicity question was a positive one 
which helped her to get to know her clients:
People are proud of where they come from, so I mean, that’s something; 
why should it [ethnic registration] be an issue? And what is nice, well 
that is my opinion anyway, clients who come from elsewhere, they 
always like to, I mean they enjoy talking about their special things, 
their culture and traditions. It is always interesting.
Midwife (group 4)
Midwifery participants voiced other privacy related concerns related to the 
nature of genetic disorders in relationship with paternity:
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Well, I think it can be really tricky, it’s the same with a rhesus negative 
status when a woman is convinced that her partner is also rhesus 
negative and that she doesn’t want the anti-D (…) Some things might 
come out just like with this [HbP testing] he can or cannot be the father. 
Midwife (group 6)
It appears that worries such as above stem from the fact that the midwives 
have the impression that women or couples may not be able to see the potential 
impact of accepting screening. Finding an appropriate way of informing women in 
pregnancy may thus be complicated in more ways.
ethnic awareness and good practice
Despite the sensitivities voiced by participants, they appeared to be familiar with 
identifying ethnicity for (other) health purposes and seemed to believe that it is 
good practice to be aware of different health needs amongst certain ethnic groups. 
They use their knowledge and earlier experiences to choose the appropriate care 
for their patients or clients; for example diabetes risk in Suriname people of Indian 
descent. This awareness also resulted in offering certain patients or clients a test for 
HbP carrier status:
We don’t carry out standard [HBP carrier] screening. But we do test 
people with a low Hb or those who were very anaemic in a previous 
pregnancy and actually also those people with a Mediterranean 
background; we test them for sickle cell and thalassaemia when we 
send them for the usual Hb and MCV tests as our experience tells us 
that they are very often positive [for HbP carrier status].
Midwife (group 5)
But again one participant pointed out the fact that in her practice they felt 
insecure about defining groups at higher risk of a positive HbP carrier status and as 
a result policy is inconsistent:
Part of our practice area is very white and another part has a lot of 
immigrants; probably 20-25% of our population. We screen Black 
people for sickle cell but this is quite arbitrary because some people 
who are mixed [of mixed descent] are sometimes not screened, so our 
policy is not very consistent.
Midwife (group 5)
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Attention given to ethnic differences in clinical guidelines varies. 16 In this case 
some participants felt supported by ethnic specific recommendations in their 
guidelines, underlining the importance of professional and national clinical guidance: 
I think on the basis of anaemia, of course we currently have a 
beautiful guideline for this purpose which is really easy to use; you 
just follow it and arrive at the point where you think it has to be a 
haemoglobinopathy.
GP (group 1)
practicalities in relation to (ethnicity-based) hbp carrier screening
Two practical barriers emerged during the focus group discussions; registration 
difficulties and financial issues. Despite the presented dilemmas, midwives reported 
that they have been registering ethnicity in the Netherlands Perinatal Register since 
the seventies which contains national perinatal data for research purposes and care 
improvement. Software systems are improving the registration methods:
We register by means of our LVR [national perinatal register] but this 
is only a very general if not limited registration. Mediterranean, other 
European, the groups are very “broad”. We have now started with 
[new software program for midwives] and with this program you can fill 
in country of birth, therefore you have the country of birth for everyone.
Midwife (group 3)
The practical side of implementing ethnic registration appeared to be no 
problem for the midwifery profession. However this is not the case for GPs because 
the available GP-software does not provide a simple way of doing this:
Yes, there is loads of space [in the software program] but you have 
to be able to locate it [the information on ethnicity]. Like, it’s not a 
separate field [in the program] for which you can search, which you 
can select. (…) I think a computer nerd would be able to do it but not 
GPs in general. It has to be easy otherwise you won’t do it.
GP (group 1)
Although midwifery and GP care is exempt from financial charges to patients 
or clients in the Dutch health care system, they are sometimes charged for extra 
(laboratory) services, depending on how insurance companies apply the rules. Those 
midwives who already tested for HbP carrier status, expressed concern about the 
financial implications for their clients. Unclear financial regulations are apparently 
making them feel awkward about offering such tests: 
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That depends whether or not the insurance will pay. (…) And if people, 
I mean I don’t know how much a test like that costs, but if people 
receive a huge bill which they have to pay themselves…
Midwife (group 4)
It appeared that midwives easily feel guilty about financially burdening 
their clients through the care they have proposed. Not being able to give clear 
explanations about financial implications may also result in complaints from clients.
discussion 
This study took a qualitative thematic approach to provide a deeper understanding 
of the attitudes and elucidates the perceived barriers of midwives and GPs with 
regards to ethnicity related HbP carrier screening. Four themes were identified 
showing that participants use ethnicity in daily practice for a tailored approach 
towards their patient’s or client’s health but find it difficult to adequately identify 
ethnicity whereby uneasy feelings are experienced when broaching the subject. 
Both participant groups voiced strong concerns over privacy issues of their patients 
and clients. GPs do not have the possibility to register ethnicity in their software 
programs. Midwives worried about the financial implications for their clients.
We regret the small number of GP participants in our study. This meant that the 
intended purposeful sample had to be turned into a convenience sample. Other 
studies have encountered similar problems in terms of response and indicated that 
a high workload prevented GPs from participating in research.9;17 Minimal interest 
and the GPs popularity as research objects may also have influenced the lack 
of enthusiasm. One GP in this study mentioned that the subject was low on her 
priority list considering the magnitude of (social) problems she encountered in her 
practice. It should further be emphasized that qualitative data are not intended to 
be generalized. 
The discussion on defining ethnicity was one of the most dominant in our study. 
Information on (perceived) ethnicity can be used to determine risks for certain 
disorders that occur more often in certain ethnic groups, such as HbP, cystic fibrosis, 
diabetes mellitus et cetera, but as other researchers have shown, the use of ethnicity 
is problematic in social and political terms.14;18 It is interesting to note that none of 
the participants actually thought of asking patients/clients themselves. Although 
self-defined ethnicity is favoured by some 19;20 defining ethnicity is still the subject 
of on-going debate.15;21;22 A generally accepted way of determining ethnic groups 
is by country of birth and (grand-) parents’ country of birth, but this method misses 
third and fourth generations.22 Our study results correlate with the complexity of 
determining ethnicity as demonstrated by others who have shown that a substantial 
proportion of ethnic groups give complex answers about their ethnic background 
(and which do not necessarily fit predetermined categories).18;21;23
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As opposed to Dyson’s results23 which showed no consistency in how the ethnicity 
question was interpreted (i.e. meaning place of birth, place of upbringing, family, 
ancestors or ethnic identity), the participants in this study seemed to have at least 
some awareness of the importance of ethnic origin with regards to HbP carrier 
screening. Whether this awareness is also apparent in clinical practice, is unclear. 
Our study does support Dyson’s finding that midwives feel uncomfortable asking the 
ethnicity question. One way to reduce such feelings may be by offering combined 
HbP and CF carrier screening, using a tool specifically designed for such purpose.10
GPs and midwives in this study are familiar with the use of ethnicity in daily practice 
for the purpose of tailored health care and are prepared to screen their patients for 
HbP carrier status in the future. However this also seems to create uncomfortable 
feelings which require further investigation. Although several instruments are 
available for determining ethnic HbP risk10;24, it is not known what women and 
their partners think about ethnicity-related health care, although Lakeman’s study 
reported no feelings of stigmatisation with the combined screening offer. 
Two earlier studies revealed ethnic registration to be a controversial barrier in the 
past preventing the introduction of a HbP carrier programme, which was rooted in 
the history of World War II and linked to the current nationalistic political climate. 9;14 
This study shows that these issues continue to be important.
Considering the complexity of determining ethnicity, universal screening may 
be more appropriate. However irrespective of screening method, consideration of 
ethnicity is still required to adequately inform patients or clients of their risk. A 
validated tool to support health care professionals to determine risk should therefore 
be considered. At the same time support by national policy whereby ethical and 
practical barriers are solved and financial issues clarified before such a program is 
implemented, is crucial. 
It may well be possible that for future generations the necessity to determine 
ethnicity will become obsolete as ethnic admixture becomes more common in 
our multicultural societies and complex DNA panels determining a wide range of 
genetic disorders can be offered in preconception screening.
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general discussion

This thesis has several objectives related to anaemia and haemoglobinopathies (HbP). 
The first objective is to establish the prevalence of anaemia (low haemoglobin, Hb) in 
pregnancy, and to investigate whether this was different for pregnant women of non-
Northern European descent compared with pregnant women of Northern European 
descent. Furthermore, the effect of a positive HbP carrier status on the outcome of 
pregnancy was investigated. HbP is the umbrella name for the group of autosomal 
recessive disorders that consists of sickle cell disease (SCD) and thalassaemia which 
are relatively frequent among certain ethnic groups. Subsequently, preconception 
and antenatal ethnicity-based HbP carrier screening was addressed: First the 
historical context in the Netherlands of the decision making process surrounding the 
negative outcome of the discussion whether or not to introduce an HbP screening 
programme was investigated. Next, a quantitative and a qualitative approach was 
used to investigate and explore the attitudes of midwives and general practitioners 
(GPs) towards ethnic registration and their perceived barriers to ethnicity-based 
preconceptional or antenatal HbP carrier testing.
The previous chapters have described the individual studies in detail. In this 
final chapter the main findings of the thesis are presented. These findings and 
methodological issues will be discussed in the context of the existing literature. 
This chapter ends with implications for clinical practice and recommendations for 
implementation and further research.
Main findings
prevalence of anaemia in pregnancy
In a retrospective cohort study (Chapter 2) anaemia was defined according to the 
reference values of the KNOV anaemia guideline published in 2000.1 If Hb and 
MCV are low, iron deficiency anaemia (IDA) is assumed. The overall prevalence 
of anaemia in pregnancy in the urban population of Amsterdam was 3.4% at 
booking (first visit; around 12 weeks of gestation at the time of study) and 2.7% 
at approximately 30 weeks gestation. The relative risk (RR) of anaemia at booking 
was 5.9 (95% CI 2.1-16.7) for pregnant women of non-Northern European descent, 
7.4 (95% CI 2.4-22.8) for Mediterranean women, 4.0 (95% CI 1.2-13.4) for Black 
women and ‘others’ 7.2 (95% CI 2.1-24.9) when compared with women of Northern 
European descent. The RR of anaemia at approximately 30 weeks of gestation was 
22 (95% CI 3.0-162.0) for pregnant women of non-Northern European descent, 20.8 
(95% CI 2.6-165.2) for Mediterranean women, 13.9 (95% CI 1.7-114.9) for Black 
women and 55.3 (95% CI 7.2-422.2) for ‘others’ when compared to women of 
Northern European descent. The higher risk for anaemia resulted in a higher risk for 
transferred home delivery (THD) in case of an Hb< 6.0 mmol/l as indicated by local 
policy, for non-Northern European women: RR 24.1 (95% CI: 3.3-176.7). 
General discussion
7
127
effect of hbp carrier status on outcome of pregnancy
The cohort study was followed by a systematic literature review bringing together the 
best available evidence on the effect of a positive HbP carrier status on the maternal 
and neonatal outcome of pregnancy. The systematic review identified nine studies that 
met the inclusion criteria and that were of sufficient quality for the review. No studies 
of sufficient quality were found on the effect of a positive thalassaemia carrier status. 
The heterogeneous non-pooled data showed a protective effect of sickle cell trait 
(SCT) for premature birth, low Apgar score and perinatal mortality rate. No significant 
effect was found for low birth weight, growth retardation, urinary tract infection (UTI) 
or high blood pressure. The risk of anaemia and bacteriuria was increased.
history of hbp screening in the netherlands 
Fourteen multi-disciplinary professionals participated in a so called witness seminar 
to discuss the past decision-making process regarding the possible introduction 
of an HbP (carrier) screening programme in the Netherlands. The subject of HbP 
screening first appeared on the agenda in the 1970s. As opposed to a long history 
of neglect of African-American health in the United States (US), the heritage of 
World War II influenced the decision-making process in the Netherlands. This 
heritage appeared to be multi-layered. Concerns about eugenics cast a shadow 
over the repro-genetic discussion in general. Complicated aspects of ethnicity and 
race influenced the discussion and ethnic registration, which was associated with 
World War II, surfaced as an impeding factor. In the 1990s, HbP (carrier) screening 
was found to be ‘not opportune’ due to the low prevalence, lack of knowledge 
and fear of stigmatization. Discussion of the registration of ethnicity remains on the 
political agenda, and still proves to be a sensitive subject.2 
current hbp (carrier)screening in the netherlands 
A postal questionnaire survey was used to investigate attitudes, intention and 
behaviour of 795 midwives and 551 GPs towards ethnicity-based HbP carrier 
screening. The study showed that although 45% of respondents thought that 
offering a carrier test on the basis of ethnicity alone should become national policy, 
most of them do not currently offer such a test to their patients and/or clients. 
The main factor explaining lack of intention towards offering ethnicity-based HbP 
carrier screening was subjective norm; the perception that their peers do not think 
they should offer screening. If ethnicity-based HbP carrier screening would become 
national policy, most professionals report that they would carry this out. Most 
respondents favoured ethnic registration for health purposes.
A focus group study explored the background of the attitudes of midwives and 
GPs and of their perceived barriers regarding ethnicity-based HbP carrier screening. 
Both professionals struggled with correctly identifying ethnicities at risk leading to 
several complex considerations. Acerbated by the current political climate, ethical 
concerns regarding privacy originated from World War II when ethnic and religious 
registration facilitated deportation of Jewish citizens. Some midwives thought 
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the ethnicity question may undermine the relationship with their clients. Software 
programs prevent GPs from registering ethnicity of patients at risk. Financial 
implications of HbP carrier screening for patients are also a concern. Despite 
this, both professional groups seemed positive about ethnicity based HbP carrier 
screening and are familiar with identifying ethnicity for individual patient care. 
a question of ethnicity?
The research in this thesis shows that ethnic diversity raises certain questions within 
the healthcare setting. Clinical health professionals struggle with these questions on 
a daily basis, especially those who work in areas where this diversity is greatest such 
as in the urban areas of the Netherlands. The prevalence of certain disorders differs 
between ethnic groups and therefore, health care professionals and policymakers 
should take these differences into account in the way health care is delivered to 
avoid health inequalities. This does not always happen and most professional 
guidelines lack attention to ethnic differences.3 
Ethnic differentiation in policy recommendations should be evidence based and 
lead to appropriate care for all ethnic groups. The first edition of the KNOV anaemia 
guideline did take differences between ethnic groups into account by introducing 
separate reference values for pregnant Black women, however when the guideline 
was evaluated primary care midwives in the Netherlands still commented that 
the guideline did not meet the needs of all ethnic groups and that anaemia was 
detected too late.4 Separate reference values for Black women were based on 
evidence that Hb levels among Black people are on average lower than among other 
ethnic groups. However, it is unclear whether these lower levels are physiological or 
due to underlying pathological conditions which warrant further investigation and 
treatment instead of separate reference values. Others commented that HbP carrier 
status should be investigated.4,5 By carrying out the presented research we have 
contributed to these issues that were put forward by midwives. 
ethnicity related to anaemia and haemoglobinopathy carrier status
It is evident that the question of ethnicity cannot be ignored when dealing with anaemia 
in pregnancy and when health professionals want to provide adequate care for all 
pregnant women and women with a pregnancy wish in an ethnically diverse society. 
The assumption voiced by Dutch midwives that pregnant women of non-
Northern European descent are at a higher risk of anaemia was confirmed. 
However, this finding is not easy to interpret. First, ethnicity was defined according 
to the National Perinatal Register as identified by the midwife: practice based but 
perhaps with suboptimal validity. Besides these groups, as used in the study, are 
very heterogeneous. The terms ‘Northern European’ and ‘non-Northern European’ 
are obviously very broad and apply to a large variety of ethnic groups. However, 
so are the terms used for sub-groups: Mediterranean may mean anything from 
Italian, Croatian and Turkish to Moroccan whereas “Black” could be anyone with 
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a background from the wide diversity of the African continent, the former Dutch 
colonies of Suriname and the Antilles and so on. Besides the obvious geographical 
and genetic (HbP) differences, combining women in these groups ignores 
more complex but very relevant issues such as migration, differences between 
generations, socio-economic factors and culture, which may all influence lifestyle 
and nutritional factors and therefore also anaemia. Second, although the study 
confirms a difference in risk for anaemia amongst different ethnic groups, it is 
unable to elucidate on the factors that lie behind this finding.
From the systematic review which aimed to investigate the effect of HbP carrier 
status on the outcome of pregnancy, we can conclude that pregnant women who 
are HbP carriers are at low risk of adverse pregnancy outcomes. On the basis of the 
available evidence women can be reassured that they can continue to receive care 
in a low risk setting. 
The systematic review also encountered problems with the definition of ethnicity; 
sometimes absent or not always clearly defined. The lack of definitions was an 
overall problem in the review. This and the fact that important confounders such as 
SES were not always reported in the studies and the fact that not all studies used the 
appropriate diagnostic test for HbP6, may have influenced the results.
Considerable heterogeneity meant that pooling of the data was not possible. 
Although the HbP topic yields sufficient results in search engines such as Pubmed, 
only a few studies evaluated the effect of HbP carrier status on the outcome 
of pregnancy (see chapter 3). These studies are relatively old and have many 
methodological problems. It is curious that despite the fact that HbP are some of 
the world’s most prevalent autosomal recessive disorders with a carrier prevalence 
of up to 40% in some ethnic groups7, there is an apparent lack of research interest in 
this specific topic. This fact is also recognized by the WHO which expressed concern 
over the lack of relevant epidemiological data which may present a challenge to 
effective and equitable management of sickle cell disease and trait.8
The results of this thesis support clinicians such as midwives, obstetricians and 
GPs in providing tailored health care for pregnant women with different ethnic 
backgrounds. The European project partners of the Amsterdam declaration towards 
migrant-friendly hospitals agreed on basic principles in their statement, one of which 
was identifying the needs of people with diverse backgrounds and monitoring and 
developing services with regard to these needs.9 Although the statement is aimed 
at hospital care, it could easily be transferred to primary care. Paying more attention 
to those groups at higher risk for anaemia such as women from non-Northern 
European descent, and the complexities behind this such as the possibility of a 
positive HbP carrier status supports meeting those needs. This would answer the 
call of the WHO in 2006 to pay more attention to those a risk for HbP.8 
Professionals caring for pregnant women with different ethnic backgrounds such 
as midwives, obstetricians and GPs, should be aware of the possibility of anaemia. 
If anaemia is present, carrier status should be investigated in at least those women 
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with a higher risk ethnic background before any treatment is started, since iron 
treatment may be harmful in carriers. Asymptomatic bacteriuria and the subsequent 
risk of pyelonephritis may occur more frequently in pregnant HbP carriers; therefore 
health professionals involved should investigate pregnant women who are known 
HbP carriers more frequently for these conditions. 
carrier screening and reproductive choice
No medical service exists in isolation. The related effects of a positive HbP carrier 
status on the outcome of pregnancy and diagnostic clarity when looking at 
anaemia in pregnancy, testing for HbP carrier status also raises discussion about 
reproductive choice. Couples who are both an HbP carrier have a 25% chance of 
giving birth to an affected child with each pregnancy. Some have argued that HbP 
carrier screening should be part of the midwives’ anaemia guideline.5 However the 
answer to the question whether or not HbP carrier screening for the purpose of 
reproductive choice should be offered during the preconception period or in early 
pregnancy, does not belong in a guideline on anaemia. Moreover, the expanded 
Neonatal Screening (NNS) which was implemented in 2007 and included a test 
for SCD raised the same question: As a result of the unintended finding of HbP 
carriers in the programme, the old discussion whether or not a broad HbP carrier 
screening programme should be introduced, was renewed.10 In order to adequately 
re-address the issue of HbP carrier screening, we need to know about the barriers 
and sensitivities experienced in the past, which was why the case history of HbP 
screening policy in the Netherlands was explored.
The case history demonstrates the influence of the heritage of past events on 
general health care policy such as screening, and more specifically on HbP screening 
policy, even to this date. The results were generated through a unique research 
method which allowed for an in-depth analysis and an exploration of hidden and 
sensitive elements in the past discussion. The results of the seminar are partly 
dependent on the choice and availability of the witnesses and their recollections 
which may be hampered by the passing of time. However, by using the group 
dynamics, participants were invited to respond and add to each other’s account, 
thereby helping to reconstruct past events from different perspectives. We have 
therefore been able to address an important issue that has long been neglected. 
Interestingly, the analysis follows on from an earlier witness seminar that was held in 
the Netherlands11, which reports on the unholy alliance of political parties and the 
government against prenatal screening in the eighties out of fear for eugenics. The 
HbP witness seminar takes this one step further: Not only was reproductive screening 
politically unacceptable, but the registration of ethnicity was as well and for similar 
reasons. As opposed to a long history of neglect of African-American health in the 
US, the heritage of World War II influenced the decision-making process in the 
Netherlands causing a barrier for the introduction of HbP carrier screening. 
Strikingly, during the discussion in the nineties, no role existed for any patient 
representatives. The anthropological study that was part of the 1994 report on the 
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possibility of introducing an HbP carrier screening programme, showed very little 
knowledge amongst groups at higher HbP risk. Those familiar with HbP disorders, 
expressed a willingness to accept prenatal screening and were open to the possible 
consequences of such screening.12 Since then a few studies have been carried out 
amongst the groups at higher risk in the Netherlands.13-15 In order to resolve existing 
challenges, future decision-making on an extended screening programme needs to 
include representatives from groups most at risk of HbP to support a programme 
that adequately supports the needs of societal groups and to ensure adequate 
implementation of such a programme, as is advocated by the International Alliance 
of Patient Organizations, IAPO, in all aspects of health care.16
Long before the introduction of the English sickle cell and thalassaemia 
screening programme (http://sct.screening.nhs.uk. Last accessed 30 April 2012) 
researchers commented on the fact that long term neglect of adequate screening 
and care of HbP conditions by the British health services were pointed to by users 
as reflecting racist marginalization.17,18 Since then a comprehensive programme has 
been introduced in England. Although it does meet with difficulties, the programme 
has been successfully implemented and evaluated.19-23 Although the Netherlands 
has introduced NNS for SCD, societal discussion about HbP carrier screening is 
practically absent outside the call of a committed few10,24; the discussion does not 
seem to have moved forward from the one held in the nineties as described in the 
witness seminar.
definition of ethnicity
Difficulty in defining ethnicity appears as a central thread throughout this thesis 
and has been shown to also have methodological implications. With such obvious 
differences in prevalence in both anaemia and HbP, it is important that ethnicity 
is adequately defined to prevent underreporting. Besides, a recently published 
guideline on hypertension by the Dutch midwives organization points out that being 
of African (sub-Sahara) descent is a risk factor for hypertension in pregnancy, making 
ethnicity in itself a confounder for one of the outcomes in the systematic review25-27; 
again pointing out that an adequate ethnic definition is important.
Although the questionnaire study showed that midwives have a positive attitude 
towards ethnic registration, the results of the focus group study showed that 
both midwives and GPs find defining ethnicity problematic and complex. Mixed 
backgrounds of their patients and clients made them uncertain about whom to 
offer screening. These results correlate with the complexity of determining ethnicity 
which is often misleading as demonstrated by others.28-31 These arguments would 
therefore support a universal screening offer.
It is unclear how health professionals currently determine ethnicity. As Hinton et al. 
point out, assessing ethnicity is usually done by health professionals using their own 
judgment which is prone to errors.32 The practical problem of GPs who are unable 
to register ethnicity in their software system, may be easily solved. However the 
fact that they displayed clear ethical concerns of doing so needs further attention if 
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ethnicity based HbP carrier screening is introduced in the future. The fact that SCD is 
characterized as a “Black disease” as has been (and still is) the case in the US and the 
UK17,33-35 may further complicate ethical issues as it sets aside certain groups in society, 
especially in the current politically hostile climate. Although there is no available 
empirical evidence of racism within the Dutch health system, the uneasy feelings as 
displayed in the focus group study clearly supports concerns about this issue as has 
also been pointed out by others who call for greater awareness of such issues.36
government, law and lack of national policy
The fact that midwives (and GPs to a lesser extent) seemed less confident in their 
capabilities of carrying out a test for HbP carrier screening, may have something 
to do with a lack of knowledge among health care professionals which has been 
demonstrated by other studies directly related to HbP and CF (carrier) screening37,38 
or related to genetic knowledge in general.39 However this may also be related to 
the incorrect belief that they are legally restricted to offer preconceptional carrier 
screening because of the Dutch Population Act40 or to the fact that laboratory 
(result) forms are sometimes complicated to interpret (see Appendix 4-A). Easily 
accessible schooling for health professionals may support them to feel more secure 
about informing clients and patients about HbP carrier testing. But standardised 
laboratory forms which include advice on correct follow up when results are positive 
as is used in prenatal screening, or as used by one of the Amsterdam laboratories 
(Appendix 4-B) would further support health professionals (http://www.rivm.nl/
Onderwerpen/Onderwerpen/B/Bloedonderzoek_zwangeren/Voor_professionals. 
Last accessed 30 April 2012). 
Although the results of the questionnaire study show that lack of intention 
was mostly influenced by negative peer behaviour (social norm), a reluctance to 
initiate screening is probably largely related to the absence of appropriate policy 
direction. Normally screening programmes are initiated by government and public 
health authorities and not individual health professionals. On a European level this 
is also the advice of the Public and Professional Policy Committee (PPPC).41 This 
would suggest that without guidance by national policy, implementation may not 
be initiated by health professionals. However preconception carrier screening is 
not legally bound by the Population Screenings Act of the Netherlands (Wet op 
Bevolkingsonderzoek, WBO) and therefore does not need a governmental license.42 
This, and current political health policy which keeps governmental interference 
with preventive policy and reproductive choice to a minimum, complicates matters 
as for this reason the government may refrain from taking action. In the case of 
antenatal carrier screening the discussion may be different: Carrier screening during 
pregnancy, although also aiming to give parents reproductive choice, options 
are more restricted and could lead to prenatal diagnosis to identify a foetus with 
severe HbP, and thus could in principle result in termination of the pregnancy. An 
HbP carrier screening programme would still be regulated under the WBO but the 
question as to whether a license is required when screening would be offered in the 
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early antenatal period remains open to discussion. Unfortunately information on this 
subject does not give a definitive answer43,44 and will therefore need guidance from 
the Department of Health. 
Clearly before a genetic screening programme is introduced, it should be 
evaluated against the background of certain (internationally agreed) criteria.41,45,46 
The potential benefits and harm should be carefully considered before such a 
programme is implemented. These benefits include pre-symptomatic detection of 
genetic disorders and prevention of further harm by determining the predisposition 
of a person that may produce a hereditary disease in offspring47 and thus providing 
reproductive choice, which is the case with HbP carrier screening. The potential 
harm may include anxiety, stigmatisation and discrimination.45
The results from the focus group study underlined the necessity to solve ethical 
and practical barriers and clarify financial issues before an HbP carrier screening 
programme is implemented. Others have also highlighted the lack of financial 
resources, a high workload and the absence of a preconception care setting as 
barriers in the implementation for preconception CF carrier screening.48 There is no 
reason why it should be assumed that HbP carrier screening differs in this respect. 
Others have discussed the possibility of medicalisation: there may be no doubt that 
when preconception or antenatal carrier screening is introduced about a certain 
degree of medicalisation will occur, but this is not necessarily a moral problem. 
The facilitation of adequate informed decision making together with good quality 
provision of care of those affected by the specific disorder, in this case HbP, will 
address the main concerns.49 
Some of these issues can be dealt with by the representative organizations of 
health professionals but legal, ethical and financial barriers will need academic 
guidance and negotiation with relevant insurance bodies. The Dutch HbP patient 
organization OSCAR, indicated in a small unpublished study that their members 
encounter difficulties requesting a carrier test at their own initiative. OSCAR would 
prefer government involvement in terms of carrier screening as the organization 
has little confidence that screening will become more available when patients and 
clients have to rely on the goodwill of health professionals alone and therefore 
support the introduction of a programme similar to the one in England.49-51 
Government leadership would be preferred in order to initiate the appropriate 
changes, and may be needed in terms of clarifying legal matters. It could be the 
responsibility of the representative professional organizations of midwives and GPs 
(and possibly the obstetricians), to find appropriate strategies in dealing with ethnic 
diversity of their client and patient populations. This is supported by Achterberg’s 
study in which it was argued that effective implementation of screening for HbP 
will require changes at both regime (suppliers and users) and landscape level 
(institutions, material social, political and legal infrastructure), but that such change 
is difficult to achieve without an active orchestrating role of the government.52 
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ethnicity tailored health care
The focus group study showed that health professionals use ethnicity to deliver 
appropriate equitable health care for all groups within society. Despite the fact that 
Manna et al. dispute adequate ethnic related knowledge in guidelines, increasingly 
guidelines seem to incorporate ethnicity related health care.3,26,53,54 However, how to 
operationalise this concept is a question that is less easy to answer. The second part 
of this thesis shows that health professionals are willing to offer ethnically sensitive 
care but struggle with the concept in daily practice. A screening instrument based 
on ancestry has been shown to be effective.55,56 According to Karlson et al. ‘ethnic’ 
classifications draw on phenotypic characteristics in many surveys, in this case a 
screening instrument, which have genetic underpinnings or geographic and / or 
environmental ancestry which has been shown to influence genetic profile.57 
Ancestry seems to be less of a social construct than ethnicity. But as we have 
seen in the introduction of this thesis, some scientists belief that ancestry also has 
its limits because of a lack of understanding by the users.58 However the authors 
argue that even in the apparently clear case of a monogenic disorder such as 
sickle cell disease or thalassaemia, where genetic factors can offer insight into 
ethnic variations of these disorders, there is a complex interplay between genetic, 
environmental and socio-economic characteristics to be taken into account before 
the extent of genetic influences can be definitively established.57 For instance the 
life-span of a person with sickle cell disease or the potential influence of a positive 
carrier status on the outcome of pregnancy is influenced by more than just the 
genetic component which means that ethnic origin may be more appropriate for 
tailoring (midwifery or obstetric) health care.
Both the available screening instruments as developed by Lakeman and Dyson, 
use the term family origin55,56 but the self-assessment screening instrument by 
Lakeman et al. offers a combined offer of CF and HbP carrier screening in order 
to reduce feelings of discomfort when asking the ethnicity question, which was 
an emerging theme in our study and which was also found by others.28 If the 
implementation of a targeted screening programme is agreed upon, this would be 
the instrument of choice.
introduction of an hbp carrier screening programme in the netherlands
In England as opposed to the Netherlands which only introduced sickle cell screening 
as part of NNS, a successful combined screening programme was introduced in 
2004 (http://sct.screening.nhs.uk. Last accessed 25 April 2012). England conducts 
ethnicity based or targeted antenatal HbP carrier screening in low prevalence areas 
and universal screening in high prevalence areas. NNS for SCD and thalassaemia is 
conducted on the basis of universal screening as in the Netherlands.
The programme in England is still hampered by some implementation problems 
two of which are late screening offers when first appointments do not occur until 18-19 
weeks of pregnancy21,22 and only half of the fathers of those pregnant women who 
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are found to be a carrier, are tested.19 Besides, preconception screening is not really 
an issue (yet) in England. In general women in the Netherlands are seen between 
week 10 and 12 of pregnancy for a first visit with their midwife and sometimes even 
earlier, although it is known that some women from certain ethnic backgrounds have 
a tendency to come late into antenatal care.59,60 Preconception care has been initiated 
by all health professionals involved61-63, although the necessary financial support 
by health authorities was halted last year delaying adequate implementation.42 
The Netherlands is in a good position to implement a similar broad programme 
because of early pregnancy bookings and interest of health care professionals in 
preconception care. Previous research projects have shown that groups at higher risk 
of a positive HbP carrier status are interested in the offer of screening14,15,64 and that 
screening can work.65,66 Experience in England shows that about 30% of identified 
carrier couples during antenatal screening opt for prenatal diagnosis.19
targeted or universal screening?
Whether to offer HbP carrier screening on a targeted or universal basis, is a 
discussion initiated by the balance between genetic distribution and the use of 
public funds to implement such a programme.32 The fact that targeted screening 
on the basis of ethnicity is problematic, both from an ethical and practical point 
of view as this thesis and research by others have shown32, would favour universal 
preconception and antenatal screening. A combined offer of HbP and CF carrier 
screening such as suggested by Lakeman et al. may also circumvent issues of 
stigmatisation.56 OSCAR, the Dutch patient organisation for HbP, has expressed the 
view that the accent should not be placed upon certain ethnic groups and has 
indicated that there is a considerable group of carriers amongst their members of 
so called “autochtony descent” (Dutch term for a person whose parents were both 
born in the Netherlands).50 SCD has been wrongly addressed as a “Black disease” 
and care for these patients has been and very often still is shadowed by mistrust and 
health care discrimination.17,35
The ethnic structure of the Dutch population is not static as history has 
shown.67 This influences the prevalence of HbP and HbP carrier status. Besides, 
the association with minority ethnic groups will dilute over time as the number of 
inter ethnic relations grows and ethnic admixture becomes more common. This 
will make ethnicity less suitable for stratification of the risk of HbP carrier status. 
How this will influence other health issues is unsure but this would certainly be an 
interesting question in the future although midwives and GPs have indicated in the 
focus groups discussions that they already find this concept difficult to deal with. 
HbP should therefore be repositioned in our thinking as a health issue and not as an 
ethnic issue.68 Associating (carrier status of) HbP with particular ethnic groups may 
undermine the success of a possible screening programme. 
Considering all these factors, a universal offer of preconception and / or 
antenatal HbP carrier screening would therefore be the most equitable option. 
Extensive literature on cost effectiveness of antenatal HbP carrier screening does 
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not exist. However some argue that the potential of preconception counselling to 
prevent significant lifetime costs for affected children, may ultimately result in a 
favourable cost-savings balance. Recent research has indicated that health-sector 
costs are about 180.000 euro’s per 10.000 pregnancies.70 However this is based 
on the English health service model whereby most women receive hospital based 
antenatal care. The study was carried out in a high prevalence area and a cost-
effectiveness study may yield different results in a low prevalence area. Because 
of the involvement of public funding, it was decided that ethnicity based neonatal 
screening was unacceptable.32 Although preconception or antenatal screening does 
not have the same rational of preventing death or severe morbidity, the notions of 
equality and equity can still be applied for a preconception or antenatal offer of 
screening. Although funding for an HbP screening programme in the Netherlands 
would probably not be paid from public funds but rather through the insurance 
system, similar arguments may still apply. That aside, costs should not be the most 
important motive when deciding to implement a carrier screening programme.
In order to support women and their partners to make an informed reproductive 
choice, they need to be adequately informed about their risk which is different 
amongst ethnic groups. This and the fact that HbP comprises a broad group of 
haemoglobins of which new ones are still being identified71,72 means that the 
ethnicity question may still have to be asked in order to facilitate correct diagnosis, 
especially when specific mutations need to be confirmed. As the field of genetics 
is developing rapidly, complex DNA panels determining a wide range of genetic 
disorders including (carrier status of) HbP, may be offered to women and couples 
in the future eliminating the need to specify ethnicity. Indeed some have argued 
screening should be expanded to include autosomal recessive disorders such as 
HbP, CF and the Jewish panel which for example includes Tay Sachs disease.73
In the mean time health professionals should be adequately supported with an 
evidence based screening instrument55,56 and guidance both from government and 
their professional organizations in order to solve ethical and practical barriers. 
Based on this thesis a universal offer of preconception and antenatal carrier 
screening linked to NNS is proposed. If this is not feasible, i.e. for economic reasons, 
targeted screening such as is implemented in the programme in England, could be 
introduced but only if supported by an evidence based instrument to determine 
ethnic origin.
If we want to strive to provide adequate and accessible healthcare services for 
all, we need to find the right balance between providing equitable health care for all 
but without setting certain groups aside. If the discovery of ethnic health variations 
does more harm than good, we may need to retrace our steps.74 It is important 
that health professionals such as midwives and GPs are aware of these issues and 
that discussions on equity, equality and access are part of (continuing) education 
programmes to enable them to provide women with the care they need. 
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iMpLications for practice
The implementation of appropriate anaemia care in pregnancy should be sought 
through the representative organisations of the health professionals involved such 
as the KNOV and NHG. Publication of some of the results of this thesis was timely 
which meant that the studies were included in the literature which informed the 
current and updated KNOV guideline on anaemia in pregnancy (Appendix 1).75 Since 
the publication of the updated KNOV anaemia guideline, the NHG has updated its 
guideline on care during pregnancy and postnatal period.76 This NHG guideline 
was written in collaboration with the KNOV which meant that the KNOV anaemia 
guideline was fully incorporated into the NHG guideline. Both guidelines now tailor 
more to the needs of an ethnically diverse population of pregnant women. Further 
implementation has been encouraged by the formulation of local multidisciplinary 
guidelines based on the updated national guidelines. 
Being of non-Northern European descent has been added as a risk factor for 
anaemia in pregnancy. Pregnant women who are at higher risk of being an HbP 
carrier should have timely investigations into the cause of anaemia preferably during 
the first trimester of pregnancy so that anaemia can be appropriately managed, 
over-subscription of iron therapy will be prevented and pregnant women can use 
the knowledge of their carrier status to make appropriate reproductive choices. 
The integration of preconception care into the basic offer of health care for 
women and couples in their fertile period of life, should not be delayed any further 
and should be properly implemented and supported by the Ministry of Health (VWS), 
insurance companies and the Health Care Insurance Board (CVZ). Preconception care 
should be part of the basic insurance package for it to be accessible to all groups 
in society, especially to those groups who may need it most. Health professionals 
involved have already taken the necessary measures supported by their professional 
organizations and public information is available (http://www.strakszwangerworden.
nl and http://www.zwangerwijzer.nl. Both last accessed 08-05-2012). 
Following this, the introduction of HbP carrier screening should be considered 
possibly combined with other disorders such as CF and Tay Sachs disease as 
suggested by other researchers and the Dutch Health Council.49,77-79 Neonatal 
screening for SCD, has already been introduced in the Netherlands80, and the 
programme also identifies thalassaemia patients. This primarily benefits newborns 
with the disorder. Carrier status of the child is found as an unintended side-effect 
meaning that at least one of the parents is also an HbP carrier. Although parents have 
a possibility to opt-out on receiving this information about their child, most of them 
will be caught by surprise by this finding and few of them are adequately counseled 
by their GP.81 The knowledge for the child itself will not become relevant until he or 
she is an adult, besides, carrier testing in minors has many ethical considerations.82 
As the English programme has shown, it is also possible to use the same simple 
and cheap test to offer women an antenatal HbP carrier test. Offering the test during 
the preconception period would be preferable because it would give women the 
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most reproductive choices.14,50 This would be consistent with the advice of the Health 
Council.78 Adequate support by the Department of Health and health insurers would 
ensure that this type of care is available for all, especially those who need it most. 
For a variety of reasons preconception care reaches only very few women and 
couples at present48,83 and therefore an antenatal offer for HbP carrier screening 
should also be considered as almost all women attend antenatal services. 
So far, sufficient research data have been collected to consider a combined 
preconception, antenatal and neonatal HbP (carrier) screening programme. 
This should not be done without thorough consultation of appropriate patient 
organizations and the target populations such as couples with a pregnancy wish.
recoMMendations for further research
During the period of the studies on which this thesis is based, more questions 
related to the subject of screening for anaemia and HbP before and during 
pregnancy surfaced. Based on the results and discussion of this thesis, the following 
suggestions for further research have been formulated:
patho-physiology of anaemia and hbp carrier status
The diversity of factors involved in the aetiology of a higher risk of anaemia in 
women of non-Northern European descent, should be thoroughly investigated by 
a larger prospective cohort study allowing for adequate consideration of possible 
confounders such as SES and HbP carrier status. 
Such a cohort study could also find more evidence on the effect of a positive 
HbP carrier status on the outcome of pregnancy as highlighted by chapter 3. As 
ethnic diversity grows in our society the need for more knowledge on this subject 
increases as well. Following the advice of the WHO, routine investigations into HbP 
should become more standard in many countries making it easier to conduct a large 
well controlled prospective study to investigate any possible effect a positive HbP 
carrier status may have on pregnancy. 
The results of such a study could be incorporated into a study on how best to 
treat IDA in pregnancy, especially since very little evidence is available about the 
most optimal dosage of iron treatment for IDA in pregnancy. Iron metabolism in 
pregnancy is different when compared to non-pregnant women and iron absorption 
increases, in fact haemodilution is an essential and physiological component of 
pregnancy.84 It is unknown whether when IDA is treated, the outcome of pregnancy 
will improve. A randomised controlled trial would be able to answer this question. 
ethnicity in daily practice
The research in this thesis showed that midwives and GPs are familiar with the use 
of ethnicity in daily practice for the purpose of tailored health care and are prepared 
to screen patients for HbP carrier status in the future. However this also seemed to 
create uncomfortable feelings. It is important to investigate how to deal with these 
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feelings and how to operationalize ethnicity in such a way that neither health care 
professionals nor patients and clients are left feeling uncomfortable, stigmatised 
or discriminated against, as ethnic background becomes more important in the 
delivery of tailored and equitable care to all pregnant women. 
The assumption is that most midwives and GPs interpret the ethnicity of their 
clients and patients either by looking at their appearance or based on their country 
of origin. By only determining country of birth (and that of parents) third, fourth 
etc. generations will be missed. Besides, country of birth fails to address cultural 
and other issues that may be of importance depending on the condition. Moreover, 
the research in this thesis has shown that primary health care professionals find 
defining ethnicity and determining risk difficult, especially when mixed backgrounds 
are apparent. Dysons’ research has shown that even when asking “the ethnicity 
question”, the distinction becomes confused with other factors such as nationality 
or citizenship.28 Misplaced ideas about ethnicity may therefore ultimately influence 
quality of care, reproductive choice, especially in the case of screening for disorders 
which have a different prevalence amongst ethnic groups, such as HbP, CF and Tay 
Sachs. According to Stronks et al, in the Dutch context, country of birth complemented 
with additional indicators may be a more useful indicator for ethnicity.85,86 
Several instruments are available for determining ethnic HbP risk.55,56 Lakeman et 
al. studied the combined offer of targeted CF and HbP carrier screening during the 
preconception period and looked at the psychological effect of such a screening 
offer. However it is not known what women and their partners think about ethnicity 
related health care. Moreover the idea of ethnic targeting of carrier screening 
might reflect undesirable stereotyping of disease with specific ethnic groups as 
demonstrated in the literature from the US and England. The experience of health 
professionals with these types of instruments has not been investigated in the 
Netherlands. Both a qualitative and a quantitative approach would provide more 
information on this subject.
Screening for carrier status
Although considerable research has been produced in the Netherlands on the 
possibilities of HbP carrier screening, much of it has been on preconception 
care. Considering the limited access to preconception care at present, it may be 
more feasible to screen in pregnancy. Opportunities for reproductive choice are 
essentially different before pregnancy when compared to during pregnancy: they 
are more limited in pregnancy and may have more serious consequences such as 
decision whether or not to maintain the pregnancy if the baby is affected. Only two 
small pilot studies have been carried out in pregnancy.65,87 The voice and opinion 
of the target population, pregnant women and their partners, is absent in this. It is 
unknown what pregnant women would think of such an offer and what they would 
do with the knowledge of their carrier status. Moreover the role of fathers is under 
exposed in Dutch HbP related research. The English programme has shown that 
only half of those who are eligible are screened.19 It would be of interest to know 
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what the background is to this and if this would be applicable to the Dutch situation. 
This needs to be investigated.
equal access
As we have seen, there are many reports from researchers and authors from 
different countries across the world that highlight the ethnic controversies of social 
disadvantage attached to the services available for those who are either patients 
or carriers of HbP but very little is known about the situation in the Netherlands. 
A recent study in the Netherlands concluded that the results imply that reduced 
health related quality of life in children with SCD is mainly related to the low SES 
of this population.88 Another study on prenatal screening (unrelated to HbP) found 
ethnic differences in knowledge about prenatal screening could mainly be attributed 
to differences in levels of educational attainment.89 These are serious issues that 
affect equal access to health care. How this affects HbP carriers (and other ethnicity 
related autosomal recessive disorders such as CF and Tay Sachs) is unknown Further 
studies into experiences of those who are a carrier are needed. If equitable access to 
appropriate health care may be further compromised when people who are possible 
HbP carriers or those with HbP disorders are disproportionately from lower socio-
economic groups, policy needs to be developed based on good evidence to ensure 
that the target groups are reached. This can be done by investigating the needs of 
those groups, thereby giving groups at higher risk of a positive HbP carrier status 
more say in the health care they need. The discomfort of establishing ethnicity 
should not stand in the way of establishing equal access to health and health care 
for all groups in our society but should rather strive to support this. 
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suMMary 
The topic of this thesis is the screening of anaemia and haemoglobinopathies (HbP) 
against the background of ethnicity in pregnancy and the preconception period. 
Haemoglobinopathy is the umbrella term for the autosomal recessive disorders 
such as sickle cell disease (SCD) and thalassaemia. The thesis consists of two parts: 
The first part looks at anaemia in pregnancy amongst different ethnic groups in 
an Amsterdam population and at the effect of a positive HbP carrier status on 
the outcome pregnancy. The second part investigates the attitudes and barriers 
concerning the introduction of a ethnicity-based HbP carrier screening programme. 
chapter 1 discusses the background to and the relevance of the studies and 
introduces the research questions. Screening for anaemia, a low haemoglobin 
(Hb), in pregnancy is world wide common practice. As a result of heterogeneity in 
definitions used, blood tests, reference values and populations studied, it is difficult 
to determine the clear prevalence of anaemia in pregnancy. In the Royal Dutch 
Organisation of Midwives’ (KNOV) anaemia guideline, gestation specific reference 
values are designed to account for physiological haemodilution. The anaemia 
prevalence according to these reference values is also unknown. Besides midwives 
have questioned the policy around anaemia amongst women with different ethnic 
origins. Before anaemia policy is adjusted for specific groups of pregnant women, the 
prevalence of anaemia in different ethnic groups needs to be investigated. Depending 
on local policy, anaemia at the end of pregnancy may influence the decision about 
the place of birth. If anaemia prevalence depends on ethnic background, it would 
mean that some women may have less choice in the place of birth. 
HbP are considered to be the most prevalent monogenetic disorders worldwide. 
The prevalence of a positive HbP carrier status has been estimated at 0.03-40% 
depending on ethnic origin. Western Societies have become more and more 
multicultural and ethnically diverse, causing the prevalence of (carrier status of) HbP 
to increase. In the Netherlands, each year approximately 60 children are born with 
a serious HbP disorder. Carrier prevalence has been estimated at 4-26% for Dutch 
citizens of immigrant descent.
Despite the advice of the World health Organisation (WHO) in 2006, the 
Netherlands does not have a national programme for HbP carrier screening. To 
prevent complications and to promote health gain, universal screening for SCD 
added to the Neonatal Screening (NNS) in 2007. However the screening method 
also leads to unsought identification of carriers. In the Netherlands no negative effect 
is assumed for HbP carriers, except perhaps mild anaemia in people with alpha-
thalassaemia minor. Empirical evidence, however, seems inconclusive. It would be 
important for those involved in maternity care, such as midwives, obstetricians and 
GPs, to know if any effect of a positive HbP carrier status exists on the outcome of 
pregnancy, so that appropriate care can be given to those who need it.
The expansion of the NNS renewed the old discussion whether or not a broad 
HbP carrier screening programme should be introduced. Both the United Kingdom 
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(UK) and United States (US) have known Regarding the racial and social conditions 
related problems in both the United Kingdom (UK) and United States (US) related 
to the introduction of HbP carrier screening, the question was raised if similar issues 
were part of the decision-making process in the Netherlands. 
If a broader HbP carrier screening programme would be introduced in the future, 
primary care providers such as midwives and GPs, will be primarily called upon to 
carry out such a programme.
Following the example of the UK where an HbP screening programme was 
introduced in 2004, screening may be ethnicity based. It is unknown what primary 
health care professionals think of such a programme.
We therefore aimed to investigate midwives’ and GPs’ attitude, intention and 
behaviour towards ethnicity based HbP carrier screening as well as their ideas about 
existing barriers for the implementation of such a program. 
As both ‘ethnicity’ and ‘ancestry’ are shown to be equally complex terms and 
ethnicity is supported by literature as a proxy for ancestral or ethnic origin, this term 
was chosen to use in the study (Chapter 1). Moreover, it seems to be the acceptable 
term for health professionals.
The following research questions will be answered in this thesis:
1.  What is the prevalence of anaemia in pregnancy according to the cut-off points 
used in the KNOV anaemia guideline (2000)?
  Is there a difference in the prevalence of anaemia in pregnant women of non-
Northern European descent compared with pregnant women of Northern 
European descent?
  If so, does this difference result in a higher risk of a Transferred Home Delivery 
(THD), thus reducing the chance for non-Northern European women to choose 
their place of birth?
2.  Does being HbP carrier have any consequences for the health of pregnant 
women and does it have an effect on the outcome of their pregnancy?
3.  When did the issue of preconception, antenatal or neonatal testing of 
asymptomatic persons at risk of HbP receive attention on the agenda of the 
Dutch public health authorities and what was the background to this agenda 
setting?
  To what extent was this influenced by the political climate at the time and 
potential concerns about the role of ethnicity and the fear of discrimination?
4.  What are the attitude, intention and behaviour of midwives and GPs towards 
ethnic registration and their willingness to undertake carrier testing for clients 
and patients on the basis of ethnicity?
  What factors play a role in midwives’ and GP’s attitudes towards ethnic registration 
related to preconceptional or antenatal HbP carrier testing?
  What are the perceived barriers of these health professionals if ethnicity-based 
HbP carrier screening would be implemented in the future?
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chapter 2 describes the results of a retrospective cohort study into the prevalence 
of anaemia in pregnant women in Amsterdam according to the reference values 
used in the guideline Anaemia in Primary Care Midwifery Practice of the KNOV, 
and investigates a possible difference in prevalence between pregnant women 
of Northern European descent compared with women of non-Northern European 
descent. The study also investigated whether any difference in prevalence resulted 
in a higher risk of a transferred home delivery, thus reducing the chance for women to 
choose the place of birth. All pregnant women with a singleton low-risk pregnancy, 
who delivered their baby between 1st of January 2003 and 31st of December 2003, 
and who were registered, at one of the three primary care midwifery practices were 
included in the study. The practices were selected on the basis of urbanisation, 
resulting in an ethnic population which was comparable with the ethnic mix in other 
similarly urbanised areas in the Netherlands. This resulted in a study population of 
828 pregnant women.
The results showed a prevalence of anaemia in pregnancy of 3.4% (n = 28) at 
booking (first visit) and 2.7% (n = 22) at approximately 30 weeks of gestation. The 
relative risk (RR)of anaemia at booking was 5.9 (95% CI 2.1-16.7) for pregnant women 
of non-Northern European descent compared with those of Northern European 
descent. The RR of anaemia at approximately 30 weeks of gestation was 22 (95% 
CI 3.0-162.0) for pregnant women of non-Northern European descent compared 
with those of Northern European descent. The incidence of transferred home 
delivery was 3.1% in the study population. The RR for transferred home delivery was 
24.1 (95% CI 3.3-176.7) for pregnant women of non-Northern European descent 
compared with those of Northern European descent.
The conclusion of this chapter is that pregnant women of non-Northern European 
descent have a higher chance of anaemia in pregnancy than women of Northern 
European descent: RR 5.9, (95% CI 2.1-16.7) at booking and RR 22.0, (95% CI 3.0-
162.0) at 30 weeks pregnancy. As a result, they have a higher risk of a transferred 
home delivery, taking away their opportunity to choose the place of birth. HbP 
did not explain the higher risk of anaemia in pregnant women of non-Northern 
European descent and it was not possible to correct for socio-economic status. 
Being of non-Northern European descent should thus be added as a risk factor for 
anaemia in pregnancy until more is known about the background of this risk factor.
In chapter 3 the results of a systematic literature review into the effect of a positive 
HbP carrier status on the outcome of pregnancy are presented. The reproductive 
risk for women who are carriers of HbP is well known. However, midwives, GPs and 
obstetricians need to know whether there are other risks involved in the pregnancies 
of women who are carriers of HbP. On the basis of the following criteria a selection for 
the inclusion of studies into the review was made: Cohort and case-control studies, 
pregnant women with a singleton pregnancy, exposure of HbAS or thalassaemia 
minor and the following outcomes: urinary tract infection (UTI), anaemia, (pre-) 
eclampsia, gestational diabetes, premature labour, low birth weight, intrauterine 
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growth retardation, miscarriage, neonatal death, low Apgar score, neural tube 
defects. Quality assessment and data extraction were carried out by two researchers. 
A total of 780 scientific articles were identified of which nine were included in the 
study. As a result of considerable heterogeneity, pooling of the data was not possible. 
A protective effect of sickle cell trait was found for premature birth, low Apgar 
score and perinatal mortality. No significant effect was found for low birth weight, 
growth retardation, UTI or high blood pressure. The risk of anaemia and bacteriuria 
was increased. 
Many methodological problems were identified in the studies. The 
appropriateness of a large well controlled prospective cohort study is called for. 
Until further knowledge on this subject is generated, health care professionals need 
to be aware of the risk of anaemia and bacteruria. In conclusion, the risk for an 
adverse outcome of pregnancy in HbP carriers is low and they can continue to 
receive primary care. 
chapter 4 describes the results of a one-day witness seminar that was held in 
2009 to explore the decision-making process around the possible introduction of 
a HbP carrier screening programme in the Netherlands in the past. The central 
question that the participants, fourteen multi-disciplinary key figures, were asked to 
answer during this seminar was why the introduction of a screening programme for 
HbP was considered to be untimely, and whether ethnicity played a role given the 
race-related history in other countries surrounding the introduction of HbP (carrier) 
screening? The full transcript of the day was content-analysed together with the 
available grey and scientific Dutch literature identified on the subject. 
The results of this study show that the subject of HbP (carrier) screening first 
appeared in the literature in the 1970s. As opposed to a long history of neglect 
of African-American health in the United States, the heritage of the Second World 
War influenced the decision-making process in the Netherlands. As a consequence, 
registration of ethnicity surfaced as an impeding factor. Overall, official Dutch 
screening policy was restrained regarding reproductive issues caused by fear of 
eugenics. In the 1990s HbP (carrier) screening was found to be ‘not opportune’ 
due to low prevalence, lack of knowledge and fear of stigmatisation. Currently the 
registration of ethnicity remains on the political agenda and still proves to be a 
sensitive subject due to the political climate. Carrier screening in general never 
appeared high on the policy agenda. Complexities related to carrier screening are 
a challenge in Dutch healthcare. Whether carrier screening will be considered a 
valuable complementary strategy in the Netherlands, depends partly on participation 
of representatives of high-risk groups in policy making.
In chapter 5 the results are described of a quantitative questionnaire based on the 
Theory of Planned Behaviour which investigated the attitudes, intention and behaviour 
of midwives and GPs towards ethnicity-based HbP carrier screening. Moreover, 
registration of ethnicity is a controversial societal issue which may complicate the 
introduction of a national preconception or antenatal carrier screening programme. 
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The questionnaire was sent by mail to the total population of 1800 primary 
care midwives and a random selection of 2100 GPs. The response rate was 35% 
(midwives 44.2%; GPs 27.6%).
Most respondents favoured ethnicity registration for health purposes. Although 
45% of respondents thought that offering a carrier test on the basis of ethnicity 
alone should become national policy, it is currently not carried out. The main 
factor explaining lack of intention towards ethnicity-based HbP carrier screening 
was subjective norm, the perception that their peers do not think they should offer 
screening (52.2% variance explained). If ethnicity-based HbP carrier screening would 
become national policy, most professionals reported that they would carry this out. 
Since most practitioners look for role models among peers, debate amongst 
general practitioners and midwives should be encouraged when new policy is to 
be developed articulating the voices of colleagues who already actively offer HbP 
carrier screening. However, implementation of HbP carrier screening by GPs and 
midwives cannot be achieved without policy support at national level. 
The aim of chapter 6 was to explore attitudes and perceived barriers amongst 
GPs and midwives regarding ethnicity-based HbP carrier screening. Six focus group 
discussions were held with a total of 9 GPs and 28 midwives. GPs and midwives were 
consulted separately. The study showed that both GPs and midwives struggled with 
correctly identifying ethnicities at risk leading to several complex considerations 
such as what to do with mixed backgrounds and how far back they would have 
to look into someone’s ethnic origin. Acerbated by the current political climate, 
ethical concerns regarding privacy originated from the second World War when 
ethnic and religious registration facilitated deportation of Jewish citizens. Some 
midwives thought the ethnicity question might undermine the relationship with 
their clients. Software programs prevent GPs from registering ethnicity of patients 
at risk. Financial implications for patients were also a concern. Despite this, both 
groups seemed positive and are familiar with identifying ethnicity and use this for 
individual patient care. The chapter concluded that although health professionals are 
generally positive, ethical, financial and practical issues surrounding ethnicity-based 
HbP carrier screening need to be clarified before introducing such a programme. 
Primary care professionals can be targeted through professional organisations, but 
still need national policy support.
Finally chapter 7, the general discussion of the thesis, presents a brief overview of the 
findings which are discussed against the background of the existing literature. Besides 
this, limitations of the studies in the thesis are discussed, as well as implications for 
practice and advice on further research based on the results of this thesis.
Overall the study findings show that ethnic diversity poses certain questions 
within the healthcare setting and challenges health care professionals to deliver 
equitable health services. The results of this thesis support clinicians such as 
midwives, obstetricians and GPs in providing tailored health care for pregnant women 
with different ethnic backgrounds. Professionals should therefore be aware of the 
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increased possibility of anaemia and HbP (carrier) status in different ethnic groups. 
The prevalence of anaemia between ethnic groups differs and ethnicity affects the 
prevalence of HbP carrier status. Since anaemia, asymptomatic bacteriuria and the 
subsequent risk of pyelonephritis may occur more frequently in HbP carriers, health 
professionals involved should investigate pregnant women who are known HbP 
carriers more frequently for these conditions. 
On the basis of the available scientific evidence it can be concluded that a 
positive HbP carrier status does not seriously affect the outcome of pregnancy which 
means that carriers can continue to receive primary care during their pregnancies, 
it may influence reproductive choice. Health professionals use ethnicity to deliver 
appropriate equitable health care for all groups within society, but the results show 
that they struggle with the operationalisation of this concept, making them uncertain 
whom to offer ethnicity-based screening. A screening instrument based on ancestry 
has been shown to be effective. Although primary health care professionals are 
reasonably positive about a national HbP carrier screening programme, ethical, 
practical and financial barriers need to be solved if an ethnicity-based programme 
would be introduced.
The discussion in the Netherlands has focused primarily on equality in health 
care and concerns over stigmatisation of certain groups in society. Considering the 
complexity of determining ethnicity, increasing ethnic admixture, the view of the 
patient organisation OSCAR that the accent should not be placed on certain ethnic 
groups, a universal offer of preconception and / or antenatal HbP carrier screening 
would therefore be the most equitable option. If we want to strive to provide 
equitable healthcare services for all, it is important that health professionals such 
as midwives and GPs are aware of these issues. They must be supported in giving 
appropriate care and discussions on equity, equality and access should be part of 
(continuing) education programmes to enable them to provide women with the care 
they need. As part of meeting the needs of all societal groups, the introduction of 
HbP carrier screening should be considered, as proposed by the WHO. 
Based on this thesis a universal offer of preconception and antenatal carrier 
screening alongside the NNS is proposed. If this is not feasible, i.e. for economic 
reasons, targeted screening such as is implemented in England, could be introduced 
but only if supported by an evidence based instrument to determine ethnic origin.
The results from the studies in this thesis underline the necessity to solve 
ethical and practical barriers and clarify financial issues before a HbP carrier 
screening programme is implemented. This can only be done with adequate 
governmental leadership. Once these issues are solved health care professionals 
and their professional organisations can be called upon to meet the implementation 
requirements of such a programme.
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saMenvatting
Het onderwerp van dit proefschrift is het screenen op anemie en hemoglobinopathie 
(HbP) tijdens de preconceptieperiode en in de zwangerschap in het licht van 
etniciteit. Hemoglobinopathie is de samenvattende term voor de autosomaal 
recessieve aandoeningen sikkelcelziekte (SCZ) en thalassemie.
Het proefschrift bestaat uit twee delen: Het eerste deel concentreert zich 
op anemie tijdens de zwangerschap bij verschillende etnische groepen in een 
Amsterdamse populatie en het effect van een positieve HbP dragerschapstatus op 
de uitkomst van de zwangerschap. Het tweede deel onderzoekt de attitudes en 
de barrières met betrekking tot de introductie van een HbP dragerschapscreening 
programma gebaseerd op etniciteit.
hoofdstuk 1 gaat over de achtergrond en de relevantie van de studies en 
introduceert de onderzoeksvragen. Het screenen op anemie, dat wil zeggen 
een laag hemoglobinegehalte (Hb), tijdens de zwangerschap is wereldwijd 
geaccepteerd beleid. Vanwege de heterogeniteit in de gebruikte definities, de 
gebruikte bloedtesten, referentiewaarden en de onderzochte populaties, is het 
lastig een eenduidige prevalentie van anemie vast te stellen. In de richtlijn anemie 
van de Koninklijke Nederlandse Organisatie voor Verloskundigen (KNOV) zijn 
referentiewaarden ontwikkeld die rekening houden met fysiologische hemodilutie 
en die daarom verschillen, afhankelijk van de zwangerschapstermijn. De prevalentie 
van anemie op basis van de KNOV referentiewaarden is onbekend. Bovendien 
hebben verloskundigen vragen gesteld bij het beleid rondom anemie bij vrouwen 
met verschillende etnische achtergrond. Voordat het anemiebeleid aangepast kan 
worden voor specifieke groepen zwangere vrouwen, is het van belang de prevalentie 
in verschillende etnische groepen vast te stellen. Afhankelijk van regionaal beleid, 
kan het vóórkomen van anemie aan het eind van de zwangerschap invloed hebben 
op de plaats van bevalling. Indien anemie tijdens de zwangerschap inderdaad vaker 
voorkomt bij bepaalde etnische groepen, dan zou dit betekenen dat sommige 
vrouwen minder keuzemogelijkheid hebben ten aanzien van de plaats van bevalling.
HbP zijn wereldwijd de meest voorkomende monogenetische aandoeningen. 
De prevalentie van een positieve dragerschapstatus wordt geschat op 0,03-40% 
afhankelijk van etnische afkomst. Aangezien de westerse samenleving steeds 
multicultureler en etnisch divers wordt, wordt ook dat de prevalentie van 
HbP (dragerschap) in de samenleving steeds groter. In Nederland worden 
ieder jaar ongeveer 60 kinderen geboren met een ernstige vorm van HbP. De 
dragerschapprevalentie wordt geschat op 4-26% voor Nederlanders van niet-
westerse afkomst. Ondanks het advies van de Wereld Gezondheidsorganisatie 
(WHO) in 2006, bestaat er in Nederland geen landelijk dragerschapprogramma voor 
HbP. Ter voorkoming van complicaties en het bevorderen van gezondheidswinst, 
werd de neonatale screening (NNS) in 2007 met SCZ uitgebreid. Als nevenbevinding 
van het programma wordt echter ook HbP dragerschap bij de pasgeborenen 
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vastgesteld. In Nederland gaat men er van uit dat HbP dragerschap geen negatieve 
gezondheidseffecten heeft behalve een lichte anemie bij dragers van alfa-
thalassemie. Er is echter wat betreft de gezondheidseffecten op de uitkomst van de 
zwangerschap geen duidelijke conclusie beschikbaar op basis van wetenschappelijk 
onderzoek. Hulpverleners zoals verloskundigen, gynaecologen en huisartsen, 
zouden gebaat zijn bij wetenschappelijk onderbouwde kennis over het effect van 
een positieve HbP dragerschapstatus op de uitkomsten van de zwangerschap. 
Indien er inderdaad negatieve gevolgen zijn, kan de zorg worden aangepast.
De uitbreiding van de NNS zorgde voor een hernieuwde discussie over het al 
dan niet invoeren van een HbP dragerschap screeningsprogramma. Zowel Groot 
Brittannië (GB) als de Verenigde Staten (VS) zijn bekend met bepaalde sociale en 
raciale kwesties met betrekking tot de introductie van HbP dragerschapscreening. 
De vraag is dan ook of en hoeverre er in Nederland sprake is geweest van soortgelijke 
kwesties ten tijden van het besluitvormingsproces over het al dan niet introduceren 
van een screeningsprogramma. 
Een breed HbP screeningsprogramma zal mogelijk gebaseerd zijn op etniciteit, 
zoals in Engeland waar in 2004 een dergelijk programma werd geïmplementeerd. 
Indien in de toekomst een breed HbP programma in Nederland zal worden 
geïntroduceerd, is de verwachting dat dit voornamelijk zal worden uitgevoerd door 
verloskundigen en huisartsen in de eerstelijn. Het is onbekend wat deze eerstelijns 
hulpverleners van een dergelijk programma zouden vinden. Het doel van het 
onderzoek was daarom de attitude, de intentie en het gedrag ten aanzien van HbP 
dragerschapscreening programma op basis van etniciteit te onderzoeken en de 
mogelijke knelpunten in beeld te brengen die volgens deze hulpverleners zouden 
kunnen bestaan bij de invoering van een dergelijk programma.
Zowel ‘etniciteit’ als ‘herkomst’ blijken complexe termen. In de bestaande 
literatuur wordt ‘etniciteit’ vaak gebruikt als een ander woord voor ‘herkomst’, 
oftewel etnische herkomst. Daarom wordt er in dit onderzoek gekozen voor het 
gebruik van deze term. Bovendien lijkt etniciteit de term die het meest bekend is 
bij hulpverleners.
De volgende onderzoeksvragen zullen in dit proefschrift worden beantwoord:
1.  Wat is de prevalentie van anemie tijdens de zwangerschap gebaseerd op de 
KNOV-referentie waarden?
  Is er een verschil in de prevalentie van anemie tussen zwangeren van niet Noord 
Europese afkomst in vergelijking met zwangeren van Europese afkomst? Indien dit 
zo is, hebben deze zwangeren dan een verhoogde kans op een verplaatste thuis 
bevalling waardoor zij minder keuze hebben ten aanzien van de plaats van bevalling?
2.  Wat is het effect van HbP-dragerschap bij vrouwen op de uitkomst van de 
zwangerschap
3.  Wanneer verscheen de discussie over het preconceptioneel; prenataal en / of 
neonataal testen van asymptomatische personen met een verhoogd risico voor 
het eerst op de agenda van beleidsmakers in de Nederlandse gezondheidzorg en 
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tegen welke achtergrond gebeurde dit? Heeft het politieke klimaat van destijds en 
de rol van etniciteit en de angst voor discriminatie hier enige invloed op gehad?
4.  Wat is de attitude; de intentie en het gedrag van verloskundigen en huisartsen 
ten aanzien van de registratie van etniciteit en hun bereidheid om hun cliënten 
en/of patiënten een op etniciteit gebaseerde HbP dragerschaptest aan te 
bieden? Welke andere factoren spelen hierin een mogelijke rol en wat zijn de 
knelpunten die deze hulpverleners voorzien bij de implementatie van een op 
etniciteit gebaseerd HbP dragerschapprogramma?
hoofdstuk 2 beschrijft de resultaten van een retrospectieve cohortstudie naar 
de prevalentie van anemie bij zwangere vrouwen in Amsterdam op basis van de 
referentiewaarden in de KNOV richtlijn Anemie in de eerstelijns verloskundige 
praktijk. In de studie is een mogelijk verschil in de prevalentie tussen zwangere 
vrouwen van Noord Europese en niet-Noord Europese afkomst onderzocht. Tevens is 
nagegaan of, indien er een verschil in prevalentie bestaat, dit resulteert in een hoger 
risico op een verplaatste thuisbevalling (de zogenaamde D-indicatie) waardoor deze 
groep vrouwen minder kans heeft om zelf de plaats van bevalling te kiezen.
Alle zwangeren met een laag risico die tussen 1 januari en 31 december 2003 
bevielen van een eenling in één van drie eerstelijns verloskundigenpraktijken, 
werden geïncludeerd in de studie. De praktijken werden geselecteerd op basis 
van urbanisatie zodat de etniciteit van de onderzoekspopulatie vergelijkbaar 
was met die van vergelijkbare gebieden in Nederland. Dit resulteerde in een 
onderzoekspopulatie van 828 zwangere vrouwen.
De resultaten van deze studie laten een anemie prevalentie zien van 3,4% (n=28) 
onder zwangere vrouwen tijdens de eerste controle en 2,7% (n=22) bij ongeveer 
30 weken graviditeit. Het relatieve risico (RR) op anemie tijdens de eerste controle 
was 5,9 (95% BI 2,1-16,7) voor zwangere vrouwen van niet-Noord Europese afkomst 
vergeleken met vrouwen van Noord Europese afkomst. Het RR op anemie bij 
30 weken graviditeit was 22 (95% BI 3,0-162,0) voor zwangeren van niet-Noord 
Europese afkomst in vergelijking met vrouwen van Noord Europese afkomst. De 
incidentie van de verplaatste thuisbevalling was 3,1% in de bestudeerde populatie. 
Het RR op het risico van een verplaatste thuisbevalling was 24,1 (95% BI 3,3-176,7) 
voor zwangeren van niet-Noord Europese afkomst in vergelijking met zwangeren 
van Noord Europese afkomst.
Dit hoofdstuk concludeert dat zwangeren van niet-Noord Europese afkomst 
meer kans hebben op anemie tijdens de zwangerschap waardoor zij minder kans 
hebben om zelf de plaats van bevalling te kiezen vanwege een hogere kans op een 
indicatie voor een verplaatste thuisbevalling. HbP bleek het verschil in anemie niet 
te verklaren en voor sociaal economische factoren kon niet worden gecorrigeerd. 
Niet-Noord Europese afkomst zou daarom als risicofactor voor anemie moeten 
worden toegevoegd tot meer bekend is over de achtergrond van dit risico.
In hoofdstuk 3 worden de resultaten van een systematisch literatuuronderzoek 
gepresenteerd naar het effect van HbP dragerschap op de uitkomst van de 
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zwangerschap. Het genetische risico voor vrouwen met een positieve HbP 
dragerschapstatus is bekend. Echter verloskundigen, gynaecologen en huisartsen 
zouden ook moeten weten of er nog andere risico’s voor zwangere HbP-dragers 
zouden kunnen zijn.
Cohort en patiëntcontrole onderzoeken werden geïncludeerd op basis van de 
volgende criteria: Vrouwen zwanger van een eenling met een HbAS of thalassemie 
minor expositie en een van de volgende uitkomsten: urineweginfectie; anemie; 
(pre-) eclampsie; diabetes gravidarum; laag geboortegewicht; prematuriteit; 
dysmaturiteit; spontane abortus; perinatale mortaliteit; lage apgarscore; neuraal 
buisdefect. Kwaliteitsbeoordeling en data-extractie werden uitgevoerd door twee 
onderzoekers. Er werden in totaal van 780 wetenschappelijke artikelen gevonden 
waarvan er negen werden geïncludeerd in de studie Door aanzienlijke heterogeniteit 
van de studies was het poolen van de data niet mogelijk.
Er werd een beschermend effect gevonden van sikkelceldragerschap, op het 
voorkomen van prematuriteit; lage apgarscore en perinatale mortaliteit. Er werd 
geen significant effect gevonden voor laag geboortegewicht; dysmaturiteit; 
urineweginfectie of hoge bloeddruk. Het risico op anemie en bacteriurie was 
verhoogd bij sikkelceldragerschap.
Er werden nauwelijks studies gevonden die het effect van dragerschap op 
thalassemie onderzochten. Er werden veel methodologische knelpunten in de 
studies geïdentificeerd. Het zou daarom zinvol zijn om een grote prospectieve 
cohortstudie uit te voeren om een betere uitspraak te kunnen doen over het effect 
van HbP dragerschap op de uitkomst van de zwangerschap. Tot er meer bekend is 
over dit onderwerp moeten verloskundige hulpverleners er van uitgaan dat er een 
grotere kans op anemie en bacteriurie bestaat bij dragers. Concluderend is het 
risico op een ongunstige uitkomst van de zwangerschap laag bij HbP dragers en kan 
de zorg in de eerstelijn plaats vinden.
hoofdstuk 4 beschrijft de resultaten van een witness seminar, gehouden in 
2009 waarbij gedurende één dag het besluitvormingsproces in het verleden 
rondom de eventuele introductie van een Nederlands screeningsprogramma 
voor HbP-dragerschap werd onderzocht. Deelnemers, veertien multidisciplinaire 
sleutelfiguren, werden gevraagd de volgende centrale vragen te beantwoorden: 
Waarom werd de introductie van een HbP screeningprogramma in de jaren ‘90 niet 
opportuun geacht en heeft de factor etniciteit een rol gespeeld gezien de raciaal 
gerelateerde geschiedenis in andere landen met betrekking tot de introductie van 
een dergelijk dragerschapprogramma? Het volledige transcript van die dag en de 
beschikbare wetenschappelijke en grijze Nederlandse literatuur over dit onderwerp 
werden op inhoud geanalyseerd.
De resultaten van dit hoofdstuk laten zien dat het onderwerp HbP (dragerschap-) 
screening voor het eerst in de jaren ‘70 in de literatuur verscheen. Door raciale 
tegenstellingen is HbP dragerschap in de Verenigde Staten lang verwaarloosd. In 
Nederland daarentegen hebben de erfenis van schuldgevoelens en ervaringen uit 
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de Tweede Wereldoorlog de besluitvorming beïnvloed. De registratie van etniciteit 
is gezien de geschiedenis een beladen onderwerp en dit kwam dan ook als een 
belemmerende factor naar voren. Over het algemeen was het officiële Nederlandse 
beleid ten aanzien van reproductieve keuzemogelijkheden beperkt wat voornamelijk 
veroorzaakt werd door de angst voor eugenetica. In de jaren ‘90 werd verondersteld 
dat HbP (dragerschap-) screening ‘niet opportuun’ zou zijn, voornamelijk vanwege 
een lage prevalentie; gebrek aan kennis en angst voor stigmatisering.
Momenteel staat de registratie van etniciteit nog steeds op de politieke agenda 
en in verband met het huidige politieke klimaat blijft dit een gevoelig onderwerp. 
Over het algemeen heeft het onderwerp dragerschapsscreening nooit hoog op de 
politieke agenda gestaan. De complexiteit rondom dragerschapsscreening blijft 
een uitdaging in de Nederlandse gezondheidzorg. Of dragerschapscreening zal 
worden gezien als een waardevolle strategie in Nederland is deels afhankelijk van 
de deelname van vertegenwoordigers van de bevolkingsgroepen met een hoger 
HbP (dragerschap-) risico aan de beleidsvorming.
In hoofdstuk 5 worden de resultaten beschreven van een kwantitatief 
vragenlijstonderzoek, gebaseerd op de Theorie van Gepland Gedrag. Hierin werden 
de attitude, intentie en gedrag onderzocht van verloskundigen en huisartsen met 
betrekking tot HbP dragerschapscreening gebaseerd op etniciteit.
Daarbij is het zo dat de registratie van etniciteit gezien wordt als een controversieel 
maatschappelijk onderwerp wat de introductie van een landelijk preconceptioneel 
en prenataal screeningprogramma zou kunnen bemoeilijken. De vragenlijst werd 
per post verstuurd aan alle 1800 eerstelijns verloskundigen in Nederland en 
aan een gerandomiseerde steekproef van 2100 huisartsen. De respons was 35% 
(verloskundigen 44,2%; huisartsen 27,6%). 
Respondenten zijn voorstander van etniciteitsregistratie, het bevordert volgens 
hen het geven van zorg op maat. Hoewel 45% van de respondenten voorstander is 
van een op etniciteit gebaseerd landelijk screeningsbeleid voor HbP dragerschap, 
voert geen van hen dit momenteel uit. Dit lijkt vooral te worden verklaard doordat 
zorgverleners vermoeden dat hun collega’s ook niet screenen (52,2% verklaarde 
variantie). Indien HbP dragerschapscreening landelijk beleid zou worden, zouden 
de meeste eerstelijns hulpverleners dit uitvoeren.
Omdat de meeste hulpverleners hun collega’s gebruiken als rolmodel zou het 
goed zijn om de collega’s die deze screening al wel aanbieden te betrekken bij 
implementatie van een eventueel toekomstig HbP screeningsbeleid. Het is echter 
wel zo dat de implementatie door verloskundigen en huisartsen van een dergelijk 
screeningprogramma niet zal plaatsvinden zonder landelijke beleidsondersteuning.
Het doel van hoofdstuk 6 was het exploreren van de attitudes en de te verwachte 
barrières van huisartsen en verloskundigen ten opzichte van op etniciteit gebaseerde 
HbP dragerschapscreening. Er werden zes focusgroepdiscussies gehouden met een 
totaal van negen huisartsen en 28 verloskundigen. De groepen met verloskundigen 
en huisartsen werden apart bevraagd.
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De studie liet zien dat zowel huisartsen als verloskundigen moeite hebben 
met het correct identificeren van etniciteit met een verhoogd risico. DIt leidde tot 
complexe overwegingen, zoals wat te doen bij een gemengde afkomst en hoever 
moet worden terug gekeken naar iemands etnische afkomst bij het vaststellen 
van een verhoogd risico. Verergerd door het huidige politieke klimaat, komen de 
ethische bezwaren voort uit de Tweede Wereldoorlog toen etnische en religieuze 
registratie de deportatie van joodse inwoners heeft gefaciliteerd. Een aantal 
verloskundigen had het gevoel dat door de etniciteitvraag de relatie met hun cliënt 
op het spel zou komen te staan. Softwareprogramma’s weerhielden de huisartsen 
ervan om de etniciteit van hun patiënten te registreren. Financiële gevolgen voor 
patiënten waren ook een zorg voor hulpverleners. Desondanks leken beide groepen 
eerstelijns hulpverleners positief over en zijn zij bekend met het identificeren van 
etniciteit in individuele patiëntenzorg. De conclusie van dit hoofdstuk is dan ook dat 
hulpverleners over het algemeen positief zijn over op HbP dragerschapscreening 
gebaseerd op etniciteit. Ethische, financiële en praktische zaken moeten echter nog 
worden opgehelderd voordat een screeningsprogramma kan worden geïntroduceerd. 
Eerstelijns hulpverleners kunnen worden bereikt via hun beroepsorganisaties, maar 
hebben bij de implementatie landelijke beleidsondersteuning nodig.
De algemene discussie van het proefschrift, hoofdstuk 7, geeft een kort overzicht 
van de resultaten in het licht van de bestaande literatuur. Daarnaast worden 
besproken: de beperkingen van het uitgevoerde onderzoek, de betekenis van de 
resultaten voor het veld en aanbevelingen voor verder onderzoek t.
Over het algemeen laten de studieresultaten zien dat etnische diversiteit 
leidt tot een aantal vraagstukken in de gezondheidszorg die een uitdaging zijn 
voor hulpverleners bij het leveren van gelijkwaardige zorg. De resultaten van dit 
proefschrift ondersteunen clinici zoals verloskundigen; huisartsen en gynaecologen 
bij het geven van zorg op maat aan zwangeren met verschillende etnische 
achtergronden. Hulpverleners zouden zich meer bewust moeten zijn van een 
grotere kans op anemie en een positieve HbP (dragerschap-) status in verschillende 
etnische groepen. De prevalentie van anemie verschilt tussen etnische groepen 
en etniciteit heeft invloed op de prevalentie van HbP dragerschap. Omdat anemie 
en asymptomatische bacterurie en het daaraan gerelateerde risico op pyelitis 
vaker kunnen voorkomen onder zwangere HbP dragers, moeten verloskundige 
hulpverleners hier alerter op zijn bij deze groep zwangeren.
Hoewel er momenteel geen bewijs bestaat dat een positieve HbP 
dragerschapstatus ernstige gevolgen heeft voor de uitkomst van de zwangerschap 
en deze zwangeren daarom in de eerste lijn onder zorg kunnen blijven,, kan dit wel 
van invloed zijn op hun reproductieve keuzes. Etniciteit wordt door zorgverleners 
gebruikt om gelijkwaardige zorg te geven aan alle groepen in onze maatschappij, 
maar de resultaten laten zien dat zij worstelen met de operationalisatie van dit 
concept waardoor zij onzeker zijn aan wie zij screening zouden moeten aanbieden. 
Een screeningsinstrument dat is gebaseerd op oorspronkelijke afkomst is 
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bewezen effectief. Eerstelijns hulpverleners zijn redelijk positief over een landelijk 
dragerschapsprogramma voor HbP, maar ethische, praktische en financiële barrières 
moeten eerst worden opgelost alvorens een op etniciteit gebaseerd programma 
wordt geïntroduceerd.
In Nederland heeft de discussie zich voornamelijk gefocust op gelijkheid in 
de gezondheidszorg en zorgen over stigmatisering van bepaalde groepen in de 
maatschappij. Gezien de complexiteit van het vaststellen van etniciteit, de steeds 
groter wordende smeltkroes van etniciteiten, de mening van de patiëntenorganisatie 
OSCAR die vindt dat de nadruk niet moet worden gelegd op bepaalde etnische 
groepen, lijkt een universeel aanbod om tijdens de preconceptieperiode of aan het 
begin van de zwangerschap op HbP dragerschap te screenen de meest gelijkwaardige 
optie. Indien we willen streven naar gelijkwaardige gezondheidszorg voor iedereen 
dan is het van belang dat hulpverleners zoals huisartsen en verloskundigen zich 
hiervan bewust zijn en worden ondersteund in het uitvoeren van deze zorg. De 
discussie over gelijkwaardigheid, gelijkheid en gelijke toegankelijkheid van zorg 
horen onderdeel te zijn van het (continue) opleidingsproces zodat zorgverleners in 
staat worden gesteld vrouwen de zorg te geven die zij nodig hebben. De introductie 
van een screeningsprogramma voor HbP dragerschap zoals voorgesteld door de 
WHO ligt in het verlengde hiervan en zou daarom moeten worden overwogen.
Gebaseerd op dit proefschrift is een universeel aanbod van preconceptie 
en prenatale screening op HbPaan te bevelen, naast de NNS. Indien dit niet 
mogelijk is, bijvoorbeeld om economische redenen, dan is doelgerichte 
HbP dragerschapscreening op basis van etniciteit een mogelijkheid, zoals 
geïmplementeerd in Engeland. Wel moet dit worden ondersteund door een 
wetenschappelijk ontwikkeld instrument om etniciteit te bepalen.
De uitkomsten van de studies in dit proefschrift benadrukken de noodzaak om 
ethische en praktische barrières op te lossen en financiële onduidelijkheden op te 
lossen alvorens een screeningsprogramma te implementeren. Dit kan alleen met een 
duidelijke beleidsuitspraak van de overheid. Wanneer deze zaken zijn opgehelderd, 
kan de vraag bij de betreffende beroepsorganisaties worden neergelegd om het 
voorgestelde programma te implementeren. 
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danKwoord / acKnowLedgeMents
In het boemeltje van Bilthoven naar Utrecht, daar is het begonnen: “Ga nou 
gewoon met haar praten; je kunt altijd kijken wat je doet en er altijd weer mee 
ophouden.” Maar ik ben opgevoed met het idee dat waar je aanbegint dat maak je 
ook af. Daarom ligt er nu dit boekje. Een boekje dat er nooit was geweest zonder 
de aanmoediging en ondersteuning van velen die ik hierbij graag wil bedanken.
Allereerst wil ik mijn collega’s bedanken (daarbij tel ik voor het gemak ook de 
huisartsen) die mij hun vertrouwen schonken en mij toe hebben gelaten in hun 
praktijk of deelgenomen hebben aan het onderzoek. Ook de deelnemers aan het 
witness seminar horen hierbij. Zonder jullie was het simpelweg niks geworden.
Prof. ALM Lagro-Janssen en Prof. MC Cornel. Lieve Toine als ik bij jou vandaan 
kwam had ik altijd vleugeltjes: je geloof in mij heeft me veel goed gedaan. Toen 
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appendix 1: Knov guideLine suMMary
Anemie in de verloskundige praktijk
praktijkkaart behorend bij de gelijknamige KNOV-standaard 2010
Tijdens de zwangerschap wordt het Hb 
gecontroleerd op de volgende momenten:
• Tijdens de eerste controle
• Rond 20 weken: indien risicogroep voor anemie
• Rond 30 weken: alle zwangeren
• 3-6 wk na start behandeling (vervolgcontrole)
Hb-referentiewaarden (p5-waarden) in mmol/l
Preconceptioneel 7,5
Zwangerschap (in wk Am))
tot en met 13 7,1
14 tot en met 17 6,8
18 tot en met 21 6,5
22 tot en met 37 6,3
vanaf 38 6,5
Postpartum (in wk)
1-5 6,5
6  7,2
Risicogroepen met verhoogde kans op anemie in de zwangerschap (20 wk controle)
• Zwangere tieners 
• Zwangere vrouwen van niet-Noord-Europese afkomst
• Vrouwen die binnen een jaar na de geboorte van een vorig kind zwanger zijn
• Zwangeren met slechte voedingsgewoonten 
• Zwangere vrouwen die bekend zijn met dragerschap van hemoglobinopathie
• Vrouwen met een meerlingzwangerschap
Schema A. Eerste controle hemoglobinebepaling (referentiewaarde tot 14 wk)
Hemoglobinegehalte in mmol/l actie 
 ≥ 7,1 (p5) • vervolgcontrole bij 20 weken bij risicogroepen 
• vervolgcontrole bij 30 weken bij alle zwangeren (inclusief risicogroepen)                                 
                                                                                                   ga door naar schema B
< 7,1 (p5) maar ≥ 5,6 MCV-bepaling                                                                           ga door naar schema C 
Niet-Noord-Europese afkomst: HbP-bepaling
< 5,6 Verwijzing huisarts voor nadere diagnostiek 
Schema B. Vervolgcontrole hemoglobinebepaling bij 20 of 30 weken
zwangerschapsduur hemoglobinegehalte in mmol/l actie
20 weken  ≥ 6,5 (p5) vervolgcontrole Hb bij 30 weken
30 weken  ≥ 6,3 (p5) geen verdere vervolgcontrole meer nodig
20 weken  < 6,5 (p5) MCV- bepaling                ga door naar schema C
30 weken  < 6,3 (p5) MCV- bepaling                ga door naar schema C
Gehele zwangerschap  < 5,6 Verwijzing huisarts voor nadere diagnostiek 
Schema C. Aanvullende diagnostiek d.m.v. MCV-bepaling bij een laag Hb
MCV-gehalte (in fL) actie
80-100 Geen verdere vervolgcontrole Hb meer nodig (hemodilutie)
70-80 IJzergebreksanemie: schrijf ijzermedicatie voor                     ga door naar schema D
< 70 Verwijzing huisarts voor nadere diagnostiek, cave HbP 
≥ 100 Verwijzing huisarts voor nadere diagnostiek, cave Vit B12/foliumzuurdeﬁ ciëntie 
A
B
C
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Schema D. Vervolgcontrole na 3-6 weken ijzersuppletie
vergelijking met vorige Hb-bepaling actie
Hb gestegen en ≥ p5 6 weken onderhoudsdosering: 1 tablet ferrofumaraat 200 mg, om de dag 
Hb gestegen maar nog < p5 Controleren therapietrouw
Voortzetting ijzermedicatie
Opnieuw Hb-controle na 3-6 weken
Hb gezakt of gelijkgebleven Bij adequate inname: verwijzing huisarts voor nadere diagnostiek 
Schema E. Preconceptiezorg
• Bepaal het Hb bij vrouwen die één of meer risicofactoren voor anemie hebben.
•  Veronderstel een ijzergebreksanemie bij een te laag Hb (< 7,5 mmol/l)
Schrijf 1 tablet ferrofumaraat 200 mg per dag voor, voor een periode van 6 weken
• Verwijs in alle gevallen de vrouw met anemie naar de huisarts
• Bespreek de mogelijkheid van dragerschapsdiagnostiek naar HbP met vrouwen van niet-Noord-Europese afkomst
Schema F. Hemoglobinecontrole tijdens de postpartumperiode
Indicatie Hb-controle Hb Actie 
Einde kraambed; bij ﬂ uxus zonder 
ingezette behandeling
< 6,5 mmol/l Start ijzermedicatie en 
controle na 6 weken
Controle ingezette behandeling, 
3-6 weken na start ijzerbehandeling 
in zwangerschap of kraambed
< p5 Verwijzing huisarts
≥ p5 Onderhoudsdosering 6 weken
Bij de nacontrole 6 weken post partum 
wanneer de vrouw:
-  op dat moment nog (een onder-
houdsdosis) ijzertherapie heeft;
-  postpartum is behandeld in verband 
met een ﬂ uxus
< 7,2 mmol/l, maar gestegen Continueren behandeling en na 3-6 
weken een Hb-controle bij de huisarts.
< 7,2 mmol/l, niet gestegen Indien therapietrouw adequaat:
Verwijzing huisarts voor 
verdere diagnostiek
≥ 7,2 mmol/l Stoppen behandeling
Verwijzing voor verdere diagnostiek naar de huisarts
• Bij een Hb van < 5,6 mmol/l
• Bij een MCV van < 70 fL of een MCV ≥ 100 fL
• Indien iemand niet reageert op ijzertherapie
• Onderzoek naar (dragerschap van) hemoglobinopathieën
Medicatie
• 1 tablet ferrofumaraat 200 mg (1 x 65 mg elementair ijzer)
• Inname vóór de maaltijd
• Bij gastro-intestinale klachten: inname ná de maaltijd of dosering verminderen
Hemoglobinopathie (dragerschap)
Bepaal bij zwangeren die bekend zijn als drager van HbP en een laag Hb/MCV hebben, 
eerst een serumferritine alvorens te behandelen met ijzermedicatie.
Zwangeren die bekend zijn met dragerschap van HbP worden gesuppleerd met foliumzuur 0,5 mg/dag.
D
E
F
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Appendix 2: Quantative survey 
Uw mening over advisering over dragerschaptest erfelijke bloedarmoede 
 
Er ontstaan steeds meer initiatieven om verschillende etnische bevolkingsgroepen voor te lichten over 
erfelijke bloedarmoede (hemoglobinopathieën (HbPs)), zoals sikkelcelziekte en thalassemie en de 
mogelijkheid om zich op dragerschap hiervan te laten testen. Sinds 2007 wordt op landelijk niveau via 
de hielprik gescreend op sikkelcelziekte. Ook dragers van deze ziekte worden daarbij opgespoord.  
Onbekend is wat u als
 
eerstelijns hulpverlener vindt van het testen op dragerschap van 
hemoglobinopathie op basis van etniciteit.  
Wij vragen u daarom onderstaande vragen te beantwoorden ongeacht of u cliënten uit de 
risicogroep in uw praktijk heeft en ongeacht of u deze dragerschaptest aanbied. Dit kost u niet 
meer dan vijf minuten, maar levert belangrijke en onmisbare informatie op. Uw antwoorden worden 
strikt vertrouwelijk en anoniem verwerkt.  
 
Alvast hartelijk dank voor uw medewerking! 
 
 
1. Wat vindt u ervan om uw cliënten uitsluitend op basis van etniciteit een test op dragerschap van 
erfelijke bloedarmoede (HbP) aan te bieden (zonder dat er sprake is van een positieve (familie) 
anamnese en/of anemie verschijnselen)?  
 
Graag per item op een schaal van 1-7 uw mening weergeven (omcirkelen); svp ALLE items 
scoren.  
 
• goed   1  2  3  4  5  6  7 slecht  
• belangrijk   1  2  3  4   5  6  7  onzin  
• bezwaarlijk 1 2 3 4  5 6 7 gemakkelijk 
• wenselijk   1  2 3  4   5  6  7  onwenselijk  
• schadelijk  1  2  3  4   5  6  7  bevorderlijk  
• discriminerend  1  2  3  4   5  6  7  een  
voorrecht  
 
 
2. Biedt u cliënten zonder positieve (familie) anamnese en/ of  anemie verschijnselen aan om zich te 
laten testen op dragerschap van erfelijke bloedarmoede (HbP), uitsluitend op basis van etniciteit?  
 
nooit   1  2  3  4   5  6  7  altijd  
 
 
3. Bent u van plan om in de toekomst uw cliënten een test op HbP dragerschap aan te bieden 
uitsluitend op basis van etniciteit (dus zonder dat er sprake is van familiegeschiedenis of 
anemie)?  
 
zeker niet   1  2  3  4   5  6  7  zeker wel  
 
 
4. Denkt u dat uw collega’s vinden dat aan cliënten uitsluitend op basis van etniciteit een test 
naar dragerschap van erfelijke bloedarmoede (HbP) moet worden aangeboden?  
 
zeker niet   1  2  3  4   5  6  7  zeker wel 
 
  
5. Kunt u op dit moment daadwerkelijk elke cliënt  een test op HbP-dragerschap aanbieden 
uitsluitend op basis van etniciteit als u dat zou willen?  
 
zeker niet   1  2  3  4   5  6  7  zeker wel  
 
 
Kunt u uw antwoord kort toelichten: 
………………………………………………………………………….. 
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6. Biedt u cliënten met een onbegrepen anemie, maar zonder positieve familieanamnese,  aan om 
zich te laten testen op HbP dragerschap?  
 
nooit   1  2  3  4   5  6  7  altijd  
 
 
7. Vindt u dat standaard aanbieden van een HbP dragerschaptest uitsluitend op basis van etniciteit 
landelijk beleid moet worden?  
 
ja    nee  
      
 
8. Bent u van plan om uw cliënten een test op HbP dragerschap aan te bieden uitsluitend op basis 
van etniciteit (dus zonder dat er sprake is van familiegeschiedenis of anemie) indien dit landelijk 
beleid wordt?  
 
zeker niet   1  2  3  4   5  6  7  zeker wel  
 
 
9.    Wat vindt u van het registreren van de etniciteit van uw cliënten?  
 
Graag per item op een schaal van 1-7 uw mening weergeven, graag ALLE items scoren 
 
• goed   1 2 3 4 5 6 7 fout 
• schadelijk  1 2 3 4 5 6 7  bevorderlijk 
• zinvol    1 2 3 4 5 6 7 onzin 
• lastig   1 2 3 4 5 6 7 handig 
• discriminerend 1 2 3 4 5 6 7 onschuldig 
• bezwaarlijk 1 2 3 4 5 6 7 wenselijk 
 
Tenslotte volgen hier nog een paar algemene vragen: 
 
 Kunt u een schatting maken van het percentage cliënten die u jaarlijks ziet en die afkomstig zijn uit etnische 
minderheidsgroepen?     
Ongeveer    % 
 
 
 Heeft u de afgelopen twee jaar bijscholing gevolgd op het gebied van erfelijke bloedarmoede (HbP) (kruis 
het juiste hokje aan)?   
Ja    Nee  
 
 
 Hoe lang bent u werkzaam als verloskundige ?   Jaar 
(of als huisarts)     
 
 Mijn praktijk bevindt zich (kruis het juiste hokje aan) 
 
In een stad in de Randstad  In een dorp in de Randstad 
 
In een stad buiten de Randstad   In een dorp buiten de Randstad 
 
 
 Heeft u verdere opmerkingen over dit onderwerp en/ of de vragenlijst? Graag hier vermelden. 
 
 
 
 
Appendix 3: Question route  
 
Focusgroep discussie 
Hartelijk dank voor uw medewerking! 
 
U kunt de vragenlijst versturen in de bijgevoegde antwoordenveloppe. 
(een postzegel is niet nodig) 
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focusgroep discussie
Algemeen welkom (15 min): 
Welkom allemaal op deze focusgroep bijeenkomst over het screenen op 
hemoglobinopathie in de eerstelijn. Heel fijn dat jullie tijd hebben willen vrij maken 
om mee te doen aan dit onderzoek.
*Korte introductie van jezelf (discussieleider & secondant)
Graag wil ik jullie allereerst vragen om jullie mobiele telefoons uit te zetten.
Jullie hebben vorig jaar allemaal de vragenlijst over dit onderwerp ingevuld. Naar 
aanleiding hiervan willen wij graag dieper ingaan op het onderwerp. Het gaat dus 
om jullie mening over het screenen op hemoglobinopathie op basis van etniciteit.
OZ vraag:
Wat zijn de gedachten en ideeën van eerstelijns hulpverleners 
met betrekking tot preconceptie en prenatale screening van 
hemoglobinopathieën gebaseerd op etniciteit? 
Wat zijn de mogelijkheden en wat zijn de knelpunten?
Start van discussie
Eerste helft 45 min.
1) Introductie deelnemers dmv kennismakingsrondje (kort!):
  Wat is je naam en in wat voor een gebied ben je werkzaam (stad / platteland)
  Wordt er in jouw praktijk getest op hemoglobinopathie? 
  Wie test je wel en wie test je niet?
2) Registratie etniciteit
   Als we het hebben over het aanbieden van screenen is dan iedereen gelijk? 
Met andere woorden zijn er groepen die wel of geen screening aan wordt 
geboden?
   Je kunt bijvoorbeeld ook screening aanbieden aan bepaalde groepen op 
basis van vooraf gestelde criteria.
  Screenen op basis van etniciteit is bijvoorbeeld een mogelijkheid.
 
   Wat is het eerste dat bij je opkomt als de term “screenen op basis van 
etniciteit” hoort?
  Wat vinden jullie van het registreren van etniciteit (algemeen)?
   Voordelen
   Nadelen
    Is dit überhaupt wel nodig (het registreren)? (je zou bijv. wel op 
basis van etniciteit kunnen screenen maar de etniciteit hoef je 
bijvoorbeeld niet te registreren)
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  Gebruiken jullie etniciteit op andere momenten in de zorgverlening?
   Bijvoorbeeld bij het inschatten van risico, denk aan bijv. diabetes, 
hoge bloeddruk etc.
   Stel dat screening op HbP zou worden geïntroduceerd in Nederland, zou 
etniciteit hier dan een rol in moeten spelen?
   Hoe bepaal je iemands etniciteit?
   Wie bepaalt tot welke etnische groep iemand behoort? 
    In hoeverre verwachten jullie knelpunten bij het registreren van 
etniciteit?
    Wat hebben jullie nodig om te kunnen screenen op basis van 
etniciteit?
    Hoe zouden jullie omgaan met iemand met een gemengde 
etniciteit?
   Hoe zouden patiënten/cliënten dit ervaren naar jullie mening?
   Zou universele screening beter/handiger zijn?
pauZe (15 min)
Tweede helft : 45 min.
3) Neonatale screening (hielprikscreening) > kort! 
Is met name om even te laten “mopperen” en als bruggetje naar volgende stap in 
discussie.
Jullie zijn al bekend met het screenen op bepaalde erfelijke ziektes tijdens de 
neonatale periode, nl het hielprikprogramma dat in 2007 is uitgebreid.
  Wat vinden jullie van deze screening, wat zijn jullie gedachten hierover?
    Heeft implementatie aan behoefte voldaan? > NB hier opletten 
dat de discussie niet verzandt in klagen over hielprikprogramma, 
eventueel een kort rondje om gal te spuien.
    Wat vinden jullie van de nevenbevinding, nl dat dragerschap van 
HbP wordt gerapporteerd? 
   In hoeverre zijn er knelpunten? 
4) Preconceptionele & prenatale screening
NB Voor het preconceptioneel screenen op HbP is geen vergunning vereist
Screening op HbP kan ook uitgebreider worden aangeboden: We willen het nu 
gaan hebben over het screenen niet alleen na de geboorte maar ook hiervoor, nl 
tijdens de preconceptie periode en in de zwangerschap.
   Wat zouden jullie er van vinden indien ook preconceptioneel en prenataal 
op HbP wordt gescreend? 
183
   Wat zijn jullie gedachten hierover?
    Wat zou er voor zorgen dat jullie screening op HbP zouden gaan 
uitvoeren in de toekomst?
   Stel dat we in Nederland uitgebreide screening zouden gaan invoeren, hoe 
zouden we dat  dan het beste kunnen doen ?
   Wat zouden jullie nodig hebben voor de implementatie hiervan?
   Wat zijn de kansen  / positieve kanten van dergelijke screening?
   In hoeverre verwachten jullie knelpunten hierbij?
Bijvoorbeeld in Engeland is in 2004 een uitgebreid screeningsprogramma 
geïntroduceerd. Hierbij wordt preconptioneel, prenataal en postnataal screening op 
HbP aangeboden. In de hoogrisico gebieden, dus daar waar een hoge prevalentie 
van (dragerscha) op HbP is, wordt iedereen gescreend. In de gebieden waar de 
prevalentie van (dragerschap van ) HbP laag is, wordt op basis van een vragenlijst 
de etnische afkomst bepaald en op basis daarvan wordt al dan niet gescreend. 
(familie oorsprong vragenlijst uitdelen > is vertaalde versie van die in Engeland
Wat vinden jullie van een dergelijk overheidsprogramma?
  Zou een dergelijk instrument ondersteunend zijn?
  Verwachten jullie knelpunten hierbij? Zo ja, welke?
5  Als er uigebreide screening wordt aangeboden dan is er blijkbaar toch nog een 
groep hulpverleners die niet van plan is screening op basis van etniciteit uit te 
voeren (dit kwam uit de vragenlijst) indien dit landelijk beleid zou worden.
  Wat vinden jullie hiervan > hoe kan dit ?
   Wat zou de mogelijke uitleg kunnen zijn van deze bevinding?
    Wat verstaan jullie onder een landelijke beleid? (bv waar komt dit 
vandaan?)
    Maakt het uit waar de richtlijn / landelijk beleid vandaan komt > 
beroepsvereniging / overheid?
afsluiting
Wij wilden graag jullie mening horen over de eventuele knelpunten bij het invoeren 
van een screeningsprogramma op hemoglobinopathie. Dat hebben we geprobeerd 
boven water te krijgen met de vragen die we gesteld hebben. 
•	 Is er nog iets dat we vergeten zijn te vragen?
•	 Had een van jullie nog iets willen zeggen waarvoor je eerder niet de kans hebt 
gekregen?
Heel hartelijk dank voor jullie komst. Mochten jullie achteraf nog vragen hebben 
dan kunnen jullie contact opnemen met Suze Jans s.jans@vumc.nl
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Verloskundige kunnen uren schrijven voor het kwaliteitsregister van de KNOV. Dit 
valt onder “vrije ruimte” Jullie ontvangen van Suze Jans een mailtje ter bevestiging 
van deelname.
•	 Graag op de  lijst je emailadres nakijken> dit geldt dus alleen voor de 
verloskundigen
•	 Graag aftikken op lijst of deelnemer aanwezig was
Ook worden er declaratieformulieren uitgedeeld. Deze kunnen worden ingevuld en 
opgestuurd in bijbehorende enveloppe.
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Appendix 4b: SAmple of lAborAtory reSultS b
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